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ABSTRACT 
 
Using Ion Mobility-Mass Spectrometry to Understand Amyloid β-Protein Assembly:  
The Effects of Small Molecule Inhibitors and Familial Mutations 
 
by 
 
Xueyun Zheng 
 
 Amyloid β-protein (Aβ) has been correlated with Alzheimer’s disease (AD) which is 
the most common form of dementia. Aβ proteins assemble into oligomers, large aggregates, 
protofibrils before growing into fibrils. Recently more and more evidence has shown that the 
intermediate, oligomeric states of Aβ, rather than the fibrils are correlated with AD 
pathology. Among them, the 56 kDa dodecamer species was identified as a proximate toxic 
agent for AD onset. Therefore to understand the early oligomerization of Aβ proteins and to 
target the early assembly of Aβ are of significance for therapeutic strategy for AD treatment. 
In this thesis work, we use mass spectrometry coupled with ion mobility spectrometry 
method (IM-MS) to investigate the early assembly of Aβ proteins.  
 In the first, we sought to search for small molecule inhibitors for Aβ and understand 
their binding interactions and the mechanism of inhibitory actions. Several classes of small 
molecules, including Z-Phe-Ala-diazomethylketone (PADK), two derivatives of the Aβ C-
terminal fragment Aβ(39-42), molecular tweezers, and ML, have been studied and shown 
different effects. These studies of small molecule inhibitors show that ion mobility 
 xii 
 spectrometry method has emerged to be a powerful tool for the screening and understanding 
of small molecule inhibitors for AD and other amyloid diseases.  
 In the second, we sought to understand the effects of amino acid substitutions on Aβ 
structure and aggregation. Two recently discovered familial mutations at Ala2 (A2) within 
Aβ, a protective A2T mutation and a recessive A2V mutation were investigated. Our ion 
mobility studies reveal different assembly pathways for early oligomer formation for each 
peptide and provide a basis for understanding how these two mutations lead to, or protect 
against, AD. 
 Lastly, we also sought to understand the early assembly of amyloid β-protein (Aβ) 
from different rodent species. We investigate the biophysical and biological properties of Aβ 
peptides from humans, mice (Mus musculus), and rats (Octodon degus).  
 In conclusion, we have successfully applied ion mobility spectrometry method to 
understand complicated aggregation systems. This provides a powerful tool to screen small 
molecule inhibitors for Aβ proteins and sheds light onto their inhibitory mechanisms. The 
studies of Aβ mutants imply that ion mobility method can be used as new tool in developing 
an understanding of the effect of familial mutations on Aβ assembly in AD and the assembly 
of other mutated protein systems. 
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Chapter 1 
Introduction 
 
 
 
 
 
1.1 Protein Aggregation Diseases 
Proteins, which are composed of polypepetide chains of amino acids, are essential 
and perform a variety of functions within living organisms. Most proteins can function 
properly only when they are folded into certain specific and stable structure. Protein folding 
is the process that an unstructured protein undergoes certain conformation changes to reach 
its native state1. To ensure a protein folds appropriately is critical for its proper cellular 
function. How and whether a protein folds depend primarily on its amino acid sequence and 
the cellular environment surrounding the polypeptide chains. However, under certain 
 
 
1 
circumstances, protein misfolding or unfolding can occur1-2. When protein folding is 
unsuccessful, the protein is usually redirected to the proteasome where it is proteolytic 
degraded3. If not cleared appropriately, these misfoled or disordered proteins often aggregate 
and accumulate intra- or extracellularly and eventually become problematic and cause 
diseases4. Amyloidosis diseases are one of these protein aggregation diseases, which are 
caused by aggregation and accumulation of amyloid-forming proteins5-6. These diseases 
include Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, etc. (some examples 
are provided in Table 1.1)7. The amyloidosis deposits of the protein aggregates can occur in 
some parts of the body, extracellularly or intracellularly. 
Table 1.1 List of some amyloidosis diseases and the corresponding amyloid-forming 
proteins implicated in each case. 
Disease Aggregation Protein 
Alzheimer’s disease Amyloid β and Tau protein 
Parkinson’s disease α-Synuclein 
Prion disease Prion protein 
Frontotemporal dementia Tau protein 
Huntington disease Huntington with polyglutamine expansion 
Type II diabetes Islet amyloid polypeptide (IAPP) 
Cataract γ-Crystallin 
 
These amyloid-forming proteins exist in a complex dynamic equilibrium between 
soluble monomeric or oligomeric states and various insoluble states of higher-order 
aggregates. The aggregation depends on the protein concentration, interactions with other 
proteins and the cellular environment. Studies showed that the aggregation usually starts 
with a lag phase which contains oligomers and small aggregates, follows by a rapid 
 
 
2 
elongation phase and then reaches a stationary phase when the amyloid fibrils are formed8 
(Figure 1.1). A better understanding of the factors that affect this equilibrium is of 
significance for determining how protein aggregation occurs and for developing effective 
therapies against the amyloidosis diseases6. In this thesis, we aimed to understand the 
aggregation of amyloid β-proteins that are related to Alzheimer’s disease. 
 
Figure 1.1 Aggregation kinetics for amyloid growth. 
 
1.2 Alzheimer’s disease 
1.2.1 Alzheimer’s Disease and Prevalence 
Alzheimer’s disease (AD) is a degenerative brain disease and is the most common 
form of dementia (other forms of dementia include Vascular dementia, Dementia with Lewy 
bodies, Fronto-temporal dementia which includes Pick's disease, etc.)9. It was first described 
by a German physician Dr. Alois Alzheimer in 190610. He found dramatic shrinkage and 
abnormal deposits in and around nerve cells in the brain autopsy of his patient Auguste D. 
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who suffered profound memory loss10. AD is characterized by damage of neurons in the 
brain and causes a decline in memory, language, problem-solving and other cognitive and 
executive functions that affect daily activities, and eventually leads to death.  
Nowadays, there are 47.5 million people having dementia worldwide and there are 
7.7 million new cases every year11. AD may contribute to 60–70% of cases and therefore it 
has become one of the most important diseases. AD is an age-related disease and often 
occurs in senior people with age of 65 years and older. As the population ages and life spans 
continue to increase, the prevalence will increase. By 2050, the number of patients with AD 
worldwide is estimated to be 135 million.  
Therefore to understand the pathology of AD and develop therapeutic strategy for 
AD treatment is of significance and it has become one of the hot research topics for 
scientists. 
1.2.2 Symptoms of Alzheimer’s disease and Diagnosis 
AD and other dementia affect each patient in a different way, which might depend on 
the impact of the disease and the personality of the patient before becoming ill. The 
symptoms of AD vary among individuals and the progression of disease varies greatly. 
People with AD live an average of eight years, but some people may survive up to 20 years. 
The symptoms linked to AD and other dementia can be understood in three stages.  
Earliest Alzheimer’s Stage: The earliest stage of AD can began as early as 20 years 
or more before the symptoms can be detected and they are often overlooked as the changes 
are gradual. The most common initial symptom in AD is memory decline, a gradually loss 
of ability to remember new information. This is because the first formation of plaques and 
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tangles and neuron damages often start from the hippocampus region in the brain that is 
involved in formation of new memory and learning. The common signs in the earliest stage 
include forgetfulness, becoming lost in familiar places and losing track of the time, etc9. 
Middle Stage of Alzheimer's: The mid to moderate stage can last from 2 to 10 years. 
As the plaques and tangles build up more in the hippocampus region and spread to other 
parts of brain, the neuron damages spread to other regions in the brain which start to display 
other malfunctions and difficulties. As a result, the patients start to have serious problems 
with memory or thinking and have difficult with work or social life. As the disease 
progresses, the patients may experience changes in personality and behavior and have 
trouble recognizing friends and family members. The signs and symptoms become clearer, 
and many people with Alzheimer's are first diagnosed in these stages9,12. 
 Last stage of Alzheimer’s: The last stage of AD may last 1 to 5 years. As the disease 
advances, the plaques and tangles spread to the whole brain and most of the cortex of the 
brain is seriously damaged. The brain shrinks dramatically due to widespread cell death. The 
patients often become totally dependent and inactive. Memory disturbances are serious and 
the physical signs and symptoms become more obvious. The symptoms include becoming 
unaware of the time and place, having difficulty recognizing relatives and friends. The 
patients often experience changes in behavior and personality, including aggression, apathy 
and depression, etc11. 
AD diagnosis: AD can only be confirmed by brain autopsy after death, by the 
identification of amyloid plaques and neurofibrillary tangles in the brain13. However, a 
variety of approaches and tools are available to help make a diagnosis of AD. The physician 
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will ask to obtain a medical and family history, especially psychiatric history and history of 
cognitive and behavioral changes. Cognitive tests and physical and neurologic examinations, 
including tests of memory, attention and language, will be conducted.  
 
1.3 Amyloid β-protein and Alzheimer’s disease 
1.3.1 Amyloid β-protein  
AD is a complicated disease and its aetiology has not been fully understood. One of 
the classical hallmarks of AD histopathology is the extracellular deposits of amyloid plaques, 
which are primarily composed of the Amyloid β-protein (Aβ) (Figure 1.2A)6. A second 
hallmark of AD is the presence of intracellular neurofibrillary tangles, which are composed 
of abnormal, hyperphosphorylated tau protein (Figure 1.2B)6. In this thesis, we focus on 
understanding the assembly of Aβ proteins. 
 
 
 
6 
Figure 1.2 Characteristics of Alzheimer’s disease. (A) Amyloid plaques. A human cortical 
section from an AD patient, stained with an amyloid-β (Aβ)-specific antibody. (B) 
Neurofibrillary tangles (indicated by an arrow). A human cortical section from an AD 
patient, stained with a phospho-tau-specific antibody. The images are reproduced from 
reference 6 with permission. 
 
Aβ is, in reality, not one but a group of peptides with various lengths between 36 to 
43 amino acid residues (primary sequence is shown in Figure 1.3). Aβ peptides are derived 
from the type-1 transmembrane protein, amyloid precursor protein (APP), through 
proteolytic cleavage by β- and γ-secretases14.  
 
Figure 1.3 The production of Aβ proteins and formation of amyloid plaques in vivo. Image 
of amyloid plaque is adapted from Figure 1-2A which is reproduced from reference 6 with 
permission. 
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Aβ exist in vivo primarily as 40- or 42-amino-acid long peptides. The most common 
and abundant form is Aβ40, which constitutes ~90% of all Aβ species.15 However, it is 
significantly less toxic in cells. Even though Aβ42 is a relatively minor constituent (~9% of 
all Aβ species), it is highly neurotoxic and much more aggregation-prone than Aβ40. Aβ42 
has been found to be the primary component of amyloid plaques (Amino acid sequence of 
Aβ42 is provided in Figure 1.4).  
 
 
Figure 1.4 The primary sequence of Aβ42 peptide. Positively charged amino acid residues 
are noted in blue and negatively charged residues are noted in red.  
 
         The physiological role of APP and Aβ is unclear. However, studies have shown that 
the onset of AD may be connected with an imbalance of the production and clearance of 
Aβ14. Recently, scientists were able to quantify Aβ production and clearance from 
cerebrospinal fluid of individuals with and without AD. Compared to the balanced rates for 
healthy individuals, the AD patients showed an increased ratio of Aβ production over 
clearance16.  
1.3.2 Amyloid β-protein aggregation 
        Once released into the extracellular environment, Aβ monomer starts to self-associate 
with each other to form small oligomers and eventually grow into fibrils. The structure of 
Aβ fibrils has been well characterized, consisting of β-sheet strands17.  
          Formation of Aβ fibrils in vitro and in vivo is a complex process involving multiple 
intermediate oligomeric species. More and more evidence showed that these oligomeric 
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species are highly neurotoxic. It is believed that these intermediate oligomeric states, rather 
than the final product, fibrils, are the proximal neurotoxins acting in AD.18-21 Immediately 
upon dissolution in vitro, Aβ42 forms small oligomers, including dimers and tetramers, as 
well as paranuclei (pentamers and hexamers) that self-associate to form decamers and 
dodecamers.22-24 However, Aβ40 forms only dimers and tetramers before slowly self-
assembling into fibrils (Figure 1.5). Among these species, the 56-kDa dodecamer has been 
identified as a plausible cause of memory deficits in the AD brain25 and in transgenic mice26.  
 
Figure 1.5 Schematic of oligomerization patterns for Aβ40 and Aβ42 proteins. Aβ40 is 
noted in red and Aβ42 is noted in blue. M, D, Te, H and Do represent monomer, dimer, 
tetramer, hexamer and dodecamer, respectively. 
 
1.3.3 Amyloid cascade hypothesis of AD 
Briefly, in a health brain, neuron cells are connected and communicated through 
synapses (Figure 1.6). In general, signal or information is carried from one neuron to another 
through the chemicals called neurotransmitters. The exon sends the signal to another neuron 
by release the chemical neurotransmitters to its receptors on the dendrites of the other 
neuron. The dendrites receive the signal and transport the information as an electric signal to 
the body. However, in the brain of AD patients, this neurotransmission process is disrupted. 
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Eventually the synapses are destroyed and the neuron cells are killed, as a result, the 
communication network of the brain is damaged and therefore causes failure of many 
functions of the brain27.  
 
Figure 1.6 Signal transmission between two neurons through a synapse. Neurons send 
signals through axons and receive signals through dendrites. The junction at which two cells 
meet is the synaptic cleft. Neurotransmitters are released from the axon of one neuron to the 
receptors on the dendrite of another. 
 
Currently, the amyloid cascade hypothesis (Figure 1.7) is widely accepted to explain 
AD pathology28. It is suggested that deposition of Aβ peptide in the brain is a crucial step 
that ultimately leads to Alzheimer’s disease. Abnormal high level of Aβ protein present in 
the brain, which can be resulted from overproduction, decreased clearance or increased 
Aβ42/40 ratio, and start to assemble and aggregate into soluble oligomers and eventually 
grow into Aβ fibrils. These intermediate forms, soluble oligomers have been shown be 
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synaptotoxic and neurotoxic. The deposited Aβ triggers or accelerates Tau phosphorylation 
and aggregation into tangles, which ultimately leads to neuronal loss28. However, how Aβ 
trigger Tau pathology and how Tau pathology leads to neuronal loss are unclear and remain 
elusive. 
 
Figure 1.7 Amyloid cascade hypothesis for AD pathology. 
 
Several possible receptors have been proposed for Aβ oligomers or amyloid β-
derived diffusible ligands (ADDLs) and mediating their synaptotoxic effects (Figure 1.8)27. 
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For example, nerve growth factor receptor, p75NTR, has been shown to play a role in Aβ-
induced cell death (apoptosis) through its downstream effectors, such as c-Jun N-terminal 
kinase. The N-methyl-D-Aspartate (NMDA) receptor, which is a glutamate receptor, can 
also bind ADDLs. Glutamate is an important neurotransmitter in the brain involved in 
learning and memory. When glutamate is attached to NMDA receptor, NMDA permits 
calcium to enter the cell, which is an important process for cell signaling, as well as learning 
and memory. On the other hand, ADDLs bind to NMDA receptor, and cause imbalance in 
Calcium homeostasis in the cell, leading to increased oxidative stress and loss of synapses. 
The Frizzled receptor has also been implicated as a receptor for Aβ oligomers.  ADDLs bind 
to Frizzled receptor and inhibit Wnt signaling, relieving the inhibition on Gsk3b signaling 
and thereby leading to hyperphosphorylation of Tau protein. APP and Prion protein (PrPC) 
are also receptors for ADDLs for its mediation of synaptic dysfunction. In addition, Aβ 
oligomers have been shown to form pores in the membrane and act as ion channels which 
lead to abnormal ion transport, such as calcium or zinc ions, into the cell and causes cellular 
dysfunction and synapse loss27.  
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 Figure 1.8 Possible receptors for Aβ oligomers and pathways. This figure is reproduced 
from reference 27 with permission. 
 
1.4 Therapeutic strategy for AD 
1.4.1 Current available treatments for AD symptom  
There is no cure for AD so far and the treatments aim to slow the AD symptoms. 
These treatments temporarily improve symptoms of AD by increasing the amount of 
neurotransmitters in the brain (see Figure 1.8). There are five drugs approved by the U.S. 
Food and Drug Administration (Table 1.2). These drugs rescue the communication process 
through two different mechanisms: inhibiting the activity of cholinesterase or slowing down 
the release of calcium into the cell which thereby slows down the cell damage process. 
Donepezil, galantamine and rivastigmine are cholinesterase inhibitors and therefore slow 
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down the process that cholinesterase degrades the neurotransmitter. Memantine, on the other 
hand, works by regulating the activity of glutamate. In the brain of AD patients, excess 
glutamate is released from the damaged cells, which results in too much calcium in the cell 
and thereby facilitates cell damage. Memantine blocks the NMDA receptor and thereby 
helps prevent this destructive process. 
Table 1.2 Current available drugs for AD approved by FDA (Reproduced with permission 
from Alzheimer’s Association, http://www.alz.org/). 
Drug  name Brand name Approved for FAD approved 
1. Donepezil Aricept All stages 1996 
2. Galantamine Razadyne Mid to moderate 2001 
3. Memantine Namenda Moderate to severe 2003 
4. Rivastigmine Exelon All stages 2000 
5. Donepezil and Memantine Namzaric Moderate to severe 2014 
 
However, none of the treatments available today slows or stops the damage of 
neurons in the brain. Efforts are input in the understanding of AD onset and developing 
drugs targeting amyloid β and its aggregation, aiming to stop the progress of the disease. 
 
1.4.2 Therapeutic Strategy for AD 
Based on the amyloid cascade hypothesis, there are three major strategies for AD 
therapy and prevention (Summarized in Table 1.3). The first one is preventing Aβ 
production. This can be achieved by inhibiting or modulating the β- and/or γ-secretase 
enzymes.29 However, this approach has been problematic because both secretases cleave 
substrates other than APP, which play important roles in other functional biological 
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processes.30-32 Another potential strategy is enhancing the clearance of Aβ oligomers and 
aggregates from the brain.33 This can be accomplished either by facilitating degradation of 
Aβ by proteases34 or other clearance mechanisms such as Aβ immunotherapy35. The third 
strategy is directly remodeling the aggregation of Aβ into clearance-prone structures. 
Table 1.3 Three strategies for AD therapy. 
Approach Therapy 
Inhibition of amyloid production 
γ-Secretase inhibitors and modulators 
β-secretase inhibitors 
Promotion of amyloid clearance Aβ immunotherapy 
Inhibition of amyloid aggregation Aβ inhibitors 
 
Small molecule inhibitors for Aβ: Many natural proteins, peptides and small 
molecules have been discovered to interact with Aβ and modulate Aβ self-assembly36. 
Among them, small molecules are particularly attractive as a direct therapeutic strategy for 
the treatment of AD37-38. For instance, biologically active molecules from green-tea ((–
)epigallocatechin-3-gallate, EGCG) or the Indian spice turmeric (curcumin), have been 
found to prevent Aβ aggregation and inhibit Aβ-induced toxicity39-40. Inositol stereoisomers 
have been found to interact with Aβ and attenuate its neurotoxic effects41-42. C-terminal 
fragments of Aβ42 and many polyphenol molecules have been shown to inhibit Aβ 
oligomerization, aggregation, and toxicity43-47. In this thesis work, we evaluated the effects 
of several classes of small molecules on Aβ aggregation (Chapters 3-6). 
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1.5 Familial Alzheimer’s Disease 
1.5.1 Familial Alzheimer’s disease 
AD is an age related disease and usually occurs sporadically in senior people above 
65 years old (95% of all AD cases). However, 5% of AD cases occur below age 65. These 
early onset AD cases are often caused by genetic mutations, named familial AD (FAD). 
These mutations occur primarily in three genes, the APP48-49, presenilin 1 (PS1)50-51, or 
presenilin 2 (PS2)52 genes (Table 1.4). Missense mutations of PS1 and PS2 genes often 
cause over production of Aβ42 and therefore lead to early onset of AD, which are the 
primary cause of autosomal dominant AD53.  
Table 1.4 Confirmed genetic factors related to Alzheimer’s disease: relationships to the 
amyloid-β phenotype14.  
Chromosome Gene Defects Phenotype 
21 APP mutations ↑ Production of all Aβ peptides or Aβ40 
14 Presenilin 1 mutations ↑ Production of Aβ42 
1 Presenilin 2 mutations ↑ Production of Aβ42 
 
 
1.5.2 Genetic mutations in APP 
Numerous FAD-related mutations in the APP gene have been identified and many of 
them are near β- or γ-secretase cleavage sites. This results most commonly in 
overproduction of Aβ or relative increases in the amount of Aβ42 that is produced relative to 
Aβ4014,54. Moreover, many mutations in the APP gene occur within the Aβ sequence (Figure 
1.9), and such single amino acid substitutions in Aβ primary sequence are very likely to 
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affect the biophysical and aggregation properties of Aβ. Many mutations in the APP gene 
result in amino acid substitutions within the central region of Aβ, for instance, Flemish 
(A21G)55, Arctic (E22G)56, Dutch (E22Q)57, Osaka (E22Δ)58, Italian (E22K)59 and D23N 
(Iowa)60 mutations. The resulting peptides exhibit distinct aggregation propensity and 
toxicity. The central region of Aβ has been shown to be crucial for the initial nucleation of 
Aβ folding and assembly61. Mutations near this region may disrupt the Aβ conformation, 
resulting in increased aggregation propensity and formation of toxic oligomers62.  
 
 
Figure 1.9 Familial mutations in APP gene within Aβ sequence. 
A number of APP mutations result in amino acid substitutions at the N-terminus, and 
these substitutions alter Aβ assembly. These include the English (H6R)63-64, Tottori (D7N)63-
66, and Taiwanese (D7H)67 mutations. Most recently, two new APP mutations have been 
described that result in the substitutions A2T and A2V can be important in Aβ structure and 
assembly68-69. Many of these familial mutations cause early onset of disease. However, A2T 
is the first one that was found to protect against AD and protect cognitive decline in the 
elderly without AD68. Single mutations in Aβ can cause dramatic effects on AD etiology, 
therefore to understand the effects of these mutations is of significance for understanding 
these familial AD and their future therapeutic development. Thus it is another important 
focus of this thesis work (Chapters 7 and 8).  
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Chapter 2 
Ion Mobility Spectrometry 
 
 
 
 
 
Due to the aggregation property, the Aβ proteins have been very difficult to be 
studied by traditional analytical techniques. For example, spectroscopic techniques such as 
Circular dichroism (CD), IR spectroscopy and NMR can measure only the average 
properties of all species (form monomer, oligomers, protofibrils to fibrils) in the solution. X-
ray crystallography, on the other hand, requires crystal samples which only applied to 
amyloid fibrils. It is impossible to isolate single oligomer without cross-linking or other 
chemical methods. Therefore, it is necessary to use non-traditional techniques to investigate 
amyloid proteins. Here, we use ion mobility spectrometry (IMS) coupled to mass 
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spectrometry (MS) method to study the structures and assembly of these Aβ proteins, and 
evaluate the effects of small molecules and familial mutations. 
IMS is capable of separating species with different in size or shape, based on their 
mobility in an inert buffer gas under an electric field. Ion mobility provides insights into the 
structure. When coupled with mass spectrometry (MS), IMS–MS provides a powerful 
hybrid analytical tool that can be applied in environmental, biological, structural, 
pharmaceutical, and other applications. The instrument setup used in this thesis is drift tube 
ion mobility spectrometry (DTIMS)1-2 and therefore only this method is described in detail. 
Other ion mobility instrument setups include Traveling Wave ion mobility spectrometry 
(TWIMS)3-4, high filed asymmetric ion mobility spectrometry (FAIMS)5 and differential 
mobility spectrometry (DMS)5, etc.   
 
2.1 Ion Mobility Theory 
The ions drift through a buffer gas (used helium in this work) under the influence of 
a weak uniform electric field, E. The ions are accelerated along the field lines, scatter in 
random directions due to collision with the buffer gas and diffusion. Under the low field 
condition, the ions are given enough time to reach equilibrium with the gas molecules. As a 
result, the ions travel with constant velocity parallel to the field lines and their sizes grow 
due to diffusion. The constant drift velocity, vd, is determined by the forward accelerating 
force of the field and the retarding decelerating force of collisions. It is proportional to the 
electric field: 
                                     𝑣𝑣𝑑𝑑 = 𝐾𝐾 ∙ 𝐸𝐸                                             (2.1) 
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Using kinetic theory6, the momentum transfer and energy gained by the ions from 
the electric field is balanced with the energy lost in buffer gas collisions. The collision cross 
section σ can be derived,  
                                  𝐾𝐾 =  3𝑒𝑒
16𝑁𝑁
 ( 2𝜋𝜋
𝜇𝜇𝑘𝑘𝐵𝐵𝑇𝑇
)1 2⁄  1
𝜎𝜎
                                     (2.2)   
Here, q is the ion charge, N is the buffer gas number density at STP, μ is the reduced 
mass of the ion–He collision, and kB is the Boltzman constant. The mobility (K) and the 
collision cross section (σ) provide information about the three-dimensional conﬁgurations of 
the ions. This equation demonstrates that the ion mobility depends on the gas pressure, the 
temperature, the electric field, the size or shape of the analyte ions and the interactions of the 
ion and the buffer gas. Under the same pressure and temperature, ions with smaller cross 
section have larger mobility and drift faster. In contrast, ions with large cross section have 
small ion mobility and drift slower (Figure 2.1). 
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 Figure 2.1 Illustration of the ion mobility separation (a) of isomers and (b) oligomers with 
the same m/z. 
 
2.2 Collision Cross Sections Measurement 
During the experiment, the time the analyte ions spending inside and outside the drift 
cell with length l, before reaching the detector is measured directly as arrival time, tA. It is 
related to the drift velocity of the ion: 
𝑣𝑣𝑑𝑑 =  𝑙𝑙𝑡𝑡𝑑𝑑 =  𝑙𝑙(𝑡𝑡𝑎𝑎−𝑡𝑡0)                              (2.3) 
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The absolute ion mobility is dependent on the temperature (T) and the pressure (P) of 
the buffer gas, so it is typically converted to K0, the standard or reduced mobility: 
 𝐾𝐾0 = 𝐾𝐾 ∙ 𝑃𝑃760 ∙ 273.16𝑇𝑇                                               (2.4) 
The reduced mobility K0 can be determined from the instrument parameters by using 
equation 2 and plotting tA versus P/V7  
𝑡𝑡𝐴𝐴 =  𝑙𝑙2𝐾𝐾0 ∙  273.16760 𝑇𝑇 ∙  𝑃𝑃𝑉𝑉 + 𝑡𝑡0                                        (2.5) 
In equation 4, l is the length of the drift cell, V is the voltage across the drift cell, and 
t0 is the time the ions spend outside the drift cell before hitting the detector. Equation 5 gives 
the arrival time as a function of P/V, with a slope that is inversely proportional to K and t0 as 
the y-intercept. All of these quantities are either known constants or are measured for each 
experiment. tA is measured under different P/V values by keeping constant and changing the 
drift voltage V. Therefore K0 can be determined by plotting tA versus P/V at a given 
temperature (Figure 2.2). Once the ion mobility is determined for a given species, an 
experimental collision cross section can be calculated by using Equation 2.  
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 Figure 2.2 Example of an arrival time, tA, versus P/V plot to determine the mobility of a 
given species. The slope of the curve is inversely proportional to the mobility and y-
intercept is equal to t0. 
 
2.3 Instrumentation 
2.3.1 Ion mobility Instrument 
A home-built ion mobility spectrometry-mass spectrometer was used for the majority 
of the experiments in this thesis. A schematic of this instrument is shown in Figure 2.3. A 
detailed description of the instrument can be found in literature8, here only brief introduction 
is shown below.  
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 Figure 2.3 Schematic of an ESI-ion mobility mass spectrometer. (a) source roughing, (b) 
capillary, (c) vacuum chamber, (d) entrance ion funnel, (e) (g) (i) ion optics, (f) temperature-
controlled drift cell, (h) quadrupole mass analyzer, (j) detector, (k) conversion dynode.  
 
The ions are generated continuously by a nano-electrospray ionization (ESI) source. 
ESI is one of the soft ionization methods that cause little or no fragmentation of the analyte 
compound. The nanospray tips are made in house with borosilicate glass capillary (0.69 mm, 
o.d 1.2 mm, Sutter Instruments). Briefly, the capillary is heated and pulled by a glass tip 
puller (Sutter Instruments) and then coated with gold. A few microliters of analyte solution 
is loaded into the nanospray tip and mounted onto a xyz linear translational stage. A high 
voltage of ~700-1400 V with respect to the entrance of the instrument is applied to the 
needle to generate charged ions continuously.  
The generated ions travel through the capillary (0.010 in. i.d., 3 in. long) in front of 
the instrument and enter a high vacuum chamber where they are focused by the ion funnel. 
The ion funnel is a high transmission RF ion guide device that compresses the divergent ion 
stream down into a small diameter, and moves the ions from the source region into the drift 
b
a
c
d e f g h i j
k
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cell without the use of high acceleration fields which thus avoids high-energy ion-neutral 
collisions that may cause fragmentation or conformation changes.  
A pulse of ions is injected into a 4.503 cm long drift cell. The drift cell consists of a 
copper cell body that can be heated by electrical heaters and cooled with a flow of liquid 
nitrogen, a copper end cap with separate temperature control and a ceramic ring that 
separates the end cap from the cell body. The cell temperature can be varied from 80 to 
above 800K. The cell is filled with 3-5 torr helium gas and applied with a weak electric field, 
ranging from 2 to 20 V/cm to allow experiment conditions within the low field limit that is 
required for ion mobility measurements.  
The ions exiting the drift cell are mass analyzed with a quadrupole mass ﬁlter (4000 
amu; Extrel; Pittsburgh, PA). The quadrupole can be set to scan over a mass range to 
generate a mass spectrum or can be set to select only a particular ion of interest to pass 
through for arrival time recording. 
The ions exiting the quadrupole are attracted to a conversion dynode (4 kV) and 
detected by a channel electron multiplier. The signal output is amplified by a preamp (Ortec), 
and recorded on a multichannel scalar (MCS plus; EG&G Ortec, Oak Ridge, TN).  
 
2.3.2 Experiments 
Mass Spectrum Scan: 
The scan mode is used to record a mass spectrum, which allows us to characterize 
the contents of the analyte sample and identify ions of interest for further analysis. In this 
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mode, the instrument is run in a continuous mode and the quadrupole is set to scan over a 
desired mass range and the ion current is recorded. 
Arrival time distributions 
To record an arrival time distribution (ATD), the ion gate is set on and a pulse of 
analyte ions are injected into the drift cell. Ion this mode, the quadruple is set to select only 
the ion of interest to pass through and the ion current is detected as a function of arrival time 
(started with the pulse injection). This can be repeated at different drift voltages to measure 
the ion mobility.  
 Injection energy study 
To assign the peaks in the ATDs unambiguously and better understand the 
distributions for different conformers or oligomers, the ATDs are often measured at different 
ion injection energies. The voltage between the last lens of ion funnel and the drift cell 
entrance orifice determines the ion injection energy. The injection energy can be varied from 
∼20 to ∼150 V and is typically 20-60 V. At low injection energy, the ions are rapidly 
thermalized by cooling collisions with the helium gas in the drift cell. At high injection 
energy, the ions are given energy that can lead to internal excitation before reaching thermal 
equilibrium. Such internal excitation can cause isomerization into low energy structure or 
dissociation of large noncovalent complexes into small species9. Usually the injection 
energy is kept as low as possible to minimize thermal heating of the ions during the injection 
process.  
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2.3.3 Resolution 
The resolution of an ion mobility drift tube depends on a number of factors, not only 
the time spread due to ion diffusion in the drift cell, but also the time spread that occurs 
outside the drift tube (the initial width of injected ion pulse and the time spread created in 
both the exit funnel and in the quadrupole and detector). The resolution power of an IMS 
device is a function of drift field and temperature of buffer gas10: 
𝑡𝑡𝑑𝑑
𝑡𝑡1/2 =  14  � 𝑞𝑞𝑘𝑘𝐵𝐵𝑙𝑙𝑙𝑙2�1/2 [𝑉𝑉𝑑𝑑𝑇𝑇 ]1/2                     (5) 
where td is the drift time, t1/2 is the width of the peak at half-height, q is the ion charge, Vd is 
the voltage drop across the drift cell, kB is Boltzmann’s constant and T is the temperature of 
the buffer gas.  Following the equation, to increase the resolution, it requires to decrease the 
temperature of the buffer gas or to increase the electric field. However, increasing E requires 
increasing in drift length or gas pressure correspondingly to keep E/N constant and to stay in 
the low-field regime required for ion mobility experiments. With a high pressure of buffer 
gas, it is difficult to inject the ions into the drift cell. High injection energy is required to 
inject the ions into the drift cell, which in turn may lead to dissociation or fragmentation of 
the analyte ions. The length of the drift cell is limited by the diffusion of ions as they travel 
through the drift cell. The ions will lose to the wall if the drift cell is too long. Therefore, the 
resolution power is limited by the balance of ion energy, technical feasibility and the 
quantities determining the resolution. 
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2.3.4 Calculating the theoretical shape for a single structure in an 
ATD 
The width of a single analyte ion structure in an ATD can be calculated by using 
kinetic theory6, which gives information on the structural distribution favored in the ATD. 
The ion packet is taken as a periodic delta function and the flux is given by equation: 
Φ(0, 𝑧𝑧, 𝑡𝑡) = 𝑠𝑠𝑠𝑠𝑒𝑒−𝛼𝛼𝛼𝛼
4(𝜋𝜋𝐷𝐷𝐿𝐿𝑡𝑡)1/2 ∙ �𝑣𝑣𝑑𝑑 + 𝑧𝑧𝑡𝑡� ∙ �1 − 𝑒𝑒− 𝑟𝑟𝑜𝑜24𝐷𝐷𝑇𝑇𝛼𝛼� ∙ 𝑒𝑒− 𝑟𝑟𝑜𝑜24𝐷𝐷𝑇𝑇𝛼𝛼                (2.6) 
Here z is the length of the drift cell, r0 is the radius of the initial ion packet, a is the area of 
the exit aperture, DL and DT are the longitudinal and transverse diffusion coefficients, s is the 
initial ion density and α is the loss of ions due to reactions in the drift cell. If the width of a 
feature in the experimental ATD is broader than the calculated one, then the feature possibly 
represents a family of structures, rather than a single structure. 
 
Figure 2.4  Example of an experimental ATD (solid line) in comparison with a calculated 
theoretical shape for a single structure (dashed line). The experimental ATD is broader than 
the dashed line, indicating there is a family of conformation instead of a single structure. 
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2.4 Theoretical calculations for collision cross sections 
To obtain structural information from ion mobility experiments, collision cross 
sections can be calculated for theoretical structures generated by various molecular 
modeling methods and compared with experimental values. Experimental cross section 
determined in an ion mobility experiment depends on the shape of the analyte ions and it is 
an orientation averaged result. The simple way to calculate the collision integral for an ion 
colliding with buffer gas atoms is projection approximation method (PA). This method 
essentially calculates the average projection cross section as a model structure is rotated 
through different orientations using hard spheres with a specific radius for each atom in the 
system11-12. It is fairly quick, however it does not correctly describe the scattering process of 
buffer gas molecules and often fails for large systems (>200 atoms). A more accurate 
approach is the trajectory method (TJ)13. This TJ method treats the ion itself as a collection 
of atoms, each of which is represented by a Leonard-Jones (12-6-4) potential, and calculated 
the sum of these individual potentials to obtain the effective potential of the ion. The 
orientation averaged collisional cross-section is then determined by integrating over all 
possible collision geometries. However, the TJ method is computationally expensive, which 
takes very long time to calculate the cross sections for large systems. Recently, a new 
method projection superposition approximation method (PSA)14-17 was developed. It is 
based on the PA method but corrects both size and shape effects, which gives accurate 
results for various complex molecular geometries and is low computational cost. In this 
thesis work, we used PSA method for calculating theoretical cross sections.  
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Chapter 3 
Z-Phe-Ala-diazomethylketone (PADK) Modulates 
Aβ42 Early Assembly 
 
 
 
 
 
 
 
This chapter is reproduced partially with permission from: 
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M. T. Bowers, “Z-Phe-Ala-diazomethylketone (PADK) disrupts and remodels early 
oligomer states of the Alzheimer disease Aβ42 protein”, Journal of Biological Chemistry 
2012, 287, 6084-6088, Copyright © 2012, by the American Society for Biochemistry and 
Molecular Biology   
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3.1 Introduction 
Recently, more and more evidence has shown that the early oligomer states of Aβ42 
are important for AD development.1-3 In solution, Aβ42 forms dimer, tetramer, paranuclei 
(pentamer and hexamer), decamer and dodecamer before aggregation into fibrils.4-5  Among 
them, the 56 kDa-dodecamer has been identified as a proximate toxic agent for AD.6-7 
Therefore, to target the early assembly of Aβ42, especially the dodecamer formation is an 
important therapeutic strategy for AD treatment.  
Small molecules are especially attractive as Aβ42 aggregation inhibitors.8-9  To date, 
many small molecules have been discovered and/or designed to have such effect. Natural 
bioactive molecules, for example, green extract EGCG,10 turmeric curcumin,11 and 
polyphenol compounds12 have been discovered to be active inhibitors for Aβ42-induced 
neurotoxicity. Many small molecules are specifically designed and synthesized to target 
Aβ42 aggregation.  
As discussed in Chapter 1, the important aspect of therapeutic strategy for AD is to 
reduce the level of Aβ proteins by reducing the Aβ production by inhibiting the γ-secretase 
activity or by facilitating Aβ clearance by enhancing lysosomal proteases. Molecules have 
been discovered to up-regulate the levels of lysosomal enzymes and thereby result in 
reduced Aβ level in the brain.13 For example, a small molecule, Z-Phe-Ala-
diazomethylketone(PADK, chemical structure is provided in Figure 3.1), which was used as 
a lysosomal enzyme up-regulator, has recently been shown to selectively increase the 
Cathepsin B level in the central nervous system. The increased cathepsin B level has 
enhanced the clearance of Aβ proteins and thus reduced Aβ levels in the brain, which in turn 
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offset the defects in synaptic composition and cognitive functions in the transgenic AD mice 
models.14  
 
Figure 3.1 Chemical structure of Z-Phe-Ala-diazomethylketone (PADK) molecule. The 
molecular weight is 394.  
 
As PADK is a small molecule, it is very likely that PADK may interact with Aβ 
itself directly. Here, we used ion mobility spectrometry-mass spectrometry (IMS-MS) 
coupled with all atom molecular dynamics (MD) simulation method to probe the interaction 
of PADK and Aβ42.  
Ion mobility spectrometry (IMS)15 is suitable to separate species with the same mass-
to-charge ratio but different structures or oligomer sizes. It has been developed and applied 
to investigate the structure and the early assembly of amyloid β-proteins and the interactions 
of small molecules with Aβ.5,16-19 MD simulations provide an insight into the detail of the 
interactions of protein and small molecule on the atomic level.17 Our results provide an 
example of small molecules directly targeting Aβ42 and inhibiting its aggregation and 
 
 
42 
toxicity, shedding lights on future small molecule therapeutic development of AD and other 
diseases. 
 
2.2 Experimental Methods 
Peptides and Sample Preparation:  
PADK was obtained from Bachem Americas, Inc. (N-1040; Torrance, CA). Full-
length Aβ42 protein was synthesized by N-9-fluorenylmethoxycarbonyl (FMOC) 
chemistry.20 The samples were purified by reverse-phase HPLC and their integrity validated 
by mass spectrometry and amino acid analysis. Lyophilized Aβ42 protein was dissolved in 
10 mM ammonium acetate buffer (pH 7.4) with a final protein concentration of 10 μM. 
Concentrated PADK molecule was added to the Aβ42 with a final small molecule 
concentration of 10 or 100 μM.  
Ion Mobility Spectrometry-Mass Spectrometry (IMS-MS): 
Mass spectrometry analysis and ion mobility studies were performed on a home-built 
nanoESI instrument described in Chapter 2.3. 
Transmission Electron Microscopy (TEM):  
Microscopic analysis was performed by using a FEI T-20 transmission electron 
microscope under 200 kV. The Aβ42 samples were prepared under the same procedure as 
that for mass spectrometry analysis. The samples were kept in refrigerator (~4 °C) for 2 
weeks. For TEM measurements, 10 µL aliquots of samples were spotted on glow-discharged, 
carbon-coated copper grids (Ted Pella, Inc). The samples on grids were stained with 10 mM 
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sodium metatungstate aqueous solution for 10 min and gently rinsed twice with DI-water. 
The sample grids were then dried in room temperature before TEM analysis. 
Molecular Dynamics Simulations:  
System preparation: Our simulation systems contain one Aβ42 peptide and one 
PADK molecule, ~5500 water molecules, and three Na+ ions to neutralize the system. The 
initial structure of Aβ42 is the most abundant one from the previous study by Garcia and 
coworkers21 (Figure 3.9).  PADK is initially placed ~15 Å away from the Aβ42 surface. The 
solute is immersed in a truncated octahedral box (a = b = c = ~69 Ǻ, α= β = γ = 109.47º) 
filled with water molecules. The Duan et al. all-atom point-charge force field (AMBER 
ff03)22 is used to represent the peptides. This force field has been successfully used to model 
the binding of Aβ(39–42) to Aβ40/ Aβ42 peptides19,23, the binding between Aβ 
protofibrils,24 and the binding of fluorescent dyes to Aβ protofibrils.25 The water solvent was 
explicitly represented by the TIP3P26 model. 
Binding Simulations: The AMBER 9 simulation suite27 is used in molecular 
dynamics simulations and data analysis. After an initial energy minimization, a total of four 
simulations were performed with different initial random velocities. The random velocities 
of atoms are generated according to the Maxwell-Boltzmann distribution at 500 K. A 10 ps 
run at 500 K is used to further randomize the orientations and positions of the two peptides. 
The production run (150 ns) is at 310 K, including a short, 1-ns molecular dynamics in the 
NPT ensemble mode (constant pressure and temperature) to equilibrate the solvent and 149-
ns dynamics in the NVT ensemble mode (constant volume and temperature). Periodic 
boundary conditions are imposed on the system. The particle-mesh Ewald method28 is used 
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to treat the long-range electrostatic interactions. SHAKE29 is applied to constrain all bonds 
connecting hydrogen atoms, enabling a 2-fs time step used in the dynamics. To reduce 
computation time, non-bonded forces are calculated using a two-stage RESPA approach30 
where the short-range forces within a 10 Å radius are updated every step and the long range 
forces beyond 10 Å are updated every two steps. The Langevin dynamics is used to control 
the temperature (310K) using a collision frequency of 1 ps-1. The center of mass translation 
and rotation are removed every 500 steps, which removes the “block of ice” problem.31-32  
The trajectories were saved at 10-ps intervals for analysis. In total, 64 Opteron CPU cores 
(2.3 GHz) were used for ~20 days to complete the 4 binding simulations (a cumulative MD 
time of 0.6 μs for the system). 
Clustering analysis: To gain a better understanding of the binding interactions, the 
stable complexes (atom contacts >20) are grouped into different structural families based on 
the Cα Root Mean Square Deviation (RMSD) of the complex (cutoff of 5 Å) using the 
GROMACS protocol.33 Representative structures (centroids) of the top abundant clusters 
from the combined 4 runs of each system are shown Figure 3.11.   
Collision Cross Section Calculation: The centroids of the top abundant clusters are 
also used to calculate their collision cross sections by a projected superposition 
approximation (PSA) method.34-37 To correlate better with the solvent-free experiments, 
these solution-phase structures are converted to ‘dehydrated’ structures via a 500,000-step 
energy minimization in vacuum prior to cross-section calculations. This “dehydration” 
generally reduces the overall size of the structures, while maintaining their solution 
structural features and in this paper these structures are referred to as “dehydrated solution 
structures”. 
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3.3 Results 
3.3.1 Mass spectrometry: PADK binds directly to Aβ42 monomer and small oligomers 
Mass spectra of the pure Aβ42 sample and Aβ42: PADK mixtures (1:1 and 1:10 
ratios) were recorded to probe whether PADK interacts with Aβ42 directly besides its 
positive effects on lysosomal enzyme expression and Aβ42 clearance. As shown in Figure 
3.2c, the mass spectrum of the pure Aβ42 sample shows three peaks corresponding to charge 
states of z/n = -4, -3 and -5/2, where z is the charge and n is the oligomer number. The mass 
spectrum of the 1:1 mixture of Aβ42 and PADK (Figure 3.2b) shows additional peaks tailing 
z/n = -3 and -4 Aβ42 species which correspond to Aβ42-PADK monomer complexes. Up to 
four PADK molecules are observed to bind to Aβ42 monomer. Moreover, there are two 
additional z/n = -5/2 peaks corresponding to Aβ42-PADK oligomer complexes. These 
results clearly show that PADK binds directly not only to the Aβ42 monomers but also to 
the Aβ42 oligomers. The 1:10 mixture shows even more abundant Aβ42-PADK complexes 
(Figure 3.2a). Note that the relative intensity of the z/n = -5/2 Aβ42 peak (labeled with a 
triangle) for the 1:10 mixture is significantly decreased compared to that of the pure Aβ42 
sample or 1:1 mixture, suggesting there are less z/n = -5/2 oligomers. Taken together, these 
mass spectrometry results indicate that PADK binds directly to Aβ42 monomer and 
oligomers, and inhibits the formation of Aβ42 oligomers.  
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 Figure 3.2 Mass spectra of the Aβ42 samples with and without PADK. The charge state of 
each species is labeled with z/n, where z is the charge and n is the oligomer number. The 
PADK molecule is noted with circle, the pure Aβ42 peaks are labeled with triangle and the 
Aβ42-PADK complexes are labeled with stars. 
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3.3.2 Ion mobility study: PADK modulates Aβ42 oligomer distribution 
To examine the effect of PADK on the oligomer distribution of Aβ42, the ATDs of 
the z/n = -5/2 for the Aβ42 samples with and without PADK are recorded and shown in 
Figure 3.3. As shown in Figure 3.3c, the ATD of the pure Aβ42 shows four features with 
arrival times at ~710, 660, 610 and 530 μs, which were previously assigned as Aβ42 dimer, 
tetramer, hexamer and dodecamer, respectively, based on their cross sections (See ref. 9 for 
detailed discussion of the z/n = -5/2 peak assignment). The ATDs for the 1:10 mixture and 
the 1:1 mixture of Aβ42 and PADK (Figure 3.3a and 3.3b) show only three features with 
arrival times at ~710, 660 and 610 μs, which can be assigned as Aβ42 dimer, tetramer and 
hexamer, respectively, based on their cross sections. There is no feature with lower arrival 
time, suggesting the formation of dodecamer is inhibited by PADK. Moreover, the relative 
intensity of the hexamer feature in the 1:10 mixture is significantly lower than that in the 1:1 
mixture or the pure Aβ42 sample, suggesting the formation of hexamer is inhibited by 
PADK as the PADK concentration increases.  
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 Figure 3.3 ATDs of the z/n = -5/2 peaks for Aβ42 samples with and without PADK. The 
oligomer number (n) is noted for each feature. The dashed lines represent the shape for a 
single structure.  
 
The ATD of the z/n = -5/2 peak for the 1:10 mixture was monitored on the second 
day and still shows only three features of dimer, tetramer and hexamer, while the pure Aβ42 
shows very noisy ATD containing dimer, tetramer, hexamer, decamer and dodecamer 
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(Figure 3.4). These results show that PADK effectively inhibits the formation of Aβ42 
oligomers, especially the hexamer and dodecamer formation. 
 
Figure 3.4 ATDs of the z/n = -5/2 peaks for the Aβ42 sample with and without PADK on 
the second day. The oligomer number (n) of each feature is noted. 
 
To explore the interactions of PADK with Aβ42 oligomers, the ATDs of the z/n = -
5/2 Aβ42-PADK oligomer complexes were recorded and shown in Figure 3.5. The [2 + 1] 
complex (m/z = 1884) shows only three features with arrival times at ~750, 700 and 640 μs, 
which are assigned as Aβ42 dimer, tetramer and hexamer based on their cross sections, 
suggesting there is one, two and three PADK molecules complexed with Aβ42 dimer, 
tetramer and hexamer, respectively. The signal of the [2 + 2] species (m/z = 1963) is 
relatively lower than that of [2 + 1] species, however, we managed to obtain its ATD (Figure 
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3.5b). The ATD is slightly noisy but still only shows three features corresponding to Aβ42 
dimer, tetramer and hexamer complexed with two, four and six PADK molecules, 
respectively. The results of these Aβ42 oligomer complexes indicate that PADK not only 
binds to Aβ42 monomer but also binds to Aβ42 dimer, tetramer and hexamer, and therefore 
inhibits the formation of dodecamer.  
 
Figure 3.5 The ATDs of the z/n = -5/2 peaks for Aβ42 and Aβ42 oligomer complexes 
recorded at different injection energies. The oligomer number (n) is noted for each feature. 
 
To assign the peaks in ATDs unambiguously and better understand the Aβ42 
oligomer distributions, the ATDs of the z/n = -5/2 peaks for the 1:10 mixtures were recorded 
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under different injection energies and are shown in Figure 3.6. The injection energy of the 
ions can be varied from ∼20 to ∼150 eV. At low injection energy, the ions are rapidly 
thermalized by cooling collisions with the helium gas in the drift cell and therefore large 
complexes can be preserved through the process. At high injection energy, the ions are given 
sufficient energy to lead to internal excitation which can cause isomerization into low 
energy structure or dissociation of large noncovalent complexes into smaller species. At 
lower injection energy (Figure 3.6a, top panel, IE = 40 eV), the ATD for the z/n = -5/2 Aβ42 
oligomer show a dominant tetramer, a relatively lower hexamer and a minor dimer. At high 
injection energy (Figure 3.6a, bottom panel, IE = 100 eV), the hexamer feature disappears 
while the dimer and tetramer features increase and become dominant peaks. This suggests 
the hexamer species were dissociated into smaller oligomers. Similar trend is observed for 
ATDs of [2 + 1] and [2 + 2] oligomer complexes. Through such injection energy study, we 
can unambiguously assign the three features in ATDs of the z/n = -5/2 oligomer and 
complexes for the Aβ42 and PADK mixture as dimer, tetramer and hexamer and their 
PADK complexes. Indeed PADK binds to Aβ42 small oligomers and inhibits the formation 
of dodecamer. 
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 Figure 3.6 ATDs of the z/n = -5/2 Aβ42 oligomer peaks for the 1:10 mixture of Aβ42 and 
PADK recorded under different injection energies (40 eV and 100 eV). The oligomer 
number (n) of each feature is noted. With higher injection energy, the intensity of the 
hexamer feature decreases and the dimer feature increases, suggesting the larger oligomers 
dissociated into smaller oligomer when given enough energy. 
 
3.3.3 PADK remodels Aβ42 early assembly 
To explore whether PADK is able to remodel Aβ42 oligomerization, the pure Aβ42 
sample was prepared and incubated to allow the formation of oligomers, and concentrated 
PADK was added to the sample and ATD of the z/n = -5/2 was monitored over time. As 
shown in Figure 3.7a, the ATD of the -5/2 peak for the Aβ42 samples after ~5 hours’ 
incubation on ice forms dimer, tetramer, hexamer and dodecamer. Immediately following 
the addition of 1:10 PADK, the ATD of z/n = -5/2 Aβ42 peak shows only three features of 
dimer, tetramer and hexamer, with the absence of dodecamer. This is significant and 
suggests that PADK is able to remove preformed Aβ42 dodecamers. As the incubation time 
increases, the relative intensity of the hexamer feature decreases, suggesting PADK also 
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removes preformed hexamers. These results suggest that PADK not only inhibit the 
formation of dodecamer and hexamer, but also disaggregates preformed dodecamer and 
hexamer. These results are of significance and consistent with our previously reported 
results.38  
 
 
Figure 3.7 A time-dependent study of PADK remodeling preformed Aβ42 oligomers. a-e) 
ATDs of the z/n = -5/2 peaks of for the Aβ42 sample before and after the addition of PADK. 
The oligomer number (n) is noted for each feature. 
 
3.3.4 PADK inhibits Aβ42 fibril formation 
To explore whether PADK has positive effect on Aβ42 fibril formation, the Aβ42 
samples after IMS studies were kept in a 4 °C refrigerator for two weeks and examined by 
transmission electron microscope (TEM). As shown in Figure 3.8, the Aβ42 sample without 
PADK shows long fibrils. The Aβ42 sample with 1:10 PADK presents shows almost no 
fibrils, indicating PADK inhibits fibril formation. However, the sample with 1:1 PADK still 
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shows some fibrils, indicating a low concentration of PADK does not stop the Aβ42 fibril 
formation. 
 
Figure 3.8 TEM images of Aβ42 samples without and with PADK. The scale bar is 
indicated for each image. 
 
3.3.5 Molecular dynamics simulations: Insight into the detail of PADK-Aβ42 
interactions 
To understand the binding interactions of PADK molecule with Aβ42 at an atomic level, 
all-atom molecular dynamics (MD) binding simulations were performed by constructing a 
system consisting of one PADK and one Aβ42 molecule. The most populated conformation 
of Aβ42 peptide from previous study (Figure 3.9a) was used as the initial conformation in 
our simulations to enable efficient sampling of the most important conformations.39  
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 Figure 3.9 The starting structures of Aβ42 (derived from previous study) and PADK. The 
side-chains of E22, D23 and K28 are shown (blue: positively charged, red: negatively 
charged). The α-helical, 3-10-helical, β-extended, β-bridged, turn and coiled conformations 
are colored in purple, blue, yellow, tan, cyan and white. The positively charged N-termini 
and negatively charged C-termini are indicated by blue and red balls, respectively. 
 
To visualize the overall binding, we superimposed the stable complexes (those with 
atom contacts > 20) identified from the trajectories in Figure 3.10. The widespread cloud of 
the overall protein backbones (grey) suggests Aβ42 protein in the complexes has great 
flexibility, which is expected as the Aβ42 protein is natively disordered. As shown in the 
overlapped complex structures (Figure 3.10), PADK (cyan balls) binds to multiple sites of 
Aβ42, including the C-terminal, central hydrophobic core and the N-terminal regions. This 
suggests PADK interacts with Aβ42 through multiple modes which might contribute to its 
effective inhibitory activity. 
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 Figure 3.10 Binding interactions of PADK and Aβ42: Superposition of the complexes, 
where the protein backbones are represented by the grey lines and the PADK are noted with 
the larger cyan balls. The positively charged N-termini and negatively charged C-termini are 
noted with small blue and red balls, respectively. 
 
To gain further insight into the different binding modes of PADK to Aβ42, the stable 
complexes were classified into different structure families. The centroids of the top 
structural families (>4% of the population) for the Aβ42-PADK complexes are shown in 
Figure 3.11. The collision cross section of each structure was calculated and listed together 
with the structures. The top eight structural families (Figure 3.11 A-F) comprise 83% of the 
total stable complex snapshots.  
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A  (32%, 751 Å2) B  (24%, 727 Å2) 
 
C (11%, 726 ) 
  
 
D (7%, 799 Å2) E (5%, 780 Å2) F (4%, 854 Å2) 
 
Figure 3.11 Representative structures of the Aβ42-PADK complexes from the most 
populated structural families (A-F). Only the side-chains in contact with PADK are shown 
(blue: positively charged, red: negatively charged and black: hydrophobic). The backbone of 
PADK is also in black. α-helical, 3-10-helical, β-extended, β-bridged, turn and coiled 
conformations of Aβ42 are colored in purple, blue, yellow, tan, cyan and white. The 
positively charged N-termini and negatively charged C-termini are indicated by blue and red 
balls respectively. The abundance is noted below each structure. 
 
To facilitate visualization, the 2D interaction diagrams are plotted in Figure 3.12 for 
the representative structures of the top three structural families. Several notable features are 
observed: (1) PADK molecule adopts an extended conformation, interacting fully (B) or 
partially (A and C) with the C-terminal β-strands of Aβ42. Because the C-terminal β-strands 
play a critical role in the Aβ42 oligomerization, the interaction with PADK would interrupt 
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the oligomerization and thus reduces the toxicity. (2) Intermolecular hydrogen bonds are 
formed between the backbone of PADK and Aβ42 in A and B. As shown in model A, 
PADK forms three hydrogen bonds with residues Asp2, Glu3 (2 hydrogen bonds formed) in 
the N-terminal region and one with Val40 on the C-terminal region. In structure B, PADK 
forms two hydrogen bonds with Leu34 and Val39 on the C-terminal region.  These 
intermolecular interactions suggest that PADK fully interacts with Aβ42, not only with C-
terminal but also with N-terminal region. (3) The π-π interactions are also observed in A 
(PHE 4 and HIE 6) and C (PHEs 4, 19 and 20). (4) Hydrophobic contacts are observed in A-
C.  
 
 
 
 
A (32%, 751 Å2) 
 
B (24%, 727 Å2) 
 
C (11%, 726 Å2 ) 
 
Figure 3.12 2D interaction diagrams of the Aβ42-PADK complexes from the top three 
populated structural families (Figure 3.11A-C).  The abundance and the collision cross 
section are noted. The amino acid residues of Aβ42 are noted with balls that are labeled with 
three letter and position in Aβ42 sequence, intermolecular H-bonds are indicated by purple 
arrows. HIE is neutral Histidine with hydrogen on epsilon nitrogen. 
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3.3.6 The structure of monomer complex 
The z/n = -3 Aβ42 monomer and monomer complexes were measured and the results 
are shown in Figure 3.13. The ATD of Aβ42 monomer shows two features which were 
previously assigned as a gas-phase compact conformer (M1) and a solution-like conformer 
(M2)17. The ATD of Aβ42 monomer with one PADK bound shows two similar features. By 
analog, they can be assigned as gas-phase conformer and solution-like conformer. The cross 
sections were measured and show ~7-9% increase in size after the addition of one PADK 
(Table 3.1), which suggests the binding of PADK to Aβ42 makes it more extended. The 
experimental cross section for the solution-like structure of [1+1] complex is similar to the 
theoretical values for the three populated structures from our simulation results, especially 
the most populated structure (751 Å2, Figure 3.11a). This suggests our simulation results are 
consistent with our experiment results.  
 
Figure 3.13 The ATDs of z/n = -3 monomer and complex. M1 and M2 represent two 
monomer conformers for Aβ42.  
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Table 3.1. Cross sections of z/n = -3 Aβ42-PADK complexes. The error of the cross 
sections is within 1%. 
 Charge Cross sections(σ, Å
2) 
Aβ42 -3 643 702 
Aβ42 + 1 PADK -3 688 765 
Aβ42 + 2 PADK -3 739 835 
Aβ42 + 3 PADK -3 759 879 
 
3.4 Discussion and Conclusions 
PADK has been shown to be a potent lysosomal enzyme up-regulator which results 
in enhanced Aβ clearance and offsets Aβ-induced toxicity.14 In this work, we investigate the 
direct effects of PADK on Aβ42 aggregation on molecular level and probe with theoretical 
study to understand their interactions on atomic level.  
Our mass spectrometry analysis shows that PADK binds to Aβ42 monomer and 
small oligomers (dimer, tetramer and hexamer). Up to four PADK molecules were observed 
to bind to Aβ42 monomer with relative abundant intensities, suggesting that PADK bind to 
Aβ42 with relatively high affinity. Moreover, two z/n = -5/2 oligomer complex peaks were 
observed, indicating PADK not only binds to Aβ42 monomer but also binds to Aβ42 small 
oligomers. Notably, the relative intensity of the z/n = -5/2 peak is significantly lower in the 
1:10 mixture of Aβ42 and PADK than that in the pure Aβ42 sample or the 1:1 mixture, 
suggesting that the oligomer formation is inhibited by PADK and the inhibitory ability of 
PADK increases as the concentration increases.  
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 Notably, our ion mobility study of the z/n = -5/2 peak for the Aβ42 samples with 
PADK presence only shows dimer, tetramer and hexamer, with the absence of dodecamer, 
indicating that PADK inhibits the formation of dodecamer. In addition, the intensity of the 
hexamer is lowered in the 1:10 mixture, suggesting that PADK also partially inhibits the 
formation of hexamer. The ATDs of the z/n = -5/2 oligomer complexes show only dimer, 
tetramer and hexamer, suggesting PADK also binds to Aβ42 small oligomers and thereby 
inhibits the dodecamer formation. Our ion mobility studies also show that PADK is able to 
completely dissociate preformed Aβ42 dodecamers. Moreover, the relative intensity of the 
hexamer decreases over time of incubation, suggesting PADK is also able to dissociate 
preformed hexamers slowly over time and reverse the aggregation equilibrium toward 
smaller oligomers. These results are of significance and consistent with the previous study 
that showed PADK has positive effect in reducing the Aβ42 level in the brain of the 
transgenic AD mouse model, which in turn offset the cognitive deficit. Our study suggests 
that these positive effects of PADK in AD do not only result from the important role of 
PADK as a lysosomal enzyme up-regulator, but also result from the direct interactions of 
PADK with Aβ42 molecules modulating its aggregation.  
 Our all-atom MD simulation study showed that PADK binds to Aβ42 on several 
regions, including the C-terminal, N-terminal and Central regions. The C-terminal region of 
Aβ42 has been shown to be critical for Aβ assembly and aggregation. Therefore to disrupt 
the conformation of the region and alter Aβ42 assembly is a promising strategy. The most 
populated structure families obtained from MD simulations show that PADK adopts an 
extended conformation which fully interacts with the C-terminal β-strand of Aβ42. 
Moreover, PADK also forms intermolecular hydrogen bonds with the residues on the C-
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terminal region, suggesting the interactions in the C-terminal regions are of significance for 
PADK’s inhibitory activity. It is very likely that PADK disrupts the structure of the C-
terminal region and thereby disrupts Aβ42 assembly and aggregation.  
 Aromatic interactions have been shown to play an important role in the binding 
interactions of Aβ protein and its inhibitors12. We expected such interactions to be important 
for PADK’s inhibitory activity because it contains two aromatic groups. Our MD simulation 
results suggest that PADK interacts with the aromatic residues in Aβ42 through π-π 
interactions. Such interactions are notable in the N-terminal and central regions, PHE 4 and 
HIE 6 in structure A and PHEs 4, 19 and 20 in structure C (Figure 3.12), which are expected 
as these regions contain a high content of aromatic residues. Hydrophobic interactions are 
observed through the most populated structures, suggesting they are important for PADK 
interacting with Aβ42. Taken together, our MD simulations suggest that PADK interacts 
with Aβ42 through multiple modes on multiple sites which disrupt Aβ42 folding and 
assembly and thereby inhibits the formation of toxic oligomers. 
 Overall, our ion mobility studies reveal the direct positive effects of PADK on Aβ42 
oligomerization and MD simulations suggest multiple interaction modes contribute to the 
structure-function relationship for PADK’s inhibitory activity. This study provides an 
example of PADK as an effective small molecule inhibitor for Aβ42 aggregation and 
toxicity and sheds lights on the further development of small molecule therapeutic discovery. 
This study also demonstrated that ion mobility spectrometry combined with theoretical 
simulations has become a powerful tool in the discovery and understanding of small 
molecule inhibitors for Aβ and AD treatment.  
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Chapter 4 
Mechanism of C-Terminal Fragments of Amyloid β-Protein as 
Effective Aβ Inhibitors: Do C-Terminal Interactions Play a Key 
Role in Their Inhibitory Activity? 
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4.1 Introduction 
Short peptides derived from Aβ sequence itself, and their derivatives have been 
shown to disrupt Aβ assembly and inhibit its toxicity.1-2 The C-terminal region of Aβ42, 
which is highly hydrophobic, has been shown to play an important role in controlling Aβ 
structure stability and self-assembly.3-4 Thus researchers hypothesized that peptides derived 
from the C-terminus of Aβ42 can serve as Aβ inhibitors as they may interact with C-
terminal hydrophobic region of Aβ and be coassembled into Aβ42 oligomers, and thereby 
disrupt their structures and inhibit their toxicity.5 Indeed this C-terminal interaction 
hypothesis has leaded to the discovery of several effective C-terminal fragment (CTF) 
inhibitors for Aβ42 neurotoxicity, including peptides ranging from Aβ(29-42) to Aβ(39-
42).5  
Aβ(39-42), the shortest peptide studied, was shown to modulate Aβ oligomerization 
and inhibit Aβ neurotoxicity.6-7 It is particularly interesting because it is a small molecule 
which can easily penetrate into the membrane barriers. Thus it is very important to 
understand the mechanism of its inhibitory activity for its future drug development and other 
peptidomimetics based drug discovery. Previous theoretical study showed that Aβ(39-42) 
binds to several regions of Aβ42, including the N-terminal, central hydrophobic core and the 
C-terminal regions.6 However, interaction with which region is the key for its inhibition 
activity remains unclear. To better understand the mechanism of action for Aβ(39-42), two 
terminal modified Aβ(39-42) analogs, N-terminal acetylated Ac-VVIA and C-terminal 
amidated VVIA-NH2, were designed to test the charge effect on the interactions of Aβ(39-
42) and Aβ42. Previous studies have shown that modifications at the terminus has very 
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different effects on Aβ toxicity: VVIA-NH2 inhibits Aβ-induced toxicity while Ac-VVIA 
does not.7  
Here, ion mobility spectrometry coupled mass spectrometry (IMS-MS) and all-atom 
molecular dynamics (MD) simulations were used to investigate the interactions between 
these two Aβ(39-42) analogs and the full length Aβ42. This study provides an example of 
ion mobility spectrometry combined with theoretical modeling as a powerful tool to 
understand the mechanism of Aβ C-terminal fragments as small molecule inhibitors for Aβ 
assembly and sheds light on the future peptidomimetics based therapeutic strategy for AD 
and other diseases.  
4.2 Experimental Procedures 
Peptides and Sample Preparation:  
Full-length Aβ42 was synthesized by N-9-fluorenylmethoxycarbonyl (FMOC) 
chemistry.8 Aβ(39-42) derivatives were prepared using a microwave-assisted peptide 
synthesizer as described previously7. The peptides were purified by reverse-phase HPLC 
and their integrity validated by mass spectrometry and amino acid analysis.  
Ion Mobility Spectrometry-Mass Spectrometry (IMS-MS):  
Lyophilized Aβ42 protein was dissolved in 10 mM ammonium acetate buffer (pH 
7.4) with a final protein concentration of 10 μM. Mass spectrometry and ion mobility 
measurements were performed on a home-built nanoESI instrument, which has been 
described in Chapter 2.3.  
Transmission Electron Microscopy (TEM): 
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Microscopic analysis was performed by using a FEI T-20 transmission electron 
microscope under 200 kV. The Aβ42 samples were prepared under the same procedure as 
that for mass spectrometry analysis. The samples were kept in refrigerator (~4 °C) for 2 
weeks. For TEM measurements, 10 µL aliquots of samples were spotted on glow-
discharged, carbon-coated copper grids (Ted Pella, Inc). The samples on grids were stained 
with 10 mM sodium metatungstate aqueous solution for 10 min and gently rinsed twice with 
DI-water. The sample grids were then dried in room temperature before TEM analysis. 
Molecular Dynamics Simulations: 
System preparation: Our simulation systems contain one Aβ42 peptide and one 
Aβ(39-42) derivative (VVIA-NH2 or Ac-VVIA), ~8000 water molecules, and several Na+ 
ions to neutralize the system. The initial peptide structures are the most abundant one from 
the previous study by Garcia and coworkers3 for Aβ42, and from our own previous study9 
for Aβ(39–42).  The Aβ(39-42) derivative is initially placed ~15 Å away from the Aβ42 
surface. The solute is immersed in a truncated octahedral box (a = b = c = ~69 Å, α= β = γ = 
109.47º) filled with water molecules. The Duan et al. all-atom point-charge force field 
(AMBER ff03)10 is used to represent the peptides. This force field has been successfully 
used to model the binding of Aβ(39–42) to Aβ40/ Aβ42 peptides6-7, the binding between Aβ 
protofibrils,11 and the binding of fluorescent dyes to Aβ protofibrils.12 The water solvent was 
explicitly represented by the TIP3P13 model. 
Binding Simulations: The AMBER 9 simulation suite14 is used in molecular 
dynamics simulations and data analysis. After an initial energy minimization, a total of eight 
simulations (four runs for each system) were performed with different initial random 
velocities. The random velocities of atoms are generated according to the Maxwell-
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Boltzmann distribution at 500 K. A 10 ps run at 500 K is used to further randomize the 
orientations and positions of the two peptides. The production run (150 ns) is at 310 K, 
including a short, 1-ns molecular dynamics in the NPT ensemble mode (constant pressure 
and temperature) to equilibrate the solvent and 149-ns dynamics in the NVT ensemble mode 
(constant volume and temperature). Periodic boundary conditions are imposed on the system. 
The particle-mesh Ewald method15 is used to treat the long-range electrostatic interactions. 
SHAKE16 is applied to constrain all bonds connecting hydrogen atoms, enabling a 2-fs time 
step used in the dynamics. To reduce computation time, non-bonded forces are calculated 
using a two-stage RESPA approach17 where the short-range forces within a 10 Å radius are 
updated every step and the long range forces beyond 10 Å are updated every two steps. The 
Langevin dynamics is used to control the temperature (310K) using a collision frequency of 
1 ps-1. The center of mass translation and rotation are removed every 500 steps, which 
removes the “block of ice” problem.18-19  The trajectories were saved at 10-ps intervals for 
analysis. In total, 128 Opteron CPU cores (2.3 GHz) were used for ~50 days to complete the 
8 binding simulations (a cumulative MD time of 1.2 μs for the two systems). 
Clustering analysis: To gain a better understanding of the binding interactions, the 
stable complexes (atom contacts >20) are grouped into different structural families based on 
the Cα Root Mean Square Deviation (RMSD) of the complex (cutoff of 5 Å) using the 
GROMACS protocol.20 Representative structures (centroids) of the top abundant clusters 
from the combined 4 runs of each system are shown in the Figures 4.8-4.9.   
Collision Cross Section Calculation: The centroids of the top abundant clusters are 
also used to calculate their collision cross sections by a projected superposition 
approximation (PSA) method.21-24 To correlate better with the solvent-free experiments, 
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these solution-phase structures are converted to ‘dehydrated’ structures via a 500,000-step 
energy minimization in vacuum prior to cross-section calculations. This “dehydration” 
generally reduces the overall size of the structures, while maintaining their solution 
structural features and in this paper these structures are referred to as “dehydrated solution 
structures”. 
4.3 Results 
4.3.1 Mass spectrometry: VVIA-NH2 binds directly to Aβ42 monomer and oligomers 
The mass spectra of Aβ42 samples with and without VVIA analogs were recorded 
and shown in Figure 4.1a-c. The mass spectrum of Aβ42 sample without VVIA analogs 
shows three peaks corresponding to the z/n = -4, -3, -5/2 charge states, where z is charge and 
n is oligomer number. In the mass spectrum of a 1:5 mixture of Aβ42 and VVIA-NH2 
(Figure 4.1a), there are more peaks in addition to the three Aβ42 peaks. These peaks 
correspond to z/n = -4 and -3 complexes of Aβ42 with one and two VVIA-NH2 molecules 
bound (labeled with stars). Moreover, there is a peak tailing the z/n = -5/2 Aβ42 peak which 
corresponds to -5/2 complex of Aβ42 oligomers with VVIA-NH2 molecules bound. This 
indicates VVIA-NH2 binds directly not only to Aβ42 monomer but also to Aβ42 oligomers. 
The mass spectrum of a 1:5 mixture of Aβ42 and Ac-VVIA (Figure 4.1b) shows only one 
additional monomer complex peak, suggesting only one Ac-VVIA binds directly to Aβ42 
monomer. These results suggest that VVIA-NH2 binds directly to Aβ42 with relatively 
higher affinity than Ac-VVIA to Aβ42. 
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 Figure 4.1 a-c) Mass spectra of Aβ42 samples with and without CTF molecules. The charge 
states of each species are labeled with z/n, where z is charge and n is oligomer number. The 
Aβ42 peaks are denoted with rectangle, CTF molecules are denoted with circles and the 
complexes of Aβ42 with CTF molecules are denoted with stars.  
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4.3.2 Ion mobility studies: VVIA-NH2 and Ac-VVIA modulate the early assembly of 
Aβ42 
To probe the effects of the two VVIA analogs on the early oligomer formation of 
Aβ42, an ion mobility study was performed and the results are shown in Figure 4.2. The 
ATD of the -5/2 peak for Aβ42 alone (Figure 4.2c) shows four features with arrival times at 
~710, 680, 610 and 540 μs, which were previously assigned as Aβ42 dimer, tetramer, 
hexamer and dodecamer, respectively, based on their cross sections (see ref. 8 for a detailed 
discussion of -5/2 ATD assignment). The dodecamer was previously identified as a 
proximate toxic agent for AD pathology.25-26 The ATD of the -5/2 peak for the Aβ42 sample 
with VVIA-NH2 (1:5 ratio, Figure 4.2a) shows only three features with arrival times at ~720, 
680, and 620 μs, which can be assigned as dimer, tetramer and hexamer, respectively, based 
on their cross sections. There is no feature with shorter arrival times, indicating there is no 
dodecamer or other larger oligomer formed with the presence of VVIA-NH2. The ATD of 
the -5/2 peak for the Aβ42 and Ac-VVIA mixture (1:5 ratio, Figure 4.2b) shows three 
similar features corresponding to dimer, tetramer and hexamer, suggesting AC-VVIA also 
inhibits the formation of Aβ42 dodecamer. 
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 Figure 4.2 a-c) ATDs of the z/n = -5/2 peak for Aβ42 samples with and without CTF 
molecules. The oligomer number (n) is noted for each feature. The dashed lines represent 
the shape for a single structure favored in the ATD. 
 
As shown in Figure 4.1a, an additional z/n = -5/2 oligomer complex peak was 
observed for the mixture of Aβ42 and VVIA-NH2, therefore its ATD was also recorded to 
better understand the effect of VVIA-NH2 on the Aβ42 oligomer distribution and the result 
is shown in Figure 4.3. The ATD shows three features with arrival times at ~750, 710 and 
640 μs, which can be assigned as dimer, tetramer and hexamer complexes, respectively, 
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based on their cross sections. This is of significance and suggests there are one, two and 
three VVIA-NH2 molecules binding to Aβ42 dimer, tetramer and Aβ42 hexamers, 
respectively, which is not observed for the sample with Ac-VVIA.  
 
Figure 4.3 ATD of the z/n = -5/2 complex peak for Aβ42 sample with VVIA-NH2. The 
oligomer number (n) is noted for each feature. 
 
Taken together, these mass spectrometry and ion mobility results suggest that VVIA-
NH2 and Ac-VVIA both bind directly to Aβ42 directly and modulate the dodecamer 
formation. However, VVIA-NH2 binds directly not only to Aβ42 monomer but also to Aβ42 
small oligomers (dimers, tetramers and hexamers), while Ac-VVIA only binds to Aβ42 
monomer. These results of VVIA-NH2 are similar to previous results of wild type VVIA 
that it bound to Aβ42 monomer and small oligomers and modulated dodecamer formation.6 
This is of significance and supports the fact that both wild type VVIA and VVIA-NH2 
inhibit the Aβ42-induced toxicity whereas Ac-VVIA does not inhibit Aβ42 toxicity.6-7  
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 4.3.3 Disaggregation of preformed Aβ42 dodecamer by VVIA analogs 
To test whether these VVIA analogs can disaggregate preformed Aβ42 oligomers, 
concentrated VVIA-NH2 or Ac-VVIA was added to pre-aggregated Aβ42 sample and the 
ATDs of the z/n = -5/2 Aβ42 were recorded during different time periods. As shown in 
Figure 4.4a, after ~5 hours’ incubation, the wild type Aβ42 forms dimer, tetramer, hexamer 
and dodecamer. Immediately after the addition of VVIA-NH2, the ATD of z/n = -5/2 Aβ42 
(Figure 4.4b) shows only three features corresponding to dimer, tetramer and hexamer, with 
the absence of dodecamer feature. The disappearance of dodecamer suggests that VVIA-
NH2 is able to disassociate preformed dodecamer. The ATD of the -5/2 peak for the Aβ42 
sample with the addition of Ac-VVIA (Figure 4.4e) also shows only dimer, tetramer and 
hexamer. However, the Aβ42 sample with Ac-VVIA shows a noisy and broader ATD than 
that of VVIA-NH2 sample, which suggests that there may be more families of oligomer 
structures for the Aβ42 sample with Ac-VVIA. This is important and consistent with 
observation that the Aβ42 sample with the addition of Ac-VVIA is more difficult to work 
with. The sample with Ac-VVIA addition becomes difficult to spray and the signal-to-noise 
of the z/n = -5/2 ATD decreases over time. After three hours, it became impossible to get the 
sample with Ac-VVIA to spray and no data was able to be collected any more. In contrast, 
the Aβ42 sample with the addition of VVIA-NH2 works smoothly during the whole 
experiment time, even after several days.  
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 Figure 4.4 A time-dependent study of disaggregation of preformed Aβ42 oligomers by 
VVIA derivatives. a) ATD of the z/n = -5/2 peak for Aβ42 sample which was preincubated 
on ice for five hours. b-d) ATDs for the z/n = -5/2 peak for Aβ42 sample after the addition 
of VVIA-NH2 and recorded at 10 min, 2 hr and after 1 day. e-g) ATDs of the z/n = -5/2 peak 
for Aβ42 sample after the addition of Ac-VVIA and recorded at 10 minutes, 2 hours and 3 
hours. The oligomer number is noted for each feature in the ATDs.  
 
The ATD of the -5/2 peak recorded on the 2nd day (Figure 4.4d) still shows only 
dimer, tetramer and hexamer. These results and observation suggest that VVIA-NH2 can not 
only inhibit the formation of Aβ42 dodecamer but also remove the pre-formed dodecamer. 
On the other hand, Ac-VVIA which appears to inhibit dodecamer formation, may actually 
lead to formation of other larger oligomers or aggregates which clogged the spray tips. 
These results are consistent with the previous studies showing that VVIA-NH2 was an 
effective Aβ42 inhibitor whereas Ac-VVIA was not.7 
4.3.4 VVIA-NH2 and Ac-VVIA do not inhibit Aβ42 fibril formation 
The wild type VVIA was previously shown to modulate the Aβ42 oligomer 
formation but did not to inhibit the Aβ42 fibril formation. In this work, the effects of VVIA-
NH2 and Ac-VVIA on fibril formation were examined by TEM and the results are shown in 
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Figure 4.5. After two weeks’ incubation at 4 °C, the Aβ42 samples form abundant long 
fibrils, regardless of the presence of VVIA-NH2 or Ac-VVIA molecules. This suggests that 
neither VVIA-NH2 nor Ac-VVIA inhibits Aβ42 fibril formation, which is similar to that of 
the wild type VVIA. 
 
Figure 4.5 a-c) TEM images for Aβ42 samples without and with VVIA derivatives. The 
scale bar is 200 nm.  
 
4.3.5 Modeling the interactions of Aβ42 with VVIA-NH2 or Ac-VVIA 
To probe the interaction of these two VVIA analogs with the full-length Aβ42 at an 
atomic level, a system consisting of one Aβ42 and one VVIA-NH2 or Ac-VVIA molecule 
was constructed for all-atom molecular dynamics (MD) simulations. The most populated 
conformation of Aβ42 protein from previous study3 was used as the initial conformation in 
our simulations, which enables efficiently sampling of the most important conformations 
(Figure 4.6).  
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Figure 4.6 The starting structures of Aβ42 and modified Aβ(39-42)s, as derived from 
previous studies. The side-chains of E22, D23 and K28 are shown (blue: positively charged, 
red: negatively charged). The α-helical, 3-10-helical, β-extended, β-bridged, turn and coiled 
conformations are colored in purple, blue, yellow, tan, cyan and white. The N-termini and 
C-termini of the peptide are indicated by blue and red balls, respectively. 
 
The overall binding was revealed by superimposing the most stable complexes 
identified from the trajectories and shown in Figure 4.7 (A-B). Aβ42 protein in both 
complexes shows great flexibility as indicated by the widespread cloud of the overall 
peptide backbones (grey), which is expected as Aβ42 is a natively disordered peptide. 
However, the binding of VVIA-NH2 to Aβ42 is more specific than that of Ac-VVIA. As 
shown in Figure 4.7A, the VVIA-NH2 molecules bind exclusively to only one specific 
region of Aβ42, the hydrophobic C-terminal region. The representative structure of the most 
populated structural family (57% of total population) from our clustering analysis shows that 
VVIA-NH2 binds to the edge of the C-terminal β-hairpin (Figure 4.8A). On the other hand, 
Ac-VVIA molecules are observed to bind to several regions of Aβ42, including the C-
terminal, central hydrophobic core and the N-terminal regions (Figure 4.7B and Figure 4.9). 
Clearly, the binding of Ac-VVIA to Aβ42 is more disperse and the most populated structural 
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family only contains 28% of total population (Figure 4.9A). Moreover, the Aβ42-VVIA-
NH2 complexes appear to be more rigid which display a uniform conformation. Whereas the 
Aβ42-Ac-VVIA complexes show more flexible and extended structures with slightly larger 
collision cross section.  
 
 
 
A) Aβ42 + VVIA-NH2 
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 Figure 4.7 Interactions of Aβ42 with VVIA-NH2 (A) or Ac-VVIA (B). The N-termini and 
C-termini are indicated by blue and red balls respectively. A-B): Superposition of the 
complexes where the protein backbones are represented by the grey lines and the VVIA 
derivatives are noted with the larger cyan balls.  
 
 
 
 
 
B) Aβ42 + Ac-VVIA 
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A (57%, 750 Å2) 
 
B (10%, 768 Å2) 
  
 
 
C (5%, 782 Å2 ) 
 
 
Figure 4.8 Representative structures for complex (Aβ42 + VVIA-NH2) of the most 
populated structural families from the clustering analysis. The abundance and collision cross 
section are noted. Only the side-chains in contact with VVIA-NH2 are shown (blue: positive 
charged, red: negative charged, black: hydrophobic and green: hydrophilic). 3-10- helical, β-
extended, turn and coiled conformation are colored in blue, yellow, cyan and white. N-
termini and C-termini of peptides are indicated by blue and red balls respectively. 
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A  (28%, 759 Å2 ) 
 
      B (25%, 774 Å2 ) 
 
 
C (15%, 784 Å2)  
 
Figure 4.9 Representative structures for complex (Aβ42 + Ac-VVIA ) of the most populated 
structural families from the clustering analysis. The abundance and collision cross section 
are noted. Only the side-chains in contact with Ac-VVIA are shown (blue: positive charged, 
red: negative charged, black: hydrophobic and green: hydrophilic). 3-10-helical, β-extended, 
turn and coiled conformation are colored in blue, yellow, cyan and white. N-termini and C-
termini are indicated by blue and red balls respectively. 
 
The wild type VVIA was previously shown to bind to Aβ42 at several regions, 
including the C-terminal, central hydrophobic core and the N-terminal regions.6 Here our 
binding simulations of VVIA derivatives reveal significant differences in their binding 
 
 
85 
interactions with Aβ42. While the binding of Ac-VVIA to the C-terminal part of Aβ42 is 
slightly reduced in comparison to that of the wide type VVIA,6 the binding of VVIA-NH2 to 
the C-terminal part of Aβ42 is significantly increased. The electrostatic interaction might 
contribute to these changes, because while the negatively charged C-terminal of Ac-VVIA is 
repulsive to the negatively charged C-terminal of Aβ42, the positively charged N-terminal of 
VV-NH2 is attracted to the negatively charged C-terminal of Aβ42. The correlation of 
VVIA-NH2 inhibiting Aβ42 oligomerization and toxicity and VVIA-NH2 binding 
specifically to C-terminal hydrophobic region of Aβ42 implies the important role of C-
terminal region in Aβ42 structure stability, assembly, toxicity and its inhibition by C-
terminal fragments.  
4.3.6 Aβ42 monomer complexes 
The z/n = -3 Aβ42 monomer and monomer complexes for Aβ42 and VVIA analogs 
were recorded and the results are shown in Figure 4.10 and Table 4.1. The ATD of Aβ42 
monomer shows two features which were previously assigned as a gas-phase compact 
conformer (M1) and a solution-like conformer (M2).27 The ATD of Aβ42 monomer with one 
VVIA-NH2 or Ac-VVIA bound shows two similar features. By analog, they can be assigned 
as a gas-phase-like conformer and a solution-like conformer. The cross sections were 
measured and show ~5-6% increase in size after the addition of one VVIA analog (Table 
4.1), which suggests the binding of VVIA analogs causes conformation changes in Aβ42. 
The experimental cross section for the solution-like structure is similar to the theoretical 
values for the most populated structure (Table 4.1).  
 
 
 
86 
 Figure 4.10 The ATDs of z/n = -3 monomer and complex. M1 and M2 represent two 
monomer conformers for Aβ42.  
 
Table 4.1 Experimental and theoretical cross sections of z/n = -3 Aβ42 monomer and 
complexes. The error of the experimental cross sections is within 1%. 
Species Aβ42 + 1 VVIA-NH2 + 1 Ac-VVIA 
 M1 M2 M1 M2 M1 M2 
Experimental Cross Section (Å2) 631 707 668 748 670 742 
PSA cross section (Å2)    750
a  759b 
a) from Figure 4.8A; b) from Figure 4.9 
 
 
87 
4.4 Discussion and conclusions 
Several C-terminal fragments of Aβ42, especially Aβ(39-42), have been shown to be 
effective inhibitors for Aβ early assembly and toxicity.5-7 It is critical to understand the 
mechanism of their inhibitory activity for further therapeutic development. Previous study 
have shown that wild type Aβ(39-42) modulates Aβ oligomerization but not fibril formation, 
and it binds to multiple sites on Aβ42, including the C-terminal, central hydrophobic core 
and the N-terminal regions.6 However, it is unclear which region is most important for the 
Aβ: CTF interaction and the toxicity inhibition. Here, the interactions of two modified 
Aβ(39-42) molecules, C-amidated VVIA-NH2 and N-acetylated Ac-VVIA, were 
investigated to better understand the mechanism of Aβ(39-42) inhibiting Aβ42 aggregation 
and toxicity. Previous study has shown that VVIA-NH2 inhibits Aβ toxicity while Ac-VVIA 
does not.7 Our mass spectrometry and ion mobility studies reveal that VVIA-NH2 and Ac-
VVIA have different effects on the Aβ42 early assembly. VVIA-NH2 binds directly not only 
to Aβ42 monomer (up to two VVIA-NH2 molecules bound to Aβ42 monomer were 
observed) but also to Aβ42 small oligomers (dimers, tetramers and hexamers). Consequently 
VVIA-NH2 inhibits dodecamer formation and removes preformed dodecamers. On the other 
hand, only one Ac-VVIA molecule bound directly to Aβ42 monomer was observed. Ac-
VVIA appears to modulate the dodecamer formation. However, the Aβ42 sample with 
addition of Ac-VVIA shows broader ATDs indicating a more complicated structure and 
oligomer distribution. Moreover the sample with Ac-VVIA clogged the nanospray tip easily 
and completely stopped working after three hours’ incubation, indicating there are large 
aggregates formed in the solution, which are possibly formed through other pathways that 
bypass dodecamer formation. These subtle differences reveal the different binding effects of 
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VVIA-NH2 and Ac-VVIA to Aβ42 and are consistent with their different effects in 
inhibiting Aβ42 toxicity (A summary of Aβ42 aggregation without and with VVIA analogs 
are given in Figure 4.11). 
 
Figure 4.11 Aggregation mechanism of Aβ42 in the absence or presence of VVIA-NH2 or 
Ac-VVIA. Wild type Aβ42 usually forms soluble toxic oligomers before self-assembling 
into large aggregates and fibrils. VVIA-NH2 binds directly to Aβ42 monomer and small 
oligomers (dimer, tetramer and hexamer), inhibiting the formation of dodecamer and driving 
the formation of nontoxic oligomers that eventually form fibrils. Ac-VVIA binds only to 
Aβ42 monomer, inhibiting the formation of dodecamer, however, Ac-VVIA may lead to 
other pathway without dodecamer and form other toxic oligomers or aggregates which 
eventually form fibrils. 
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Our MD binding simulations show significantly different binding interactions for 
VVIA-NH2 and Ac-VVIA with Aβ42. Ac-VVIA binds dispersedly to Aβ42 at multiple sites, 
including the C-terminal, central region and the N-terminal regions. In contrast, VVIA-NH2, 
the effective Aβ42 inhibitor, binds specifically to only the C-terminal β-hairpin region of 
Aβ42. This is of significance and implies that the interaction at the C-terminal region, rather 
than at other regions, is the key for the inhibition activity of Aβ(39-42).  
The C-terminal hydrophobic region of Aβ42 has been considered to play an 
important role in the structure stability and oligomerization of Aβ42.28 Previous studies of 
prefibrillar Aβ42 showed that Ile41 and Ala42 residues stabilize the C-terminal turn 
conformation which results in a more rigid C-terminus for Aβ42 than Aβ40.3 The increased 
conformation stability of C-terminus is correlated with the formation of more toxic 
oligomers in Aβ42, which explains how the difference of only two residues between Aβ40 
and Aβ42 can significantly change the toxicity and aggregation properties of Aβ proteins.3 
These C-terminal hydrophobic residues in Aβ42 have been considered to be the driving 
force for protein folding and self-assembly, and stabilize neurotoxic low-order oligomers.4 
Therefore the hypothesis that peptides derived from the C-terminus of Aβ42 may be 
coassembled into Aβ42 monomer and oligomers, and disrupt their structures and thereby 
inhibit their toxicity, led to the successful discovery of effective C-terminal fragment 
inhibitors.5 However, recent studies using intrinsic tyrosine fluorescence and NMR methods 
suggested that Aβ(39-42) might primarily interact with the N-terminus of Aβ42.7 Our earlier 
simulations on the binding of Aβ(39-42) to Aβ42 corroborated this picture, with Aβ(39-42) 
observed to bind to multiple sites of Aβ42. These regions included the C-terminal, central 
hydrophobic core and the N-terminal regions.6 These studies were intriguing, because they 
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did not seem in line with the original hypothesis that the C-terminal peptide inhibitors would 
specifically target the C-terminus of Aβ42. The peptide inhibitor, VVIA-NH2, binds 
specifically to the C-terminus of Aβ42 monomers and oligomers resulting in effective 
inhibition of Aβ42 toxicity. However VVIA is also an effective inhibitor of toxicity and an 
indiscriminate binder to Aβ42 so C-terminal binding cannot be the exclusive determining 
factor. What VVIA and VVIA-NH2 have in common is strong binding to both monomers 
and oligomers of Aβ42 whereas Ac-VVIA binds more weakly to Aβ42 monomer and not at 
all to its oligomers. Thus, binding to Aβ42 oligomers appears to be crucial for inhibition of 
toxicity, but more research is needed to fully understand the mechanism at play. 
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Chapter 5 
Amyloid β-protein Assembly: The Effect of 
Molecular Tweezer CLR01 and CLR03 
 
 
 
 
 
 
 
This chapter is reproduced with the permission from: 
X. Zheng, D. Liu, F.-G. Klärner, T. Schrader, G. Bitan, M. T. Bowers, “Amyloid β-protein 
Assembly: The Effect of Molecular Tweezer CLR01 and CLR03”, Journal of Physical 
Chemistry B 2015, 119 (14), 4831–4841, Copyright © 2015 American Chemical Society. 
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5.1 Introduction 
Molecular tweezers (MTs), which possess a torus-shaped cavity with a surrounding 
belt of alternating aromatic and aliphatic rings, were designed to serve as host molecules 
binding specifically to lysine and to a lesser extent to arginine residues.1-3 MTs were 
previously shown to be modulators of the aggregation of Aβ and other amyloidogenic 
proteins and effective inhibitors of the toxicity of these proteins.4 A lead MT derivative, 
CLR01 (Figure 5.1a), was shown to inhibit the toxicity of multiple amyloidogenic proteins 
in cell viability assays using cell lines and primary cell cultures4-7 and protected synaptic 
integrity and function of hippocampal and cortical neurons against the synaptotoxicity of 
Aβ42.6 In addition, peripheral administration of CLR01 in transgenic mice led to a decrease 
in amyloid plaques, neurofibrillary tangles, and brain inflammation, suggesting that it is a 
promising candidate for therapeutic development.6 
 
Figure 5.1 Molecular structures of (a) CLR01 and (b) CLR03. 
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Mechanistic investigation showed that disruption of Aβ self-assembly is mediated by 
CLR01 binding to the two lysine and the single arginine residues in Aβ.4 Dynamic light 
scattering (DLS) and electron microscopy (EM) experiments suggested that CLR01 does not 
prevent oligomer formation, but rather modulates Aβ self-assembly into formation of 
structures that are neither amyloidogenic nor toxic.4 Interestingly, by the relatively low 
resolution of DLS and EM, these structures were similar in size to the toxic and 
amyloidogenic oligomers of Aβ alone, suggesting that subtle conformational changes in Aβ 
might account for the apparent loss of amyloidogenic potential and toxic activity. However, 
the low-resolution methods could not provide information about what these changes might 
be. In addition, whether CLR01 binds Aβ monomers, oligomers, and/or larger aggregates 
has not been demonstrated directly.  
In several previous studies, a derivative called CLR03 (Figure 5.1b) was used as a 
negative control.4,6 This compound shares the polar bridgehead structure with CLR01 but 
lacks the hydrophobic arms, and therefore is not expected to bind specifically to lysine or 
arginine. Consequently, CLR03 indeed acted as a negative control and was not found to 
inhibit the aggregation and/or toxicity of amyloidogenic proteins. Nonetheless, how CLR03 
interacts with Aβ and whether it has any effect on early Aβ oligomerization of Aβ remains 
to be uncovered. 
To address all these questions, here we used ion mobility spectrometry coupled to 
mass spectrometry (IMS-MS)8-9 to investigate the effect of CLR01 and CLR03 on Aβ 
assembly.  
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5.2 Experimental Methods 
Peptide and Sample preparation: Full-length Aβ40 and Aβ42 were synthesized by 
N-9-fluorenylmethoxycarbonyl (FMOC) chemistry. The peptides were purified by reverse-
phase HPLC and their integrity validated by mass spectrometry and amino acid analysis as 
described previously.10 The samples were prepared in 10 mM ammonium acetate and the pH 
was adjusted to 7.4. Samples contained 10 µM Aβ42 and molecular tweezers at different 
concentration ratios. An Aβ42 sample without MTs was prepared under the same procedure 
as a positive control.  
Mass Spectrometry and Ion Mobility spectrometry Analysis: Samples were 
analyzed on a home-built ion mobility spectrometry-mass spectrometer8 described in 
Chapter 2.  
 
5.3 Results 
5.3.1 MS reveals different binding effects of CLR01 and CLR03 on Aβ42 
Mass spectra of Aβ42 samples in the absence or presence of MTs are shown in 
Figure 5.2. In the mass spectrum of Aβ42 alone (Figure 5.2c), there are four peaks, which 
correspond to Aβ42 species with charge states z/n = -4, -3, -5/2 and -2 (where z represents 
charge and n represents oligomer order), respectively, as described previously.11-12 In the 
mass spectrum of a 1:10 mixture of Aβ42 and CLR01 (Figure 5.2a), there are three sets of 
peaks which correspond to -4, -5 and -6 charge states of the complexes of Aβ42 with one, 
two, three, or four CLR01 molecules bound. As the mass spectrometry study was conducted 
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in negative ion mode, the binding form of CLR01 is with loss of sodium ions, which results 
in producing Aβ42 and CLR01 complexes with higher charge states. Note that no -5/2 Aβ42 
peak (m/z = 1805), which represents dimer or higher order oligomers, is observed.  This 
indicates that CLR01 disrupts the formation of Aβ42 dimers and higher order oligomers. No 
peaks of uncomplexed Aβ42 are observed in the mass spectrum, suggesting that CLR01 
binds to Aβ42 directly with high affinity and there are no CLR01-free Aβ42 species present 
in solution. 
In contrast, the spectrum of a 1:10 mixture of Aβ42 and CLR03 (Figure 5.2b) shows 
four peaks corresponding to the -4, -3, -5/2 and -2 Aβ42 species, similarly to Aβ42 alone 
(Figure 5.2c). There are two additional small peaks tailing the -3 and -4 Aβ42 peaks 
corresponding to the -3 and -4 complex species of Aβ42 with one CLR03 bound, 
respectively. The intensities of these two complex peaks are much lower than those with 
CLR01 bound suggesting that the affinity of CLR03 binding to Aβ42 is much lower than 
that of CLR01.  
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 Figure 5.2 Different binding effects of CLR01 and CLR03 on Aβ42. Mass spectra of Aβ42 
samples: a) 1:10 mixture of Aβ42 and CLR01; b) 1:10 mixture of Aβ42 and CLR03; c) 
Aβ42 alone. Each species is noted in the bracket where the first number is the number of 
Aβ42 molecules and the second number represents the number of bound small molecules. 
The charge is noted as a superscript. 
 
To better understand the effects of CLR01 on Aβ42, the mass spectra of Aβ42 with 
different ratios of CLR01 (1:1, 1:2, 1:5 and 1:10) were recorded. The mass spectra of the 
mixtures are shown in Figure 5.3. The mass spectrum of the 1:5 mixture of Aβ42 and 
CLR01 is similar to that of the 1:10 mixture (Figure 5.2c) with peaks corresponding to 
complex species Aβ42 and CLR01 with charge states -4, -5, and -6. As the concentration of 
CLR01 decreases (1:2 and 1:1 ratios), the complex species of Aβ42 and CLR01 with lower 
charge states (-4, -3, -5/2) are observed in the mass spectra. One possible explanation is that 
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CLR01 itself is slightly basic in aqueous solution and the observed binding form of CLR01 
is CLR01 with loss of one sodium ion, therefore the complexes tend to carry more charge in 
the presence of high concentration CLR01. Note that no z/n = -5/2 CLR01-free Aβ42 dimer 
peak is observed in any of the mixtures. However, in the low-ratio mixtures (1:1 and 1:2, see 
Figure 5.3a, b), the -5/2 complex peaks of Aβ42 oligomers with CLR01 molecules bound 
are observed (m/z = 1950, 2096, and 2241 representing [2+1], [2+2], and [2+3] Aβ42-
CLR01 complexes, respectively). These results suggest that CLR01 not only binds to Aβ42 
monomers, but also to small Aβ42 oligomers with high affinity, thereby disrupting the 
formation of larger Aβ42 oligomers even at 1:1 ratio. As the concentration of CLR01 
increases, the Aβ42 oligomers decrease in abundance or altogether disappear.  
 
 
101 
Figure 5.3 Mass spectra of Aβ42 and CLR01 mixtures. a-d) 1:1, 1:2, 1:5, and 1:10 ratio of 
Aβ42 and CLR01, respectively. Each species is noted in the bracket where the first number 
is the number of Aβ42 molecules and the second number represents the number of bound 
CLR01 molecules. The charge is noted as a superscript. The read dash line represents the 
theoretical position for uncomplexed -5/2 peak. 
 
5.3.2 IMS reveals CLR01 inhibiting early Aβ42 oligomerization 
To better understand the effects of CLR01 on Aβ42 oligomerization, an ion mobility 
study was conducted. No ATDs for the z/n = -5/2 Aβ42 peak (m/z = 1805) could be 
recorded as it was not observed in any of the mixtures of Aβ42 and CLR01. The ATDs of 
the [2+1] and [2+2] complex peaks were recorded and are shown in Figure 5.4b-c (The 
signal of [2+3] complex species was too weak to obtain a reliable ATD). The ATD of the -
5/2 Aβ42 peak of pure Aβ42 (Figure 5.4a) shows four features with arrival times of ~712, 
680, 620 and 540 μs, which were previously assigned as Aβ42 dimer, tetramer, hexamer and 
dodecamer, respectively, based on their cross section values (See references 12  for detailed 
discussion of the -5/2 peak assignment).  
In contrast, in the 1:1 mixture of Aβ42 and CLR01, the ATD of the m/z = 1950 peak 
(Figure 5.4b, labeled as [2+1] species) shows only two features with arrival times of 690 and 
640 μs, which are assigned as dimer and tetramer, respectively. This indicates there is one 
CLR01 molecule bound to the Aβ42 dimer and two CLR01 molecules bound to the Aβ42 
tetramer, respectively. No features at lower arrival times are observed, suggesting there are 
no Aβ42 hexamers, dodecamers or other larger oligomers formed in the presence of CLR01.  
The ATD of the m/z = 2096 peak (Figure 5.4c, labeled as [2+2] species) also shows two 
dominant features with arrival times of ~700 and 660 μs, which correspond to Aβ42 dimer 
and tetramer, respectively. This indicates that there are two CLR01 molecules bound to the 
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Aβ42 dimer and four CLR01 molecules bound to the Aβ42 tetramer. Again, the highest 
oligomers with CLR01 bound observed are tetramers and absence of features at lower 
arrival times indicates no hexamer, dodecamer or higher order oligomer formation. These 
results indicate that CLR01 not only binds to Aβ42 monomers but also to small oligomers 
and inhibits the formation of hexamer and higher order oligomers.  
 
Figure 5.4. Effects of low concentration CLR01 on Aβ42 early oligomerization. ATDs 
of a) z/n = -5/2 Aβ42 (m/z = 1805) in an Aβ42 sample without CLR01; b) z/n = -5/2 Aβ42 
and CLR01 complex (m/z = 1950); and c) z/n = -5/2 Aβ42 and CLR01 complex (m/z = 
2096) in a 1:1 mixture of Aβ42 and CLR01.  
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 The cross sections of oligomer complexes are given in Table 5.1. Interestingly, the 
cross sections of dimers with one or two CLR01 molecules bound are significantly smaller 
than that of the dimer with no ligands attached, even though their mass has increased. This 
result suggests CLR01 induces more interaction between the two monomers leading to a 
compact conformation and overall size reduction. Similarly, the cross sections of tetramers 
with two or four CLR01 molecules bound are smaller than those of the tetramer with no 
CLR01 bound. In addition, the tetramer ATD peaks with CLR01 bound (Figure 5.4b, c) are 
much narrower than in wild type Aβ42. This indicates there is little structure variation in the 
CLR01 bound tetramer while in wt Aβ42 the tetramer family of structures is both larger and 
more varied. The unbound Aβ42 tetramer normally adopts a family of structures that have a 
bent arrangement (~120° angle).12 It is likely that the tetramers with CLR01 bound adopt 
either a more closed square ring structure or a pyramidal structure accounting for the fact 
they are smaller than CLR01-free Aβ42 tetramers and that dimer cannot be added to form 
hexamer. A similar effect prevents Aβ40 from growing beyond tetramer and explains its 
greatly reduced toxicity relative to Aβ42.12 
Table 5.1 Collision Cross sections of dimer and tetramer in the uncomplexed or CLR01-
complexed -5/2 Aβ42. The error for the cross sections reported here is between 0-1%. 
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5.3.3 CLR01 remodels pre-formed Aβ42 oligomers 
To explore whether CLR01 can remodel the early oligomerization of Aβ42 not only 
immediately upon dissolution but also after the oligomers have already formed, Aβ42 was 
incubated for 4 hours on ice, following which CLR01 was added to the samples. The 
samples were incubated at a low temperature to allow quasi-equilibrium of small oligomers 
to be reached, but avoid extensive aggregation, which happens at higher temperatures and 
leads to clogging of the nano-ESI capillaries, preventing further analysis. The results are 
shown in Figure 5.5. 
Following incubation, the mass spectrum of Aβ42 (Figure 5.5a) shows four peaks 
with charge states of z/n = -4, -3, -5/2 and -2. Upon addition of CLR01 at 1:1 concentration 
ratio, new peaks appeared corresponding to z/n = -4, -3 monomer complexes and z/n = -5/2 
oligomer complexes (Figure 5.5b). Overall, the spectrum was similar to the one obtained in 
the inhibition study, with the exception that no peaks were observed with 3 or 4 CLR01 
molecules bound. The data indicate that CLR01 binds to Aβ42 monomers and preformed 
Aβ42 oligomers directly, mostly with 1:1 or 1:2 stroichiometry, whereas binding of 
additional CLR01 molecules is less likely after incubation. This suggests the existence of 
two main binding sites for CLR01 on Aβ,  Lys16 and Lys28.4  
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 Figure 5.5 CLR01 remodels the early oligomerization of Aβ42. a) Mass spectrum of Aβ42 
alone with ~4 hours’ incubation on ice; b) and c) mass spectra of Aβ42 sample immediately 
after the addition of 1:1 and 1:5 CLR01. Each species is noted in the bracket where the first 
number is the number of Aβ42 and the second number represents the number of bound 
CLR01 molecules. The charge is noted as a superscript.  
 
To test the effect of the Aβ42:CLR01 concentration ratio on the remodeling of Aβ42 
oligomerization, higher ratios of CLR01 (1:5 and 1:10, respectively) were added to 4-hour 
incubated Aβ42. The mass spectrum of the 1:5 mixture, is shown in Figure 5.5c (the result 
of the 1:10 ratio was similar to that of the 1:5 mixture and therefore is not shown). The mass 
spectrum of the 1:5 mixture showed mostly complexes of Aβ42 monomer with CLR01 
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molecules. No z/n = -5/2 peak of CLR01-free or CLR01-complexed Aβ42 was observed. 
These results suggest that high concentrations of CLR01 dissociate pre-formed Aβ42 
oligomers. Taken together, these results indicate that CLR01 remodels Aβ42 
oligomerization both at low and high concentration ratios.  
The ATD of -5/2 peak for Aβ42 alone after 4 hours’ incubation, shows four features 
corresponding to dimer, tetramer, hexamer and dodecamer (Figure 5.6a). Interestingly, the 
ATD of the z/n = -5/2 unbound Aβ42 peak (Figure 5.6b) showed only three features 
representing dimer, tetramer and a small amount of hexamer after the addition of equimolar 
CLR01. The feature representing Aβ42 dodecamer was eliminated after the addition of 
CLR01, suggesting that the binding of CLR01 dissociated the pre-formed Aβ42 dodecamer. 
Moreover, the relative intensity of the hexamer decreased significantly compared to that 
before CLR01 addition (Figure 5.6a), suggesting CLR01 began to also dissociate hexamers. 
The ATDs of the z/n = -5/2 Aβ42:CLR01 oligomer complex peaks (Figure 5.6c, d) showed 
only the two features corresponding to dimer and tetramer with CLR01 molecules bound, as 
observed immediately upon mixing of Aβ42 and CLR01 (Figure 5.4b and c), suggesting that 
binding of CLR01 to Aβ42 dimers or tetramers changes their structure so that additional 
dimers cannot be added to form hexamers.  
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 Figure 5.6 CLR01 remodels the early oligomerization of Aβ42. a) ATD of z/n = -5/2 Aβ42 
peak for the Aβ42 in the absence of CLR01 after ~4 hours’ incubation on ice. b) ATD of z/n 
= -5/2 Aβ42 peak after addition of 1:1 CLR01. c) and d) the ATDs of -5/2 Aβ42 oligomer 
complexes after addition of 1:1 CLR01 to the pre-aggregated Aβ42 sample. The oligomer 
order (n) is noted for each feature.  
 
The ATDs of the z/n = -5/2 peaks were monitored again after one day of incubation 
at 4°C and the results (see Figure 5.7) were similar to those obtained following 4 hours of 
incubation, suggesting that CLR01 maintained the distribution of Aβ42 oligomers, in which 
dodecamers were excluded and hexamers were a minor species. 
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 Figure 5.7 ATDs of CLR01 remodeling the early oligomerization of Aβ42 after one day. a-
c) ATDs of z/n = -5/2 Aβ42 peaks without and with CLR01 molecules bound. Each ATD is 
ﬁtted with multiple features using the procedure described in the experimental section. The 
oligomer order (n) is noted for each feature.  
 
5.3.4 Ion mobility spectrometry of Aβ42 monomer complexes 
The ATDs of z/n = -3 of Aβ42 monomer in the absence or presence of CLR01 (1:1) 
are shown in Figure 5.8. In the ATD of the -3 monomer peak of Aβ42 alone there are two 
dominant peaks with arrival times of ~640 and ~680 μs, previously identified as a solvent-
free conformer and a solution-like conformer, respectively.13 The ATD for the -3 peak of 
Aβ42 complexed with one CLR01 molecule shows two similar features with arrival times of 
~668 and ~712 μs. By analogy, these are assigned as the solvent-free and solution-like 
conformers of Aβ42 monomer with one CLR01 bound, respectively. 
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Figure 5.8 ATDs of z/n = -3 Aβ42 monomers in the absence (a) or presence (b) of CLR01. 
Each ATD is ﬁtted with multiple features using the procedure described in the experimental 
section. M1 and M2 represent the compact and extended conformers of Aβ42 monomers.  
 
The ATDs of z/n = -4 and -5 complexes of Aβ42 with one, two, three, or four 
CLR01 molecules bound in a 1:5 mixture, respectively, are shown in Figure 5.9. Those for 
z/n = -4 have two features in their ATDs and as the number of bound CLR01 molecules 
increases, the intensity of the compact, shorter-time feature increases, relative to the more 
extended, longer-time feature. Overall, there are no features with shorter arrival times 
detected which indicates that only monomer with CLR01 complexed is present in solution. 
The cross sections of the Aβ42:CLR01 monomer complexes are shown in Figure 5.9c. 
Addition of each CLR01 ligand increases the size of the complex by an amount comparable 
to the size of CLR01 suggesting that no major structural transitions occur in the monomers 
upon CLR01 binding. 
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 Figure 5.9 ATDs of a) z/n = -4 and b) z/n = -5 complexes of Aβ42 with one, two, three, or 
four CLR01 molecules bound in a 1:5 mixture of Aβ42 and CLR01. Each ATD is ﬁtted with 
multiple features using the procedure described in the experimental section.  c) Plots of cross 
sections of Aβ42 monomer complexes versus number of bound CLR01 molecules. 
 
5.3.5 Effects of CLR01 on Aβ40 assembly 
Aβ40 has an identical sequence to that of Aβ42 except for absence of Ile41 and 
Ala42 residues at the C-terminus, but has very different assembly and pathological 
properties. Thus, it is interesting to examine how CLR01 affects its early oligomerization in 
comparison to Aβ42. The mass spectra of Aβ40 alone and Aβ40 mixed with CLR01 at 
different ratios are provided in Figure 5.10 The mass spectrum of Aβ40 alone shows three 
peaks which correspond to z/n = -4, -3 and -5/2, similar to the spectrum of the Aβ42. The 
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mass spectra of mixtures of Aβ40 and CLR01 at different ratios show sets of peaks at charge 
states -3, -4, -5 and -6 corresponding to Aβ40:CLR01 complexes. Up to four CLR01 
molecules are observed bound to Aβ40. At lower CLR01 concentration (1:1 ratio, Figure 
5.10b), there are three z/n = -5/2 peaks at m/z = 1876, 2021, and 2167, corresponding to 
[2+1], [2+2] and [2+3] oligomer complexes of Aβ40 and CLR01. At higher concentrations 
of CLR01 (1:5 and 1:10 ratios), no -5/2 oligomer complexes were detected, suggesting that 
no dimer or higher-order oligomers formed.  
 
Figure 5.10 Mass spectra of Aβ40 and CLR01 mixtures. a) Aβ40 alone and b-d) mixtures of 
Aβ40 and CLR01 at 1:1, 1:5 and 1:10 ratio, respectively. Each species is noted in the 
bracket where the first number is the number of Aβ40 molecules and the second number, in 
red, represents the number of bound CLR01 molecules. The charge is noted as a superscript.  
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 The ATDs of these -5/2 oligomer peaks are shown in Figure 5.11 (the signal of the 
[2+3] complex was too weak to obtain a reliable ATD and therefore is not shown). The -5/2 
peak of Aβ40 (m/z = 1731, Figure 5.11a) shows two features with arrival times of ~690 and 
~620 μs which previously were assigned as Aβ40 dimer and tetramer (see reference 12 for a 
detailed discussion of the -5/2 peak assignment). For the 1:1 mixture of Aβ40 and CLR01, 
the ATDs of -5/2 [2+1] and [2+2] oligomer complexes (Figure 5.11b and c) show two 
primary features, which can be assigned as dimer and tetramer based on their cross sections. 
These results indicate that there are one or two CLR01 molecules bound to Aβ40 dimers and 
two or four CLR01 molecules bound to Aβ40 tetramers. No features at shorter arrival times 
were observed, indicating that there are no hexamer or larger oligomers formed. 
Interestingly, the intensities of the tetramer feature for [2+1] and [2+2] complex species 
(Figure 5.11b and c) are lower than that of the -5/2, CLR01-free Aβ40 tetramer feature, 
which indicates that the formation of tetramer is slower in the presence of CLR01 in the 
Aβ40 sample than in its absence.  
 
113 
 Figure 5.11 Effects of low concentration CLR01 on Aβ40 oligomerization. a) ATD of z/n = 
-5/2 Aβ40 (m/z = 1731) for Aβ40 alone; b) and c), ATDs of z/n = -5/2 Aβ40 and CLR01 
complexes (m/z = 1876 and 2021) in the 1:1 mixture of Aβ40 and CLR01. Each ATD is ﬁt 
with multiple features using the procedure described in the experimental section and the 
oligomer order (n) is noted for each feature. Note the ATDs with CLR01 bound, panels b 
and c, are significantly narrower than wild type, panel a.  
 
The ATDs of monomer complexes with charge states z/n = -3, -4, -5, or -6 are shown 
in Figures 5.12 and 5.13. The z/n = -4 species (Figure 5.13a) show two features in their 
ATDs corresponding to the solvent-free conformer and the solution-like conformer of Aβ40 
complexed with CLR01. Taken together, these results indicate that CLR01 binds to Aβ40 
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with relatively high affinity and inhibits its early oligomerization. The cross sections of 
Aβ40 monomer complexes are shown in Figure 5.13b. Similarly to the Aβ42 case, addition 
of each CLR01 ligand increases the size of the monomer complex by an amount comparable 
to the size of CLR01 suggesting that no major structural transitions occur in the monomers 
upon CLR01 binding. 
 
Figure 5.12 ATDs of z/n = -3 Aβ40 monomers in the absence (a) or presence (b) of CLR01. 
Each ATD is ﬁtted with multiple features using the procedure described in the experimental 
section. M1 and M2 represent the compact and extended conformers of Aβ42 monomers.  
 
115 
 Figure 5.13 a) ATDs of z/n = -4, -5, and -6 Aβ40 and CLR01 complexes, respectively, in 
their 1:5 mixture. Each ATD is ﬁtted with multiple features using the procedure described in 
the experimental section. b) The cross section for each feature is plotted versus the number 
of CLR01 molecules bound.  
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5.3.6 IMS reveals that CLR03 facilitates early Aβ42 oligomerization 
As noted above, CLR03 has been used as a negative-control compound, which was 
not expected to inhibit Aβ oligomerization or aggregation. Hence, we felt it important to do 
similar experiments that are reported here.  
A time dependent study of the ATDs of the -5/2 Aβ42 peak (m/z = 1805) of Aβ42 
alone and the 1:10 mixture of Aβ42 and CLR03 are shown in Figure 5.14. The ATD of the -
5/2 Aβ42 peak for the 1:10 mixture of Aβ42 and CLR03, respectively, at 30 minutes (Figure 
5.14a) shows four features that can be assigned as Aβ42 dimer, tetramer, hexamer and 
dodecamer based on their cross sections, which is similar to the results of Aβ42 alone at 30 
minutes (Figure 5.14d). Interestingly, the intensity of the dodecamer feature of the -5/2 peak 
for the mixture of Aβ42 and CLR03 is relatively higher than other features, whereas the 
intensity of the dodecamer feature of Aβ42 alone at 30 minutes is relatively lower than other 
features, suggesting that the growth of dodecamer in the presence of CLR03 is faster than in 
its absence. After up to 24 hours of incubation, the dodecamer in the Aβ42 and CLR03 
mixture becomes an even more dominant feature in the ATDs (Figure 5.14b and c), whereas 
the CLR01-free Aβ42 sample does not change substantially and appears to be in a state of 
quasi-equilibrium (Figure 5.14e and f). The observation of dodecamer and the significant 
rapid growth of dodecamer in the Aβ42 sample in the presence of CLR03 suggest that 
CLR03 not only does not inhibit the formation of Aβ42 dodecamer, but actually facilitates 
the dodecamer formation. 
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 Figure 5.14 Time-dependent ion mobility study of the effects of CLR03 on Aβ42 early 
oligomerization. a-c) ATDs of -5/2 Aβ42 peak (m/z = 1805) for the 1:10 mixture of Aβ42 
and CLR03 at different time points; d-f) ATDs of -5/2 Aβ42 peak (m/z = 1805) for Aβ42 
alone at different time points. Each ATD is ﬁt with multiple features using the procedure 
described in the experimental section. The oligomer order (n) and cross section are noted for 
each feature. 
 
ATDs of z/n = -3 and -4 peaks for Aβ42 alone and a 1:1 mixture of Aβ42 and 
CLR03 are shown in Figure 5.15. The ATD of the z/n = -3 Aβ42 peak for the mixture of 
Aβ42 and CLR03 (Figure 5.15b) shows two features at ~640 and ~680 μs corresponding to 
the compact and extended conformers, respectively, which is similar to those of Aβ42 alone 
(Figure 5.15a). Remarkably, there is another feature at a substantially shorter arrival time 
(~500 μs) as noted by the arrow in addition to the two monomer features, which is not 
observed for Aβ42 alone. This indicates the presence of relatively large oligomers (n ≥2) 
formed in the presence of CLR03. A similar feature is observed in the ATD of the z/n = -3 
peak of Aβ42 with one CLR03 bound, which corresponds to large oligomers (n ≥2). In 
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Figure 5.15e and f, dominant features with shorter arrival times are observed in the ATDs 
for z/n = -4 peaks of Aβ42 with and without CLR03 bound, in addition to the monomer 
feature, indicating the presence of large oligomers (n≥2). These results are consistent with 
the results of the ATDs of z/n = -5/2 Aβ42 peak (m/z = 1805, Figure 5.14) and further 
support the fact that CLR03 facilitates self-assembly of Aβ42. 
 
Figure 5.15 CLR03 facilitates Aβ42 oligomer formation a) ATD of z/n = -3 peak for Aβ42 
alone, b) and c) ATDs of z/n = -3 Aβ42 without and with CLR03 bound for a 1:10 mixture 
of Aβ42 and CLR03, d) ATD of z/n = -4 peak for Aβ42 alone, e) and f) z/n = -4 Aβ42 
without and with CLR03 bound for a 1:10 mixture of Aβ42 and CLR03. Each ATD is ﬁt 
with multiple features using the procedure described in the experimental section. M1 and M2 
represent two conformations of Aβ42 monomer. The arrows indicate the formation of 
oligomers (n ≥ 2) in the mixture of Aβ42 and CLR03. 
 
119 
5.3.7 CLR03 facilitates Aβ40 assembly 
The effect of CLR03 on Aβ40 oligomerization is shown in Figure 5.16. The mass 
spectrum of a 1:10 mixture of Aβ40 and CLR03 shows peaks corresponding to z/n = -3 and 
z/n = -4 monomer with one CLR03 bound but no CLR03 attachment to the z/n = -5/2 peak 
(Figure 5.16b). However, the ATD of the -5/2 Aβ40 peak (m/z = 1731) in the presence of 
CLR03 (Figure 5.16d) shows formation of both Aβ40 hexamer and dodecamer based on the 
cross section calculations. In Figure 16e the cross sections for the dimers and tetramers of 
Aβ40 are given for Aβ40 alone and for Aβ40 mixed with CLR01 and CLR03. Note that 
CLR03 significantly increases both cross sections whereas CLR01 significantly decreases 
both cross sections. Further aggregation is enhanced by CLR03 and inhibited by CLR01. 
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 Figure 5.16 CLR03 facilitates Aβ40 assembly. a-b) Mass spectra of Aβ40 samples: a) Aβ40 
alone; b) 1:10 mixture of Aβ40 and CLR03. Each species is noted in the bracket where the first 
number is the number of Aβ40 molecules and the second number, in red, represents the number of 
bound CLR03 molecules. The charge is noted as a superscript. c-d) ATDs of -5/2 Aβ40 peak (m/z 
= 1731) for the Aβ40 samples in the absence or presence of CLR03. Each ATD is ﬁt with 
multiple features using the procedure described in the experimental section and the oligomer 
order (n) is noted for each feature. e) Cross sections of -5/2 Aβ40 oligomers for samples of 
Aβ40 in the absence or presence of CLR01 or CLR03. The error for the cross sections 
reported here is between 0-1%. 
 
The ATDs of z/n = -3 and -4 peaks of the 1:10 Aβ40:CLR03 mixture (Figure 5.17) 
show features at arrival times shorter than those of monomers, suggesting formation of large 
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oligomers (n ≥2) in the presence of CLR03. Overall, these results reveal that CLR03 
facilitates early oligomerization of Aβ40. 
 
Figure 5.17 CLR03 facilitates Aβ40 assembly. a-b) ATDs of z/n = -3 Aβ40 without and 
with CLR03 bound (m/z = 1442 and 1583, respectively). c-d) z/n = -4 Aβ40 without and 
with CLR03 bound (m/z = 1081 and 1187, respectively) in the 1:10 mixture of Aβ40 and 
CLR03. Each ATD is ﬁtted with multiple features using the procedure described in the 
experimental section. The oligomer order (n) and cross section are noted for each feature.  
 
5.4 Discussion and Conclusions 
Our mass spectrometry study of the lead molecular tweezer, CLR01, and the related 
derivative, CLR03, provides novel observations that could not have been obtained 
previously due to the low resolution of the methods used. Our investigation reveals that 
CLR01 and CLR03 bind to Aβ with very different affinities. Three CLR01 molecules bind 
 
122 
with relatively higher affinity and a fourth weakly, but only one CLR03 molecule binds 
weakly to Aβ. 
The Aβ:CLR01 stoichiometry found in our study is consistent with previous data 
suggesting that there are three possible binding sites for molecular tweezers on Aβ at Arg5, 
Lys16, and Lys 28.4 Possible explanations for our observation of a fourth CLR01 molecule 
weakly binding to Aβ40 and Aβ42 could simply stem from differences in instrumentation, 
or might reflect non-discriminating electrostatic and/or aromatic interactions between Aβ 
and CLR01 molecules, which might have been broken under harsher ionization conditions in 
the study by Sinha et al.4 These nonspecific dispersive interactions could also explain the 
weak binding of one CLR03 molecule to Aβ, which was not observed within the limits of 
NMR detection in the previous study.4 
The observation of three z/n = -5/2 oligomer complexes in the 1:1 and 1:2 mixtures 
of Aβ42 and CLR01, respectively, suggests that CLR01 not only binds to Aβ42 monomers 
but also to small Aβ42 oligomers (dimers and tetramers). Moreover, IMS reveals that 
CLR01 inhibits the formation of hexamers and dodecamers. This is important as dodecamers 
have been identified as probable toxic agents in AD.12,14-15 Understanding the mechanism of 
how CLR01 blocks dodecamer formation is crucial for developing a therapeutic strategy for 
AD. Remarkably, the cross sections of the dimer and tetramer decreased substantially upon 
binding of CLR01 (See Table 5.1). These results suggest that CLR01 interacts with Aβ42 to 
change the folding of the monomer, which in turn changes the binding interface in dimer 
and tetramer formation resulting in compact structures that resist further aggregation. Once 
multiple CLR01 ligands bind to the monomer even dimer formation is prevented.  
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The ability of CLR01 to remodel early Aβ42 oligomerization after the oligomers had 
an opportunity to form and reach a quasi-equilibrium state for 4 hours was assessed by IMS 
as well. Interestingly, even at low concentration (1:1 ratio), CLR01 was capable of removing 
pre-formed Aβ42 dodecamers and hexamers. At high concentrations (1:5 and 1:10 ratios), 
CLR01 removes essentially all preformed Aβ42 oligomers. These data are consistent with 
the inhibition results immediately upon mixing Aβ42 and CLR01. It is possible that CLR01 
binds to Aβ42 monomers and oligomers and redirects them into either a slower aggregation 
process or an off-pathway set of structures. In either case, the resulting structures are non-
amyloidogenic and non-toxic.4-6 Our data reveal for the first time that the loss of amyloid-
formation propensity and toxicity correlate with disruption of the oligomerization process 
and compaction of oligomers formed in the presence of CLR01.  
Surprisingly, the related derivative, CLR03, was found to facilitate the early 
aggregation of Aβ42, especially promoting the formation of hexamers and dodecamers. 
Perhaps even more surprisingly, CLR03 also facilitated the formation of hexamers and 
dodecamers in Aβ40, which does not form these oligomers on its own. Previous studies 
showed that CLR03 did not inhibit Aβ42- or Aβ40-induced neurotoxicity.4 However, how 
CLR03 interacts with Aβ has been unclear. Given the fact that CLR03 is an organic 
phosphate, we wondered whether it is possible the addition of CLR03 has a simple “salting 
out”-like effect, which would thereby promote Aβ aggregation. To address this possibility, 
an organic phosphate, p-nitrophenylphosphate (PNPP) was added to Aβ samples and was 
found not to induce significant changes in Aβ oligomerization (see Figure 5.18). This result 
implies a simple “salting out”-like effect is not occurring for CLR03 and that CLR03 
interacts with Aβ in a specific manner.  
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 Figure 5.18 Evaluation of a putative “salting-out”-like effect of CLR03 by examining a 
simple organic phosphate, p-nitrophenylphosphate (PNPP) on Aβ42 oligomerization. a) and 
b) Mass spectra of 1:10 mixtures of Aβ42 or Aβ40 with PNPP. Each species is noted in the 
bracket where the first number is the number of Aβ40 molecules and the second number 
represents the number of bound CLR01 molecules. The charge is noted as a superscript. c) 
and d) ATDs of z/n = -5/2 peaks for 1:10 mixtures of Aβ42 /Aβ40 and PNPP. Each ATD is 
ﬁtted with multiple features using the procedure described in the experimental section. The 
oligomer order (n) is noted for each feature. 
 
A major difference between the structures of CLR01 and CLR03 is that CLR01 has a 
torus-shaped cavity whereas CLR03 does not have a cavity structure. CLR03 carries a 
bridge-like structure with negatively charged phosphate groups on each side. It is possible 
that one of the phosphate groups on CLR03 interacts with positively charged residues (Lys, 
Arg, N-terminus) of Aβ through Coulombic interactions. The other phosphate group on the 
other side of CLR03 could then attract a positively charged residue of another Aβ or Aβ 
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oligomer. Thus, by attracting positively charged residues in Aβ, CLR03 could facilitate Aβ 
oligomerization and aggregation.  
Alternatively, CLR03 may interact weakly with two positively charged groups in a 
single Aβ, resulting in no observation of peaks for single Aβ with multiple CLR03 in the 
mass spectra (Figure 5.2b). As a consequence conformation change may occur that promotes 
Aβ assembly. This is a form of salting out and it may be more effective than PNPP. 
However, the fact that assembly is promoted to structures similar to wt Aβ42, speaks against 
salting out as a dominant assembly mechanism. 
 CLR01, which also carries two phosphate groups, however, does not catalyze Aβ 
oligomerization. This suggests that inclusion of lysine or arginine inside the cavity of 
CLR01 is of paramount importance for CLR01’s mode of action. The central hydrophobic 
region of Aβ is regarded to be important for the hydrophobic clustering of Aβ. Recently a 
macrocyclic inhibitor cucurbit[7]uril has been shown to inhibit amyloid fibrillation by 
hydrophobic interactions with nonpolar phenylalanine residues of Aβ.16 CLR01, which has 
hydrophobic arms, is likely to have additional hydrophobic interactions with lysine residues. 
The binding of CLR01 to lysine residues, especially Lys16 which is close to the central 
hydrophobic region of Aβ, may result in conformation change of Aβ and compaction of Aβ 
oligomers. Our data suggest that binding of CLR01 causes Aβ monomers to either resist 
oligomer formation altogether or to redirect them to non-toxic oligomer assembly. 
 Previous detailed analysis showed that Aβ40 formed a nearly closed planar tetramer 
that resisted further dimer addition.12 Here, we found that adding CLR01 to Aβ40 
significantly reduced the cross sections of both the dimer and tetramer leading to nearly 
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isotropic assembly and reducing the likelihood of even forming the tetramer, much less 
higher-order oligomers. On the other hand, the presence of CLR03 in the solution 
significantly extended both the dimer and tetramer yielding cross sections similar to those of 
the corresponding Aβ42 oligomers and leading to hexamer and dodecamer formation. 
 The essential features of these results are given in cartoon style in Figure 5.19. Aβ42 
wt rapidly forms dodecamer but addition of the molecular tweezer CLR01 eliminates 
dodecamer formation by inducing the dimer and tetramer to form compact species that 
cannot add additional Aβ42. The opposite effect is obtained by CLR03. Aβ40 wt forms 
terminal compact tetramers but addition of CLR03 leads to open tetramer formation and 
eventual dodecamer formation. These contrary effects are potentially of great importance in 
Aβ assembly and require further study to reveal the details involved. These studies, which 
will include both high level molecular dynamics modeling and additional direct sampling of 
structures of Aβ oligomers are underway. 
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 Figure 5.19 Different effects of CLR01 and CLR03 on Aβ early oligomerization. 
Oligomerization of a) Aβ42 wild type; b) Aβ42 with the presence of CLR01; c) Aβ40 wild 
type; d) Aβ40 with the presence of CLR03. Aβ42 and Aβ40 are represented with blue and 
red balls, respectively. CLR01 and CLR03 molecules are noted as X and Y. 
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Chapter 6 
Rational design of a novel molecule that targets and 
modulates Amyloid β and Metal-Aβ Species 
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6.1 Introduction 
Development of a cure for Alzheimer’s disease (AD) has been hindered by a lack of 
understanding of both the causes and mechanisms of disease onset and progression1-5. The 
AD brain exhibits several characteristic pathological features, such as accumulation of 
misfolded amyloid-β (Aβ), metal ion dyshomeostasis and miscompartmentalization, and 
elevated oxidative stress1-10. In addition to Aβ imbalance, high levels of metal ions (Cu, ca. 
0.4 mM; Zn, ca. 1 mM; Fe, ca. 0.9 mM) have been found in Aβ plaques of AD brains2,4-5,7-
8,10-13. These metals, particularly Cu and Zn, bind to Aβ peptides facilitating their 
aggregation. Moreover, dysregulated, redox-active metal ions, Cu(I/II) and Fe(II/III), both 
unbound and bound to Aβ peptides, are observed to promote overproduction of reactive 
oxygen species (ROS) that damage biological targets such as proteins, DNA, and lipids2-3,7-
10. Overall, due to the involvement of numerous factors (e.g., metal-free/-associated Aβ 
species, metals, free radicals) and their potential inter-connections in AD pathogenesis, the 
causative agents in this multifaceted disease remain unidentified.  
Chemical reagents to target and modulate these multiple factors in AD are desirable 
to advance our understanding of AD complexity and offer possible answers for remediation. 
Toward this effort, small molecules have been developed via a rational structure-based 
approach by incorporating an Aβ-interacting framework with a metal chelation moiety into a 
single molecule designed to target metal–Aβ species5,7,12,14-19. These molecules were shown 
to control metal-induced Aβ aggregation, and attenuate ROS formation by metal–Aβ, and/or 
metal–Aβ toxicity in vitro and in living cells14-19. To the best of our knowledge, however, a 
single compound, targeting all these factors (i.e., Aβ species, metal–Aβ species, metal ions, 
and free radicals, Figure 6.1a) and regulating their reactivities, has not been reported to date. 
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Herein we present a novel ligand (ML) as the first example of a rationally designed 
molecule to afford multifunctionality within a single entity (Figure 6.1a). Our investigations 
on ML’s activity toward Aβ, metal–Aβ, metal ions, and free radicals, as well as its potential 
blood-brain barrier (BBB) permeability confirm that careful selection and consideration of 
molecular properties can result in the design of a molecule to target multiple pathological 
features of AD. 
 
6.2 Materials and methods 
Materials. All reagents were purchased from commercial suppliers and used as 
received unless otherwise noted. Aβ40 and Aβ42 were purchased from Anaspec (Fremont, 
CA, USA) or synthesized by N-9-fluorenylmethoxycarbonyl (FMOC) chemistry. The 
compounds, (8-aminoquinolin-2-yl)methanol (1)20-21 and 5-(dimethylamino)-2-
hydroxybenzaldehyde22, were prepared following previously reported procedures. NMR and 
mass spectrometric analyses of small molecules were conducted on a 400 MHz Varian NMR 
spectrometer and a Micromass LCT Electrospray Time-of-Flight (TOF) mass spectrometer, 
respectively. Trace metal contamination was removed from buffers and solutions used for 
metal binding and Aβ experiments by treating with Chelex overnight (Sigma-Aldrich, St. 
Louis, MO, USA). Optical spectra were recorded on an Agilent 8453 UV-Visible (UV-Vis) 
spectrophotometer. Transmission electron microscopic (TEM) images were taken using a 
Philips CM-100 transmission electron microscope (Microscopy and Image Analysis 
Laboratory, University of Michigan, Ann Arbor, MI, USA). Absorbance values for 
biological assays, including cell viability assay, parallel artificial membrane permeability 
assay adapted for blood-brain barrier (PAMPA-BBB), 2-deoxyribose assay, and Trolox 
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equivalent antioxidant capacity (TEAC) assay, were measured on a SpectraMax M5 
microplate reader (Molecular Devices, Sunnyvale, CA, USA). Mass spectra for investigating 
the interaction of Aβ with ML in the absence and presence of Cu(II) and Zn(II) were 
acquired on a traveling-wave Quadrupole TOF (Q-TOF) mass spectrometer (Waters Synapt 
Prototype; Milford, MA, USA)23 and a home-built electrospray ionization (ESI) ion 
mobility-mass spectrometer24. NMR studies of Aβ with ML and/or Zn(II) were conducted 
on a 900 MHz Bruker spectrometer equipped with a cryogenic probe at Michigan State 
University in Lansing, MI USA. 
Synthesis of 4-(dimethylamino)-2-(((2-(hydroxymethyl)quinolin-8-
yl)amino)methyl)phenol (ML). A solution (dry ethyl acetate (EtOAc), 8.0 mL) of 120-21 (174 
mg, 0.99 mmol) and 5-(dimethylamino)-2-hydroxybenzaldehyde22 (164 mg, 0.99 mmol) was 
stirred overnight at room temperature. After removing the solvent, the resulting solid 
material was dissolved in dichloroethane (DCE, 8.0 mL) followed by addition of sodium 
triacetoxyborohydride (NaB(OAc)3H, 420 mg, 2.0 mmol). After stirring for 24 h at room 
temperature, the crude product was purified by column chromatography (SiO2, 1:5 
hexanes/EtOAc, Rf = 0.47). The final product (orange powder, HCl salt form) was obtained 
by recrystallization (upon addition of 1:1 HCl/H2O to a MeOH solution of crude products) 
(198 mg, 0.50 mmol, 51%).  
Ion mobility-mass spectrometry (IM-MS). Lyophilized Aβ40 and Aβ42 were 
dissolved in 10 mM ammonium acetate buffer (pH 7.4) to generate a final peptide 
concentration of 10 μM for all mass spectrometry experiments. Mass spectra were recorded 
on a prototype of the commercial Waters Synapt instrument (Milford, MA, USA)23 and a 
home-built ESI ion mobility-mass spectrometer24 which is described in Chapter 2.  
134 
 
Transmission electron microscopy (TEM). Samples for TEM were prepared 
according to previously reported methods14-18,25. Glow-discharged grids (Formar/Carbon 
300-mesh, Electron Microscopy Sciences, Hatfield, PA, USA) were treated with Aβ samples 
from the inhibition and disaggregation experiments (5 μL) for 2 min at room temperature. 
Excess sample was removed using filter paper followed by washing twice with ddH2O. Each 
grid was incubated with uranyl acetate (1% w/v ddH2O, 5 μL, 1 min). Upon removal of 
excess uranyl acetate, the grids were dried for 15 min at room temperature. Images from 
each sample were taken on a Philips CM-100 transmission electron microscope (80 kV, 
25,000x magnification).  
Cell viability measurements. The murine neuroblastoma Neuro-2a (N2a) cell line 
was purchased from the American Type Cell Collection (ATCC, Manassas, VA, USA). N2a 
cells stably overexpressing the Swedish mutant (K670N and M671L) human amyloid 
precursor proteins (APP) (N2aAPPswe)26 were the generous gift of Professor Gopal 
Thinakaran (University of Chicago). Both cell lines ware maintained in media containing 45% 
DMEM, 50% OPTI-MEM, 5% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, 
GA, USA), 100 U/mL penicillin (Gibco, Grand Island, NY, USA), and 100 mg/mL 
streptomycin (Gibco). For the N2aAPPswe cell line, 0.2 mg/mL G418 (geneticin, Gibco) 
was added to the culture medium. The cells were grown in a humidified atmosphere with 5% 
CO2 at 37 °C. For the MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide), cells were seeded in a 96 well plate (15,000 cells/100 μL). The cells 
were then treated with Aβ (10 μM) with or without CuCl2 or ZnCl2 (10 μM) followed by the 
addition of ML or 1 (final concentration 10 μM, 1% v/v final DMSO concentration). After 
24 h incubation, 25 μL MTT (5 mg/mL in phosphate buffered saline (PBS, pH 7.4, Gibco 
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(Grand Island, NY, USA)) was added to each well and the plate was incubated for 4 h at 
37 °C. Formazan produced by the cells was solubilized by addition of an acidic solution of 
N,N-dimethylformamide (50%, v/v, aq) and sodium dodecyl sulfate (SDS, 20%, w/v) 
overnight at room temperature in the dark. The absorbance was measured at 600 nm using a 
microplate reader.  
2-Deoxyribose assay. The ability of ML to suppress free radical Fenton chemistry 
was determined by the 2-deoxyribose assay. The assay was performed based on previously 
established methods with some modifications36. Chelexed solutions were used and reactions 
(total volume, 200 μL) were setup by mixing, in the following order, buffer (50 mM 
NaH2PO4, pH 7.4), ligand (50-200 μM), CuCl2 (10 μM), 2-deoxy-D-ribose (15 mM), H2O2 
(200 μM), and sodium ascorbate (2 mM), and allowed to react for 1 h at 37 °C with constant 
agitation. The reactions were quenched upon addition of trichloroacetic acid (200 μL of 2.8% 
w/v) and 2-thiobarbituric acid (200 μL of 1% w/v) and heated at 100 °C for 20 min, cooled 
for 5 min, and their absorbance values at 532 nm measured immediately afterwards. In 
addition, samples without ligand were prepared as a control. Experiments were performed in 
two sets of triplicates (6 data points) and absorbance data was averaged over all six 
measurements for each ligand at each concentration. Normalized absorbance values (A/A0) 
were calculated by taking the absorbance (A) and dividing by the absorbance of the control 
(A0).  
Trolox equivalent antioxidant capacity (TEAC) assay. The antioxidant activity of 
ML and 1 was determined by the TEAC assay. The assay was performed according to the 
previously reported method with slight modifications27-28. To generate blue ABTS cation 
radicals (ABTS+•; ABTS = 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 
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diammonium salt), a solution of ABTS (7.0 mM) and potassium persulfate (2.5 mM) was 
prepared in 5 mL water and incubated for 16 h at room temperature in the dark. The 
resulting solution was diluted with EtOH to an absorbance of ca. 0.7 at 734 nm. ABTS+• 
solution (200 μL) was added to the wells of a clear 96 well plate and incubated for 5 min at 
30 °C. Various concentration (0, 1, 2.5, 5, 7.5, 10, and 15 μM) of ML, 1 (1% v/v final 
DMSO concentration), or Trolox (Trolox = 6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid; dissolved in EtOH) were added and incubated with the ABTS+• solution at 
30 °C for different time periods (1, 3, 6, and 10 min). The percent inhibition was calculated 
according to the measured absorbance at 734 nm (% inhibition = 100 × (A0 − A)/A0) and 
was plotted as a function of ligand concentration. The TEAC value of compounds for each 
time point was calculated as a ratio of the slope of the standard curve of the compound to 
that of Trolox. The measurements were carried out in triplicate.  
Parallel artificial membrane permeability adapted for blood-brain barrier 
(PAMPA-BBB) assay. PAMPA-BBB experiments were carried out using the PAMPA 
Explorer kit (pION Inc., Billerica, MA, USA) with modification to previously reported 
protocols14,18-19,25,29-30. Each stock solution was diluted with Prisma HT buffer (pH 7.4, 
pION) to a final concentration of 25 μM (1 % v/v final DMSO concentration). The resulting 
solution was added to wells of the donor plate (200 μL, number of replicates = 12 (for ML) 
and 11 (for 1)). BBB-1 lipid formulation (5 μL, pION) was used to coat the polyvinylidene 
fluoride (PVDF, 0.45 μM) filter membrane on the acceptor plate. This acceptor plate was 
placed on top of the donor plate forming a sandwich. Brain sink buffer (BSB, 200 μL, pION) 
was added to each well of the acceptor plate. The sandwich was incubated for 4 hours at 
ambient temperature without stirring. UV-Vis spectra of the solutions in the reference, 
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acceptor, and donor plates were measured using a microplate reader. The PAMPA Explorer 
software v. 3.5 (pION) was used to calculate logPe for each compound. CNS/designations 
were assigned by comparison to compounds that were identified in previous reports14,18-
19,25,29-30. 
 
6.3 Results and discussion 
6.3.1 Design consideration for a multifunctional molecule (ML)  
To develop a chemical tool capable of both targeting and modulating the reactivity of 
multiple AD pathological factors in biological systems, we designed a novel molecule (ML) 
with the potential for Aβ and metal-Aβ interaction, metal chelation, control of ROS 
generation, antioxidant activity, water solubility, and blood-brain barrier (BBB) 
permeability (Figure 6.1a). For Aβ/metal-Aβ interactions and metal chelation, ML was 
constructed by combining p-I-stilbene, a known Aβ imaging agent14,31-33, L2-b, a molecule 
previously reported to target metal–Aβ15, and 1, a metal chelator20 (Figure 6.1). For 
enhanced metal binding properties, an additional hydroxyl group, along with nitrogen and 
oxygen donor atoms from 1, was incorporated into ML affording a tetradentate ligand for 
Cu(II) with 1:1 metal-to-ligand stoichiometry20. ML was designed to accommodate a 
slightly distorted square planar geometry for Cu(II) similar to 2-[(8-
quinolinylamino)methyl]phenol20. In this conformation, the ligand cannot easily 
accommodate the preferred tetrahedral geometry of Cu(I) for redox cycles of Cu(I/II) and 
thus inhibits ROS generation. For antioxidant activity, substituents known to have 
antioxidant capability (i.e., quinoline and phenolic groups, Figure 6.1)28–30 were integrated 
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into ML. Lastly, polar functionalities (e.g., hydroxyl and amino groups) were introduced 
into the backbone for water solubility. All structural elements were selected to adhere to 
values of Lipinski’s rules and logBB for possible drug-likeness and BBB penetration (Table 
6.1)15,19,25,29-30.  
 
Figure 6.1 Rational structure-based design principle (incorporation approach) of a 
multifuncitonal ligand (ML). Atoms responsible for metal binding are in bold. Chemical 
structures: ML = 4-(dimethylamino)-2-(((2-(hydroxymethyl)quinolin-8-yl)-amino)-
methyl)phenol; p-I-stilbene = (E)-4-(4-iodostyryl)-N,N-dimethylaniline); L2-b = N1,N1-
dimethyl-N4-(pyridin-2-ylmeth-yl)benzene-1,4-diamine; 1 = (8-aminoquinolin-2-
yl)methanol.  
 
ML was synthesized by modifications of previously reported procedures (Schiff base 
condensation followed by reduction of imine to amine, ca. 50% yield) as shown in Figure 
6.220. 
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Figure 6.2 Synthesis scheme of ML compound. 
 
6.3.2 Mass Spectrometry: ML interacts with Aβ42 directly 
 To determine whether ML binds to Aβ42, the mass spectra of Aβ42 samples with 
and without ML were recorded and are shown in Figure 6.3. In the mass spectrum of a 1:5 
mixture of Aβ42 and ML (Figure 6.3a), there were three peaks corresponding to Aβ42 with 
charge (z) to oligomer number (n) ratio z/n = -4, -3, and -5/2, similar to the mass spectrum 
of pure Aβ42 without ML (Figure 6.3b). Moreover, there were two tailing peaks (m/z = 
1611 and 1719, respectively) corresponding to z/n = -3 complexes of Aβ42 with one and 
two ML molecules bound, respectively. These results show that ML binds to Aβ42 directly. 
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 Figure 6.3 ML interacts with Aβ42 directly. Mass spectra of (a) 1: 5 mixture of Aβ42 and 
ML and (b) pure Aβ42. The charge state z/n is noted for each species, where z is the charge 
and n is the oligomer number. 
 
6.3.3 Ion mobility spectrometry: ML modulates Aβ42 early assembly 
To test the effects of ML on Aβ42 assembly, the arrival time distributions (ATDs) of 
the z/n = -5/2 peaks for Aβ42 samples with and without ML were recorded and are shown in 
Figure 6.4. The ATD of the –5/2 peak of Aβ42 without ML (Figure 6.4b ) shows four 
features with arrival times at ~ 720, 680, 620, and 540 μs, previously assigned34 as the -5 
dimer, -10 tetramer, -15 hexamer, and -30 dodecamer, respectively (see ref. 32 for detailed 
discussion of -5/2 peak assignments). The dodecamers, potentially associated with memory 
impairment in mice35, is of particular interest to AD pathology. ATD of -5/2 peak for ML 
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treated Aβ42 exhibited only three features which are assigned to the -5 dimer, -10 tetramer, 
and -15 hexamer based on their cross sections (Figure 6.4a). Notably, the feature 
representing Aβ42 dodecamer is not observed in the presence of ML. In addition, the 
intensity of hexamer feature is lower compared to that of the Aβ42 sample without ML 
(Figure 6.4b). These results indicate that dodecamer formation is completely inhibited and 
hexamer formation is partially inhibited by ML.  
 
Figure 6.4 ML inhibits Aβ42 oligomerization. ATDs of the z/n = -5/2 for (a) 1: 5 mixture of 
Aβ42 and ML, and (b) pure Aβ42. The oligomer number (n) is noted for each species. The 
dashed lines represent the peak shape for a single conformation. 
 
6.3.4 ML remodeling Aβ42 oligomerization 
The ability of ML to disaggregate preformed Aβ aggregates was also explored. The 
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ATD for pure Aβ42 incubated on ice for ~4 hours shows four features corresponding to 
Aβ42 dimers, tetramers, hexamers, and dodecamers (Figure 6.5a). Concentrated ML was 
added to the pre-incubated Aβ42 sample to make a 1:5 mixture of Aβ42 and ML. The -5/2 
ATD of the mixture (Figure 6.5b) shows only three features corresponding to Aβ42 dimers, 
tetramers, hexamers. Note that the dodecamers disappears after the addition of ML, 
implying ML disaggregates pre-formed dodecamers. Taken together, these ion mobility 
studies indicate that ML not only inhibits dodecamer formation but also removes preformed 
dodecamers in the early oligomerization of Aβ42. 
 
Figure 6.5 ML remodels Aβ42 oligomerization. ATDs of the z/n = -5/2 for (a) pure Aβ42 
after 4 hours’ incubation on ice, and (b) after addition of 1:5 ML to the pre-incubated sample. 
The oligomer number (n) is noted for each species. The dashed lines represent the peak 
shape for a single conformation. 
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6.3.5 Effects of ML on Aβ40 oligomerization 
The effects of ML on Aβ40 system were investigated and the results are shown in 
Figure 6.6. In the mass spectrum of the mixture of Aβ40 and ML, a tailing peak 
corresponding to the z/n = −3 complex of Aβ40 and ML was also observed. These results 
suggest ML can directly bind to both Aβ40 and Aβ42 with either a 1:1 or 1:2 Aβ: ML 
stoichiometry. However, ML does not affect the early oligomerization of Aβ40 significantly, 
Aβ40 forming dimers and tetramers with or without ML.  
 
Figure 6.6 Effects of ML on Aβ40. Mass spectra of (a) 1: 5 mixture of Aβ40 and ML and 
(b) pure Aβ40. The charge state z/n is noted for each species, where z is the charge and n is 
the oligomer number. (c) and (d) ATDs of the z/n = -5/2 peak for 1: 5 mixture of Aβ42 and 
ML, and pure Aβ42, respectively. The oligomer number (n) is noted for each species. The 
dashed lines represent the peak shape for a single conformation. 
 
6.3.6 Effects of ML on Metal-associated Aβ42 species 
To further explore the effects of ML on metal-associated Aβ species, we performed 
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MS analysis to examine the interactions of ML and Cu(II)- or Zn(II)-associated Aβ samples. 
The results of Cu(II)-associated Aβ42 samples are shown in Figure 6.7. The mass spectrum 
of a 1:1 mixture of Aβ42 and Cu(II) without ML shows two sets of peaks for each charge 
state z/n = -4, -3, and -5/2, corresponding to Aβ42 with one and two Cu(II) binding, 
respectively (Figure 6.7b). Metal-free Aβ42 species are not observed under these conditions. 
When ML was added to preincubated Cu(II)-Aβ42, a mixture of species was perceived 
(Figure 6.7a). In addition to the peaks observed in ML-free samples corresponding to Aβ42 
with one or two Cu(II), three additional peaks representing metal-free Aβ42 with z/n = -4, -3, 
and -5/2 were also detected, indicating ML can competitively chelate Cu(II) from Aβ42. 
Note that peak intensities of Aβ42 with two Cu(II) bound decreased dramatically upon ML 
addition. A tailing peak corresponding to a complex of Aβ42 with one ML bound was 
observed. Moreover, peaks corresponding to complexes of Aβ42 and ML and one or two 
Cu(II) (m/z = 1633 and 1653, respectively) were present, indicating ML bound to Aβ42 and 
metal-Aβ42. 
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 Figure 6.7 ML interacts with Cu-associated Aβ42 species. Mass spectra of (a) an 1: 1: 2 
mixture of Aβ42, Cu(II), and ML; (b) an 1:1 mixture of Aβ42 and Cu(II). Peaks for pure 
Aβ42, Cu(II)-bound Aβ42, ML-bound Aβ42, and Aβ42-Cu(II)-ML complexes are noted 
with triangles, rectangles, circles, and stars, respectively. 
 
Zn(II)-associated Aβ40/42 were also investigated with ML. The mass spectrum of a 
1: 1: 2 mixture of Aβ42: Zn(II): ML showed peaks corresponding to Aβ42-Zn(II)-ML 
complexes (z/n= -3 and -5/2) as well as slight increased intensity of peaks corresponding 
metal-free Aβ compared to those without ML (Figure 6.8). Overall, these results indicate 
that ML not only forms complexes with both Cu(II)–Aβ and Zn(II)–Aβ but also 
competitively chelates metal ions from metal–Aβ generating metal-free Aβ species.  
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 Figure 6.8 ML interacts with Zn-associated Aβ42 species. Mass spectra of (a) an 1: 1: 2 
mixture of Aβ42, Zn(II), and ML; (b) an 1:1 mixture of Aβ42 and Zn(II). Peaks for pure 
Aβ42, Zn(II)-bound Aβ42, ML-bound Aβ42, and Aβ42-Zn(II)-ML complexes are noted 
with triangles, rectangles, circles, and stars, respectively. 
 
 
As for Aβ40, the mass spectrum of pre-incubated metal-Aβ40 treated with ML 
displayed peaks indicative of both Aβ40-metal-ML complexes and metal-Aβ40 complexes 
(Figure 6.9). 
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 Figure 6.9 ML interacts with metal-associated Aβ40 species. Mass spectra of (a) an 1: 1: 2 
mixture of Aβ40, Cu(II), and ML; (b) an 1:1 mixture of Aβ40 and Cu(II); (c) an 1: 1: 2 
mixture of Aβ40, Zn(II), and ML; (d) an 1:1 mixture of Aβ40 and Zn(II). Peaks for pure 
Aβ40, Metal-bound Aβ40, ML-bound Aβ40, and Aβ40-Metal-ML complexes are noted 
with triangles, rectangles, circles, and stars, respectively. 
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6.3.7 Effects of ML on the fibril formation of Aβ and metal-Aβ species 
Morphological alterations of Aβ species were examined by TEM and the results are 
shown in Figure 6.10. Upon incubation of both Aβ40 and Aβ42 without metal ions for 24 h 
at 37 °C, well-ordered, fibril structures were observed. Even more aggregated forms were 
observed in the presence of Cu(II) or Zn(II). Addition of ML to both Aβ40 and Aβ42 
aggregates resulted in aggregates which were much smaller and less ordered than in the 
controls in the absence of ML. These results clearly show that compound ML is able to 
inhibit metal-induced Aβ fibril formation. 
 
Figure 10. The Effects of ML on the fibril formation of Aβ and Metal-associated Aβ. TEM 
images of (a) Aβ42 and (b) Aβ40 samples with 24 hours’ incubation at 37 °C. 
- ML
+ ML
- ML
+ ML
a)
b)
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 6.3.8 ML rescues Aβ and metal-associated Aβ induced cell toxicity 
We examined the neuroprotective properties of ML toward Aβ- or metal–Aβ-
induced toxicity in murine Neuro-2a neuroblastoma cells with and without overexpression 
of the Swedish mutant human APP (N2aAPPswe AD cell line42; both Aβ40 and Aβ42 were 
examined). Cells incubated with Aβ (10 μM) for 24 h with/without metal (Cu(II) or Zn(II), 
10 μM) showed viability of ca. 70% (Aβ), ca. 60–70% (Aβ with Cu(II)), or ca. 70% (Aβ 
with Zn(II)) (Figure 6.11a). Upon addition of ML (10 μM) to Aβ-treated N2aAPPswe or 
N2a cells, ca. 100% cell survival was observed with and without metal ions (Figure 6.11a). 
Overall, our cell studies suggest ML may regulate metal-free and metal-associated Aβ-
induced toxicity in living cells. 
 
Figure 6.11 Effect of ML on toxicity triggered by metal-free Aβ and metal-Aβ species in 
N2aAPPswe cells. Cells treated with Aβ (10 μM), a metal chloride salt (CuCl2 or ZnCl2; 10 
μM), or ML (10 μM) were incubated for 24 h at 37 °C. Cell viability (%) was determined by 
the MTT assay compared to cells treated with DMSO only (0−1%, v/v) (MTT = 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide). Data are mean ± SEM, P < 
0.05, n = 3.  
150 
 
 6.3.9 ROS formation control, antioxidant activity, and BBB permeability of ML 
From a biological perspective, inhibiting ROS formation by binding and constraining 
Cu(II) from redox cycling is an attractive feature. Accordingly, we explored the inhibitory 
ability of ML toward ROS production by 2-deoxyribose assay. As shown in Figure 6.12, 
copper-mediated generation of hydroxyl radicals is significantly reduced upon treatment 
with ML.  
 
Figure 6.12 Inhibitory activity toward ROS formation in the absence and presence of 
freshly prepared Aβ40 (normal condition) and Aβ40 aggregates (inhibition and 
disaggregation conditions), determined by the 2-deoxyribose assay. The absorbance values 
are normalized compared to ligand-free condition (Aβ/CuCl2/ML = 25/10/125 μM). 
 
The antioxidant activity of ML was evaluated by the Trolox equivalent antioxidant 
capacity (TEAC) assay which measures a compound’s ability to quench ABTS cation 
radicals (ABTS+•; ABTS = 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid))27-28,36. 
ML scavenges free radicals more effectively than 1 and Trolox (vitamin E analogue) by a 
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factor of 2.6 (Figure 6.13), suggesting the presence of both quinoline and phenolic groups 
within one framework could enhance antioxidant capability. 
 
Figure 6.13 Antioxidant activity of ML, DAP, 1, and a mixture of DAP and 1 (DAP + 1) 
identified by the TEAC assay. The TEAC values are relative to a vitamin E analogue, 
Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). 
 
Lastly, for potential brain applications, the BBB permeability of ML, predicted from 
Lipinski’s rules and logBB (Table 6.1), was examined by the parallel artificial membrane 
permeability assay adapted for BBB (PAMPA-BBB)15,19,25,29-30. These values (Table 6.1), 
when compared to previously reported BBB permeable molecules25,29-30, indicate that ML 
may cross the BBB, making this molecule valuable for potential brain applications.  
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Table 6.1 | Values (MW, clogP, HBA, HBD, PSA, logBB, and −logPe)a of ML and 1. 
a MW, molecular weight; clogP, calculated logarithm of the octanol-water partition 
coefficient; HBA, hydrogen bond acceptor atoms; HBD, hydrogen bond donor atoms; PSA, 
polar surface area; logBB = −0.0148 × PSA + 0.152 × clogP + 0.139 (logBB > 3.0, readily 
crosses BBB; logBB < −1.0, poorly distributed to the brain); −logPe values were determined 
using the Parallel Artificial Membrane Permeability assay (PAMPA) and average −logPe 
values were then calculated by the PAMPA9 Explorer software v. 3.5. b Prediction of a 
compound’s ability to penetrate the central nervous system (CNS) based on suggested 
values. Compounds categorized as CNS+ possess the ability to penetrate the BBB and are 
available in the CNS. Compounds assigned as CNS−, have poor permeability through the 
BBB and therefore their bioavailability into the CNS is considered to be minimal.  
 
6.4 Conclusions 
The complexity of AD is suggested to arise from multiple pathological factors such 
as Aβ/metal-Aβ species, metal ions, and free radicals; however, the roles of individual 
elements and, more importantly, their inter-connections in disease development remain 
unclear. To advance our understanding of this aspect and target/control all these features, we 
have rationally designed a novel molecule, ML, by incorporating structural moieties for 
Aβ/metal-Aβ interactions, metal chelation, ROS generation control, and antioxidant activity 
into a single framework. Water solubility and BBB permeability were considered for 
potential biological applications, particularly in the brain, as part of our design approach. To 
the best of our knowledge, ML is the first example of a single molecule that can control 
multiple reactivities, i.e., metal-free and metal-induced Aβ aggregation, toxicity induced by 
Aβ and metal-Aβ, ROS generation, and free radical reactions. ML’s multifunctionality 
validates our rational structure-based design strategy, and substantiates that a molecule can 
be tailored to a specific purpose despite the challenges and complexity of the pathological 
features of the disease it is intended to examine. Our efforts presented herein build a 
foundation toward the development of chemical tools for uncovering complex AD 
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pathogenesis and serve as a step for the discovery of effective therapeutics for this disease. 
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the Protective A2TMutation and the Recessive A2V 
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7.1 Introduction 
Although most AD cases occur sporadically, ~5% of AD cases are caused by 
mutations in the APP1-2, presenilin 1 (PS1)3-4, or presenilin 2 (PS2)5 genes. These familial 
AD (FAD) cases, often lead to early onset of disease (<60 years of age). Numerous FAD-
related mutations in the APP gene have been identified and many of them are near β- or γ-
secretase cleavage sites. This results most commonly in overproduction of Aβ or relative 
increases in the amount of Aβ42 that is produced relative to Aβ406. However, as many 
mutations occur within the Aβ region, it is very likely that these substitutions would alter the 
structural and aggregation properties of the resultant Aβ42 and Aβ40 peptides. Notably, 
many mutations in the APP gene result in amino acid substitutions within the central region 
of Aβ, as, for example, Flemish (A21G)7, Arctic (E22G)8, Dutch (E22Q)9, Osaka (E22Δ)10, 
Italian (E22K)11 and D23N (Iowa)12 mutations. The resulting peptides exhibit distinct 
aggregation propensity and toxicity. The central region of Aβ has been shown to be crucial 
for the initial nucleation of Aβ folding and assembly13. Mutations near this region may 
disrupt the Aβ conformation, resulting in increased aggregation propensity and formation of 
toxic oligomers14.  
On the other hand, the role of the N-terminus in aggregation, toxicity and pathology 
has been less thoroughly studied due to the fact that this region appears disordered in the 
fibril state15-16. However, as with the central region of Aβ, a number of APP mutations result 
in amino acid substitutions at the N-terminus, and these substitutions alter Aβ assembly. 
These include the English (H6R)17-18, Tottori (D7N)17-20, and Taiwanese (D7H)21 mutations. 
The importance of the Aβ N-terminus in disease causation thus is clear. Most recently, two 
new APP mutations have been described that result in the substitutions A2T and A2V can be 
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important in Aβ structure and assembly22-23. In the work presented here, we elucidate the 
effects on early Aβ assembly of these two recently discovered mutations.  
The A2T substitution substantially decreases AD risk, as well as protecting against age-
related cognitive decline in the elderly without AD22. It is thought to be the first example of 
a sequence variant that protects against AD. The A2T substitution occurs immediately 
adjacent to the β-secretase site, and indeed, the mutation has been found to reduce Aβ 
production ~20% in heterozygous carriers. Such a reduction may be responsible for its 
protective function in AD pathology22. However, as the mutation is within the Aβ sequence, 
it is possible that the A2T mutation also changes the aggregation properties of Aβ proteins, 
thus contributing to its protective effect, a possibility we investigate here.  
The mutation causing the A2V substitution results in early onset AD in the homozygotes, 
whereas some protection against AD is observed in heterozygotes23. In contrast to the A2T 
substitution, A2V increases Aβ production. Interestingly, co-incubation of A2V Aβ42 and 
wt Aβ42 produced slower aggregation rates than exhibited by either peptide alone, as well as 
decreased toxicity23.  The A2V substitution accelerates Aβ42 oligomerization and also leads 
to the production of annular structures with a higher hydrophobicity than wt Aβ4224. 
A consensus regarding the effects of the A2T and A2V substitutions on Aβ assembly has 
not been reached. Two recent studies of A2T and A2V peptides reported different 
aggregation kinetics by thioflavin T (ThT) fluorescence studies. Benilova et al. showed that 
the A2T substitution has little effect on Aβ42 aggregation, but did affect its solubility25.  
Maloney et al., in contrast, showed that the A2T mutant had a lower aggregation propensity 
compared to the A2V mutant or to wt Aβ4226. For Aβ40, the A2T mutant was shown to 
 
161 
aggregate similarly to wt, whereas the A2V mutant exhibited faster aggregation and a 
shorter lag phase, making this peptide behave more Aβ42-like25-26. 
To improve our understanding of the A2T and A2V substitutions, we used ion mobility 
coupled to mass spectrometry (IM-MS) to examine the early assembly and subsequent 
aggregation of these mutant peptides. We examine here the early oligomer distributions of 
A2T- and A2V-containing Aβ40 and Aβ42 to understand how each assembles and whether 
the early assembly pathways are identical or different. We also examine the early oligomer 
distributions of mixtures of wt and mutant peptides to understand how each affects the 
other’s assembly. This provides the means to model in vitro the homozygous and 
heterozygous states that exist in humans. These studies provide mechanistic insights into the 
aetiology of FAD, mechanisms of protection from FAD, and potential targets for therapeutic 
agents. 
 
7.2 Methods 
Peptide and Sample preparation: Full-length Aβ and mutants were synthesized by 
N-9-fluorenylmethoxycarbonyl (FMOC) chemistry27. The peptides were purified by reverse-
phase HPLC and their quality validated by mass spectrometry and amino acid analysis. 
Samples were prepared in 10 mM ammonium acetate buffer, pH 7.4, at a final peptide 
concentration of 10 μM. Equimolar mixtures of wt and mutant Aβ were prepared at a total 
peptide concentration of 10 μM (5 μM of each peptide).  
Mass Spectrometry and Ion Mobility spectrometry Analysis: Most data were 
recorded on a home-built ion mobility spectrometry-mass spectrometer28 described in 
Chapter 2 or a Micromass QTOF2 quadrupole/time-of-flight tandem mass spectrometer.  
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 7.3 Results 
7.3.1 Different oligomer distributions of wt and mutant Aβ42.  
Mass spectra of wt Aβ42, A2T, and A2V were recorded individually and are shown 
in Figure 7.1. Four common peaks were observed for each peptide, corresponding to z/n 
ratios of -4, -3, -5/2 and -2, where z is charge and n is oligomer size. The mass spectrum of 
A2V Aβ42 was interesting because in addition to the four peaks, another peak was observed 
between z/n = -3 and -5/2 in the spectrum, corresponding to z/n = -8/3. This indicates the 
A2V mutant forms a trimer, which is not observed for wt or A2T Aβ42. Moreover, there is 
another peak between z/n = -4 and -3 for A2V, denoted by *, which is assigned as fragment 
peak or impurity.  
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 Figure 7.1. a-c) Mass spectra of A2T, A2V and wt Aβ42. The charge state of each species is 
noted with z/n, where z is the charge and n is oligomer number. The peak marked with * in 
panel b is assigned as a fragment peak or impurity. 
 
The arrival time distributions (ATDs) of the z/n = -5/2 peaks for all three Aβ42 
alloforms are shown in Figure 7.2. The ATD of wt Aβ42 shows four features, with arrival 
times at ~710, 670, 610 and 540 μs, which were previously assigned as Aβ42 dimer, 
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tetramer, hexamer, and dodecamer, respectively, based on their calculated collision cross 
sections (See reference 7 for detailed discussion of these assignments). However, the ATD 
of A2T or A2V Aβ42 (Figure 7.2a or b) shows only three features, with arrival times at 
~710, 670, 610 μs which were assigned as dimer, tetramer, and hexamer, respectively, based 
on their calculated cross sections. There is no feature at lower arrival time observed in either 
of the ATD for mutants, indicating no other oligomers larger than hexamers are formed. 
These results suggest the formation of Aβ42 dodecamer is inhibited by both A2T and A2V 
mutations.  
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 Figure 7.2 a-c) ATDs of z/n = -5/2 peaks for A2T, A2V and wt Aβ42. The oligomer order 
(n) is noted for each feature. The dashed lines represent the peak shape for a single 
conformation. The injection energy in panels d, e, and f is 40 eV. 
 
To assign the peaks in the ATDs unambiguously, and to better understand the 
oligomer distributions of the Aβ42 mutants, the -5/2 ATDs for Aβ42 mutants were measured 
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at different injection energies. At low injection energy, the ions are rapidly thermalized by 
cooling collisions with the helium gas in the drift cell and therefore large complexes can be 
preserved through the process. At high injection energy, the ions are given sufficient energy 
to lead to internal excitation which can cause isomerization into low energy structure or 
dissociation of large noncovalent complexes into smaller species. 
As shown in Figure 7.3, the ATDs measured at intermediate injection energy (40 eV) 
are the same ones shown in Figure 7.2b and c. When the injection energy is lowered to 25 
eV (Figure 7.3 top panel), the hexamer peak becomes especially prominent, whereas the 
tetramer and dimer features decrease. However, there are still no peaks with lower arrival 
times observed, suggesting that oligomers of size dodecamer or larger are not formed in 
solution. At high injection energy (100 eV, Figure 7.3 bottom panel), the hexamer peak 
disappears whereas the tetramer and dimer peaks dominate the spectrum. This suggests 
hexamer dissociation into smaller oligomers. These injection energy studies are fully 
consistent with the assignment of the three peaks in the ATDs as dimer, tetramer, and 
hexamer. 
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Figure 7.3 ATDs for z/n = -5/2 peaks for a) Aβ42 A2T and b) Aβ42 A2V under different 
injection energies. The oligomer order (n) is noted for each feature. The dashed lines 
represent the peak shape for a single conformation. 
 
7.3.2 Ion mobility study of z/n = -2 and -8/3 peaks: A2V Aβ42 forms trimers.  
The z/n = -2 Aβ42 is a relative low charge state of the Aβ42 alloforms and possibly 
consists of high order oligomers, making its ATD of interest. The signal of the z/n = -2 peak 
for wt Aβ42 is too low to obtain a reliable ATD, therefore no data is shown. However, we 
were able to record ATDs for the -2 peaks of A2T and A2V Aβ42 (Figure 7.4).  
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The ATD of -2 A2T Aβ42 shows three features, with arrival times at ~820, 720, 670 
μs, which can be assigned as monomer, dimer, and trimer, respectively.  Similarly, the ATD 
of the z/n = -2 A2V Aβ42 shows three features, corresponding to monomer, dimer and 
trimer. However, the relative intensity of the A2T trimer is much lower than that of its dimer 
while the relative intensity of the A2V trimer is comparable to that of its dimer, indicating 
the formation of trimer is more favored for A2V Aβ42.   
 
Figure 7.4 a) and b), ATDs of the z/n = -2 peaks for A2T and A2V Aβ42, respectively. c) 
ATD of the z/n = -8/3 peak for A2V. The dashed lines represent the peak shape for a single 
conformation. The oligomer order is noted for each feature where M represents monomer, D 
represents dimer, Tr represents trimer and H represents hexamer. The injection energy is 40 
eV. 
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Injection energy studies of z/n = -2 peaks (Figure 7.5) show that at low injection 
energies the trimer of A2V Aβ42 is dominant while the trimer of A2T Aβ42 remains minor, 
indicating trimer in the A2V mutant is significant in solution. This supports that the 
formation of trimer is more favored for A2V Aβ42 than for A2T Aβ42. 
 
 
 
Figure 7.5 ATDs for z/n = -2 peaks for a) A2T Aβ42, b) A2V Aβ42 under different 
injection energies. The oligomer order is noted for each feature where M represents 
monomers, D represents dimer and Tr represents trimers, H represents hexamer. The dashed 
lines represent the peak shape for a single conformation. 
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The ATD of z/n = -8/3 A2V Aβ42 (Figure 7.6 middle panel, 40 eV) shows two 
features, with arrival times at ~660 and 590 μs observed, which correspond to an A2V 
trimer and hexamer, respectively. The breadth of the trimer feature indicates there is a 
family of trimer structures existing in the solution. The injection energy study shows that the 
hexamer feature increases at lowest energies and the trimer peak gets sharper (Figure 7.6 top 
panel, 25 eV). At high energy (Figure 7.6 bottom panel, 100 eV), the hexamer feature 
disappears and the broad trimer feature becomes the dominant peak.  
Taken together, these ion mobility results reveal that the oligomerization pattern is 
different for each of the alloforms. wt Aβ42 forms dimer, tetramer, hexamer, and dodecamer. 
A2T and A2V Aβ42 form dimer, tetramer, and hexamer, without the formation of 
dodecamer, but A2V forms a significant trimer which is only very minor in A2T and may 
not be present in wt Aβ42 at all. 
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Figure 7.6 ATDs for z/n = -8/3 peak for A2V Aβ42 under different injection energies. The 
oligomer order is noted for each feature where Tr represents trimers, H represents hexamer. 
The dashed lines represent the peak shape for a single conformation. 
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7.3.3 Mixtures of wt and mutant Aβ42: The effects on wt Aβ42 oligomerization 
The A2T mutation has been shown to protect carriers from AD or normal age-related 
cognitive decline22. To model the effects of this peptide in heterozygotes, we created an 
equimolar mixture of A2T and wt Aβ42 and then performed MS (Figure 7.7). Four sets of 
peaks were observed, corresponding to z/n = -4, -3, -5/2 and -2 charge states. A zoom-in 
spectrum of the -5/2 region using the QTOF-MS was obtained and shows that there are three 
peaks with charge state of -5/2, which correspond to -5/2 wt Aβ42 homo-oligomers, wt/A2T 
hetero-oligomers (1:1 ratio), and A2T homo-oligomers. The ATDs of these three peaks 
(Figure 7.7b, c, d) display a similar oligomer distribution with three features with arrival 
times of ~710, 670 and 600 μs. We assign these features as dimers, tetramers, and hexamers, 
respectively. Note that no feature at shorter arrival time was observed, indicating there is no 
homo-/hetero-dodecamer or higher oligomer formation. These results indicate that the A2T 
mutant forms small hetero-oligomers (up to hetero-hexamers) with wt Aβ42 and inhibits the 
formation of wt Aβ42 dodecamer or higher oligomers.  
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 Figure 7.7 Ion mobility study of an equimolar mixture of wt and A2T Aβ42. a) A full mass 
spectrum of wt/A2T Aβ42 mixture and a zoom-in spectrum of z/n = -5/2 peaks which 
contains three species which correspond to wt Aβ42 homo-oligomers, wt/A2T Aβ42 hetero-
oligomers and A2T Aβ42 homo-oligomers. b-d) ATDs of the three -5/2 oligomer peaks.  
The oligomer order (n) is noted for each feature. The dashed lines represent the peak shape 
for a single conformation.  The injection energy in panels b, c, and d is 40 eV. 
 
Previous studies showed that A2V is a recessive mutation that causes early-onset of 
AD in homozygotes but appears protective in heterozygotes23. To provide insight into this 
these observations, we performed ion mobility studies on an equimolar mixture of wt and 
A2V Aβ42 (Figure 7.8). Similar to the A2T/wt mixture, the A2V/wt mixture shows three -
5/2 peaks, corresponding to wt Aβ42 homo-oligomers, wt/A2V hetero-oligomers (1:1 ratio) 
and A2V homo-oligomers. The ATDs of these -5/2 peaks all show three features that can be 
assigned as dimer, tetramer, and hexamer, respectively. The data show that A2V Aβ42 
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forms small hetero-oligomers (only up to hexamers) with wt Aβ42 and prevents the 
formation of larger oligomers.  
 
 
Figure 7.8 Ion mobility study of an equimolar mixture of wt Aβ42 and A2V mutant. a) A 
full mass spectrum of A2V/wt Aβ42 mixture and a zoom-in spectrum of z/n = -5/2 peaks 
which contains three species which correspond to wt Aβ42 homo-oligomers, wt /A2V Aβ42 
hetero-oligomers and A2V Aβ42 homo-oligomers. b-d) ATDs of the three -5/2 oligomer 
peaks. Each ATD is ﬁtted with multiple features using the procedure described in the 
experimental section and the oligomer order (n) is noted for each feature.  The injection 
energy in panels b, c, and d is 40 eV. 
 
There is no -8/3 trimer peak observed in the equimolar mixture of wt and A2V Aβ42. 
Moreover, the ATD of the z/n = -2 peak for the wt/A2V mixture (Figure 7.9b shows a 
dominant dimer peak and only a minor trimer peak, unlike A2V alone (Figure 7.4b). These 
results indicate that A2V trimer formation is inhibited by wt Aβ42.  
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Figure 7.9 ATDs of z/n = -2 for the A2T/wt and A2V/wt Aβ42 mixtures. The oligomer 
order is noted for each feature where M represents monomers, D represents dimer and Tr 
represents trimers. The dashed lines represent the peak shape for a single conformation. The 
injection energy in panels a, and b is 40 eV. 
 
7.3.4 Ion mobility study of Aβ40 mutants: A2V Aβ40 forms hexamer and dodecamer 
We next examined the effects of the A2T and A2V substitutions on Aβ40 assembly 
(see Figure 7.10). The mass spectra for the A2T and A2V mutants (Figure 7.10b and c) 
showed four peaks, corresponding to z/n = -4, -3, -5/2 and -2, which is similar to that of the 
wt Aβ40 (Figure 7.10a).  
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 Figure 7.10 a-c) Mass spectra of Aβ40 wt , A2T and A2V. The charge state of each species 
is noted with z/n, where z is the charge and n is oligomer number. d-f) ATDs of z/n = -5/2 
peaks for Aβ40 wt, A2T and A2V. g-i) ATDs of z/n = -2 peaks for Aβ40 wt, A2T and A2V. 
Each ATD is ﬁtted with multiple features using the procedure described in the experimental 
section and the oligomer order (n) is noted for each feature.  The injection energy in panels d, 
e, f, g, h, and i is 40 eV. 
 
The ATD of z/n = -5/2 wt Aβ40 (Figure 7.11a) displays two features, with arrival 
times at ~710 and 670 μs, which were previously assigned as Aβ40 dimer and tetramer, 
respectively29. The ATD of the z/n = -5/2 A2T Aβ40 (Figure 7.11b) again shows two 
features, with arrival times at ~710 and 670 μs, corresponding to dimer and tetramer, 
respectively. This ATD was similar to that of wt Aβ40. However, the ATD of z/n = -5/2 
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A2V Aβ40 (Figure 7.11c) shows four features with arrival times of ~710, 670, 620 and 550 
μs, which can be assigned as dimer, tetramer, hexamer and dodecamer, respectively. Hence, 
A2V Aβ40 forms hexamers and dodecamers, something not observed for wt or A2T Aβ40. 
This is consistent with previous ThT studies showing A2V Aβ40 displays a shorter lag 
phase during aggregation, which is similar to that of wt Aβ4225-26.  
 
 
Figure 7.11 a-c) ATDs of z/n = -5/2 peaks for Aβ40 wt, A2T and A2V. Each ATD is ﬁtted 
with multiple features using the procedure described in the experimental section and the 
oligomer order (n) is noted for each feature.  The injection energy is 40 eV. 
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 The ATDs of z/n = -2 Aβ40 alloforms were recorded and are shown in Figure 7.12. 
The ATD of wt Aβ40 shows a dominant dimer peak at ~720 μs and a small monomer peak 
at ~840 μs. The dimer peak is slightly broad at the bottom, which indicates there might be a 
small amount of trimer formed. The ATDs of A2T and A2V Aβ40 (Figure 7.12b and c) 
show one additional peak, with a shorter arrival time at ~680 μs, which is assigned as trimer. 
The relative intensity of the A2V trimer is greater than that of the A2T trimer or wt Aβ40 
trimer. This is consistent with the results of z/n = -5/2 peaks, which suggests that A2V Aβ40 
is aggregating into larger oligomers than is A2T and wt Aβ40.  
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Figure 7.12 a-c) ATDs of z/n = -2 peaks for Aβ40 wt, A2T and A2V. The dashed lines 
represent the peak shape for a single conformation. The oligomer order (n) is noted for each 
feature.  The injection energy is 40 eV. 
 
In summary, the A2T mutation does not significantly change Aβ40 oligomerization. 
The A2V mutation, in contrast, promotes Aβ40 oligomerization and causes it to undergo a 
more "Aβ42-like" aggregation process. Although the relative intensity of the A2V 
dodecamer is smaller than observed for wt Aβ42 (Figure 7.2c), the Aβ40 isoform is ten 
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times more abundant than Aβ42 in vivo. Hence this is a significant result and is fully 
consistent with the fact homozygous carriers of the A2V mutation develop early-onset of 
AD. 
The results of co-incubation experiments using wt and mutant Aβ40 are shown in the 
Figure 7.13 and 14. The mass spectrum of wt/A2T Aβ40 mixture (Figure 7.13a) shows four 
sets of peaks corresponding to z/n = -4, -3, -5/2 and -2 charge states. The ATDs of the -5/2 
oligomer peaks (Figure 7.13b, c and d) show two features with arrival times at ~710 and 670 
μs, which can be assigned as wt/A2T homo- or hetero-dimers, tetramers, based on their cross 
sections. This result is consistent with the results of the wt/A2T Aβ42 mixture that A2T 
inhibits the formation of wt Aβ42 dodecamer and that A2T mutation protects against AD 
and protects against the cognitive decline in the elderly without AD. 
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Figure 7.13 Ion mobility study of an equimolar mixture of Aβ40 wt and A2T mutant. a) 
Mass spectrum of Aβ40 A2T/wt mixture. b-d) ATDs of three -5/2 oligomer peaks. The 
oligomer order (n) is noted for each feature. The injection energy in panels b, c, and d is 40 
eV. 
 
Ion mobility studies of an equimolar mixture of A2V and wt Aβ40 were performed 
and the results are shown in Figure 7.14. The mass spectrum of Aβ40 wt/A2V mixture 
(Figure 7.14a) shows four sets of peaks corresponding to z/n = -4, -3, -5/2 and -2 charge 
states. The ATDs of the -5/2 oligomer peaks all display two features with arrival times at 
~710 and 670 μs, which can be assigned as wt/A2V Aβ40 homo- or hetero-dimers, tetramers 
and no larger oligomers especially hexamers and dodecamers are observed. These results 
indicate that A2V mutant forms small hetero-oligomers (hetero-dimer and tetramers) with wt 
Aβ40 and inhibits the formation of A2V Aβ40 hexamer or dodecamer. This is important 
because it indicates wt Aβ40 inhibits formation of A2V hexamer or dodecamer. Hence, 
heterozygous A2V carriers are protected from dodecamer formation while homozygous 
A2V carriers are not. 
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 Figure 7.14 Ion mobility study of an equimolar mixture of wt and A2V Aβ40. a) mass 
spectrum of the A2V/wt Aβ40 mixture. b-d) ATDs of three -5/2 oligomer peaks. The 
oligomer order (n) is noted for each feature. The injection energy in panels b, c, and d is 40 
eV. 
 
7.4 Discussion 
Our results show that amino acid substitutions at Ala2 of Aβ affect Aβ42 
oligomerization (summarized in Figure 7.15). The Iceland mutation A2T was observed to 
prevent the formation of Aβ42 dodecamer, which was previously identified as an important 
neurotoxin in AD30-31. These results are consistent with previous studies demonstrating that 
A2T is a protective mutation22. However, our ion mobility studies show that the A2T 
mutation does not have a significant effect on oligomerization of the less toxic Aβ40 
isoform.  
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The A2V mutation was observed to inhibit the formation of Aβ42 dodecamer as well. 
However, the A2V mutation leads to a much greater fraction of Aβ42 trimer formation and 
observation of a unique z/n = -8/3 trimer peak that contains a significant fraction of hexamer 
not formed in A2T or wt Aβ42. This result implies A2V Aβ42 may adopt another early 
assembly pathway through trimer that leads to toxic oligomers before going on to form 
fibrils. Even more interestingly, the A2V mutation shows significant effects on Aβ40 
assembly, resulting in the formation of Aβ40 hexamer and dodecamer, which are not 
observed for A2T or wt Aβ40. Hence, the A2V mutation changes the Aβ40 aggregation 
pathway into a Aβ42-like pathway, which is consistent with a previous ThT fluorescence 
study showing A2V has a shorter aggregation lag phase than wt Aβ4025. Although the 
relative intensity of dodecamer in A2V Aβ40 is smaller than for wt Aβ42 (Figure 7.1f), this 
peptide is ten times more abundant than Aβ42 in vivo and hence the fact it produces 
potentially toxic oligomer states will be strongly amplified in vivo. This result, while not 
proof, is entirely consistent with the fact the A2V mutant results in early onset AD in 
homozygous carriers23. 
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 Figure 7.15 Different oligomerization patterns for wt Aβ, A2T, A2V alloforms and mixtures. 
M, D, Tr, Te, H, Do represent monomer, dimer, trimer, tetramer, hexamer and dodecamer, 
respectively. 
 
The effects of the A2T and A2V substitutions on wt Aβ42 oligomerization were 
evaluated by co-incubating equimolar mixtures of the mutant and wt Aβ42 proteins. Both 
mutants formed small hetero-oligomers with wt Aβ42, including dimers, tetramers, and 
hexamers. However, no hetero- or homo-dodecamers were observed, indicating the 
formation of Aβ42 dodecamer is inhibited by the mutants. Co-incubation of A2T and wt 
Aβ40 shows formation of dimers and tetramers, which is similar to that of wt Aβ40, 
indicating no enhancement of aggregation by A2T (Figure 7.13). However, co-incubation of 
A2V and wt Aβ40 shows only homo- and hetero-dimer and tetramer formation, indicating 
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thathexamer and dodecamer formation is inhibited (Figure 7.14). This indicates that rapid 
A2V aggregation is inhibited by wt Aβ40. These results are consistent with previous studies 
suggesting that A2T protects against AD and A2V heterozygous carriers are not affected by 
this mutation22-23.  
The N-terminus of Aβ is relatively hydrophilic and appears to exist in a disordered 
state. It thus has been argued that it plays only a modest (or no) role in controlling Aβ 
assembly compared to the central hydrophobic cluster region or the C-terminus 15. However, 
we find here that single A2T and A2V amino acid substitutions  do affect Aβ 
oligomerization quite significantly, offering a mechanistic explanation for the phenotypes of 
humans expressing the cognate genes.  
Threonine (T) and valine (V) have similar sizes but different hydrophobicity. The 
substitution of the neutral alanine (A) with a nucleophilic threonine or a hydrophobic valine 
will change the hydrophobicity of the N-terminus region and perhaps change the 
conformation of Aβ. A recent simulation study of A2T and A2V Aβ42 showed significantly 
different conformational landscapes of the Aβ42 monomer32. The A2T Aβ42 mutant makes 
the N-terminus more polar, which displays unusual long-range electrostatic interactions with 
residues such as Lys16 and Glu2232. Through such electrostatic interactions, the hairpin 
structure in the central hydrophobic region is disrupted, resulting in a population of unique 
conformations with only a C-terminal hairpin. In contrast, the A2V Aβ42 shows an 
enhanced double-hairpin population due to hydrophobic interactions between the N-
terminus and distant hydrophobic regions (Central hydrophobic core and C-terminus 
hydrophobic region)32. A previous simulation showed that the A2V mutation reduced the 
intrinsic disorder and increased the hairpin population in the Aβ(1-28) monomer33. In 
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addition, a previous MD simulation study showed that the N-terminus of Aβ40 displayed a 
β-strand structure at Ala-2-Phe-4 which was not present in Aβ4234. The hydrophilic N-
termini of Aβ proteins are on the surface of the oligomers, thus the presence of an N-
terminal β-strand in Aβ40 might prevent the hydrophobic core of the oligomers from adding 
additional Aβ40 molecules to form larger oligomers, which explains why Aβ40 aggregates 
slower and forms smaller oligomers than Aβ42. Therefore the substitution of Ala with a 
hydrophobic Val may disrupt the formation of a hydrophilic N-terminal β-strand and make 
the hydrophobic core accessible for other Aβ40 molecules, shifting the A2V Aβ40 
oligomerization toward those of Aβ42.  Our ion mobility studies reveal different 
oligomerization for Aβ proteins with a single mutation in the N-terminus region and imply 
the importance of the N-terminus region for Aβ assembly, results consistent with these 
previous studies32-34. 
In this work, we have demonstrated that IMS-MS is becoming a powerful tool to 
carry out studies that lead to understanding of AD familial mutations. This is of significance 
as single mutations have been implied to be important in disease aetiology. For instance, 
recently the G127V mutation in a prion variant has been shown to completely protect 
transgenic mice from prion disease35. Hence understanding the mechanism of these positive 
substitutions becomes important for future therapeutic development. Thus IMS-MS can be 
used as a new tool to study other systems of this kind and provide an insight into their 
structure-disease relationship. 
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7.5 Conclusions 
1. The A2T mutation prevents formation of Aβ42 dodecamer both in homo- and 
heterozygotes.  The dodecamer has been implicated as a proximate toxic agent in 
AD.  
2. The A2V mutation in homozygotes also prevents dodecamer formation in Aβ42 but 
promotes trimer formation which may initiate a new pathway for early oligomer 
formation in Aβ42. 
3. The A2V mutation in homozygotes promotes hexamer and dodecamer formation in 
Aβ40, whereas wt Aβ40 assembly terminates at the tetramer. Since Aβ40 is 10 times 
more prevalent than Aβ42 in vivo, facilitation of Aβ40 hexamer and dodecamer 
formation may well explain why the A2V mutation causes early onset of AD in 
homozygotes.  
4. Both the A2T and A2V mutations eliminate dodecamer formation in heterotypic 
mixtures with wt Aβ40 and Aβ42, consistent with the protective effects of these 
substitutions in heterozygotes.  
5. Ion mobility methods are emerging as an important new tool in developing an 
understanding of the effect of familial mutations on Aβ assembly in AD and the 
assembly of other mutated protein systems. 
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Chapter 8 
Role of Species-Specific Primary Structure 
Differences in Aβ42 Assembly and Neurotoxicity 
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8.1 Introduction 
Alzheimer’s disease (AD) is the most common form of late-life dementia1. An 
important working hypothesis of disease causation is aberrant folding and assembly of 
AΒ422. This assembly leads to the production of extracellular amyloid plaques by the 
amyloid β-protein (Aβ) and of intracellular neurofibrillary tangles by tau. Such 
histopathologic findings are pathognomonic for AD and accompany progressive declines in 
cognitive ability and executive function1,3-5. AD pathology also has been observed in dogs, 
polar bears, rabbits, cows, sheep, pigs, guinea pigs, orangutans, and rhesus monkeys, but 
until recently, it has not been found in mice or rats6-8. In 2005, Inestrosa et al.9-10 reported 
that the brush-tailed rat, Octodon degus (a rodent indigenous to Chile), normally expresses 
neuronal APP695 and displays both intra- and extra-cellular deposits of Aβ, intracellular 
accumulation of phosphorylated tau, strong astrocytic responses, and pyramidal neurons rich 
in acetylcholinesterase. O. degus naturally develop these neuropathological signs of AD 
between 12-36 months of age. This pathology has been correlated with decreases in spatial 
and object recognition memory, postsynaptic function, and synaptic plasticity11-12. 
Interestingly, the brains from another rodent, the naked mole rat (the longest lived rodent, 
with a life span ≈32 years) showed levels of Aβ42 similar to a 3X-Tg-AD mouse model of 
AD13. 
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Figure 8.1 Primary structures of human, Mm, and Od Aβ42. One-letter amino acid code 
is used to present the sequences of each Aβ42 peptide. Underlined, italicized letters indicate 
amino acid differences or substitutions among the peptides. 
 
Examination of the primary structure of Aβ42 in O. degus and in the naked mole rat 
reveals 100% identity13-14, and this amino acid sequence is identical to that of human Aβ42, 
except for a His13Arg substitution (Figure 8.1). In contrast, mouse (Mus musculus; Mm) 
Aβ42 differs from human Aβ42 in having three amino acid substitutions, Arg5Gly, 
His13Arg, and Tyr10Phe6,15-17. Mutations in the amyloid β-protein precursor (APP) that 
result in amino acid substitutions at other sites in Aβ cause familial AD and cerebral 
amyloid angiopathy (CAA) 1. It is particularly interesting that an identical amino acid 
substitution in humans, His→Arg (the English mutation), but at His6 rather than His13, may 
be associated with AD18. Whether this mutation is causative or simply a polymorphism 
remains unclear, but incorporation of this substitution into Aβ has been found to 
substantially increase β-sheet formation, fibril seeding ability, and formation of toxic 
oligomers19. It thus is reasonable to hypothesize that the presence of the two additional 
amino acid substitutions in Mm Aβ42 explains why wild type mice do not show AD-like 
pathology. 
It has been suggested that species-specific differences in Aβ42 primary structure are 
key factors controlling the development of AD-like pathology15,20. However, some of the 
work in this area is contradictory16-17,21. Fraser et al. 22 and Hilbich et al. 16 argue that 
differences in primary structure do not account for the lack of amyloid deposits in the brains 
of aged rats and mice, and have no effect on the morphology and organization of fibrils. In 
contrast, Ötvös et al.15 and Dyrks et al.21 suggest that subtle interspecies differences in 
amino acid residues may account for the inability of the rodent peptide to form amyloid 
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fibrils in situ. The reductionist approach of arguing that amino acid sequence differences in 
Aβ are the sole explanation for species-specific development, or lack of development, of 
AD-like pathology, ignores the fact that mice aren’t human. Other explanations for the 
species-specific differences in neuropathology may exist. Here, we investigate how the 
natural differences in APP gene sequence among humans, Mm, and O. degus affect the 
biophysical, biochemical, and biological properties of the respective Aβ peptides. 
8.2 Materials and Methods 
Chemicals and Reagents. All chemicals were purchased from Sigma Chemical Co. 
(Saint Louis, MO) and were of the highest purity available. Water was de-ionized and 
filtered using a Milli-Q system (Millipore Corp., Bedford, MA). Xpress silver-staining 
kits were from Invitrogen (Carlsbad, CA). Buffers were prepared with sterile, autoclaved 
water containing 0.002% (w/v) sodium azide. SYPRO Orange dye was purchased from 
Invitrogen Corp. Annexin-V staining kits were purchased from BioVision, Inc, Milpitas, CA. 
Peptide synthesis and preparation. Aβ42 peptides were synthesized using 9-
fluorenylmethoxycarbonyl (Fmoc) chemistry and purified by reverse phase high 
performance liquid chromatography (RP-HPLC), essentially as described23. The identity and 
purity (usually >97%) of the peptides were confirmed by amino acid analysis, mass 
spectrometry, and reverse phase high performance liquid chromatography (RP-HPLC). 
Peptides were solvated with 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) as described 24. 
Briefly, 100-300 μg of peptide lyophilizate were dissolved in 200 μl of 100% HFIP in a 1.5 
ml V-bottom polypropylene microcentrifuge tube (Eppendorf, Fisher Scientific). Each tube 
was covered with a Kimwipe® (Fisher Scientific) tissue and placed in a chemical fume hood 
overnight to allow evaporation of the HFIP. Tubes then were placed in a SpeedVac rotary 
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evaporator (Savant SPD121P, ThermoScientific) for 2 h to ensure complete HFIP removal. 
The resulting peptide films were dissolved in 10% (v/v) 60 mM NaOH, 45% (v/v) Milli Q 
water, followed by 45% (v/v) 20 mM sodium phosphate, pH 7.5, containing 0.002% (w/v) 
sodium azide (“phosphate buffer”). The solutions then were thoroughly mixed and sonicated 
for 1 min in a Branson 1200 bath sonicator (Branson Ultrasonics Corp., Danbury, CT). The 
resulting peptide solution either was used immediately or stored at -20°C for future use. 
When used immediately, the sample was placed on ice and the peptide concentrations were 
estimated by UV absorbance (ε280=1280 cm-1M-1 for human and Od; and ε257=200 cm-1M-1 
for Mm). The final concentration of Aβ42, as necessary for each experiment, was achieved 
by dilution with phosphate buffer. Equimolar amounts of Aβ42 were used in each 
experiment and a minimum of three independent experiments were performed. 
Ion mobility-mass spectrometry (IM-MS). The Aβ42 samples were prepared in 10 
mM ammonium acetate buffer (pH = 7.4) with a final peptide concentration of 10 μM. The 
samples were analyzed on a home-built ion mobility spectrometry-mass spectrometer25, 
which has been described in Chapter 2.  
Quasielastic light scattering spectroscopy (QLS). Mm, Od, and human Aβ42 were 
dissolved at a concentration of 0.5 mg/ml in phosphate buffer, briefly vortexed, sonicated 
for 20 s, and filtered using a 20 nm Anotop filter (Whatman, Maidstone, England). Samples 
were monitored at ≈22°C for 7–10 days. Measurements were done using a custom optical 
setup comprising a 40 mW He-Ne laser (λ=633nm) (Coherent, Santa Clara, CA) and 
PD2000DLS detector/correlator unit (Precision Detectors, Bellingham, MA). Light 
scattering was measured at a 90° angle. The intensity correlation function and the diffusion 
coefficient (D) frequency distribution were determined using Precision Deconvolve software 
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(Precision Detectors, Bellingham, MA). Hydrodynamic radius RH was calculated from D 
according to the Stokes-Einstein equation ; where kB is Boltzmann's 
constant, T is Kelvin, and η is the solvent viscosity 26. 
To determine the instrument-independent rate of change in relative intensity, we 
calculate the normalized quantity (dI/dt)/I0 (units of h-1). The rate of change in scattering 
intensity, dI/dt, was determined by fitting to a linear function spanning the first hour of 
incubation. I0 was determined from the derived line It=(dI/dt)t + I0 by substitution of t=0. 
Both dI/dt and I0 depend on the aperture in which light is collected, which in turn is a 
function of the instrument used. We note that these quantities are precise, but likely not 
absolutely accurate, because the intensity versus time dependency over this time interval is 
significantly non-linear. 
Thioflavin T (ThT) binding. HFIP-treated Aβ42 peptide films were prepared in 
phosphate buffer at a nominal concentration of 1 mg/ml on ice and added to 96-well optical-
bottom microtiter plates (Thermo Fisher Scientific, Rochester NY), followed by 1.6 µl of 
ThT at a concentration of 5 mM in phosphate buffer. Phosphate buffer was added to the 
wells to produce a final volume of 200 µl and final Aβ and ThT concentrations of 20 and 40 
μM, respectively. The solutions were mixed gently by pipetting solution into and out of the 
pipette tip. The plates were sealed using an adhesive plate sealer and incubated at 37°C with 
gentle shaking (160 rpm) (Innova 4080 incubator shaker, New Brunswick Scientific, NJ). 
Fluorescence was determined using λex=450 nm and λem=482 nm. Readings were taken 
immediately (0 h), every hour for 6 h, and subsequently at 24 h intervals. Buffer alone, 
instead of peptide, constituted the ThT blank. A minimum of 5 replicates of each sample 
was measured. The mean of the blank readings were subtracted from the mean of the sample 
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readings at each time point and the corrected values, along with mean and SD, were plotted 
using KaleidaGraph (v 4.1, Synergy Software, Reading, PA). Statistical analyses (t-test and 
Mann-Whitney Rank test) were performed using SigmaStat (Jandel Scientific, San Jose, 
CA). 
Bis-ANS fluorescence. Bis-ANS (1,1′-Bis(4-anilino, 5-naphthalene sulfonic acid)) 
fluorescence was monitored periodically in 20 μM Aβ42 samples incubating at 37°C with 
shaking (160 rpm). Fifty μl of the sample (5 μM final concentration in the cuvette) was 
removed at regular intervals and added to 150 μl of 133.3 μM Bis-ANS solution in a 1.5 ml 
semi-micro disposable fluorescence cuvette (Brand, Germany). The cuvette was placed in 
the dark at room temperature (RT; 22.5 °C) for 5 min without shaking and then fluorescence 
(λex=400 nm and λem=495 nm) was determined using a Hitachi model F-4500 Fluorescence 
Spectrophotometer (Hitachi America, NJ). The excitation and emission slit widths were both 
5 nm. Each sample was read in triplicate, averaged, and corrected using a buffer blank 
incubated for the same amount of time. The samples were read at 2 h intervals for the first 
12 h and subsequently at 24 h intervals. The data were plotted in KaleidaGraph (v 4.1, 
Synergy Software, Reading, PA). Statistical analyses on the data (t-test and Mann-Whitney 
Rank test) were performed using SigmaStat (Jandel Scientific, San Jose, CA). 
Circular Dichroism Spectroscopy. Mm, Od, and human Aβ42 peptides were 
prepared from HFIP dried films at final concentrations of 20 μM. For the mixture Aβ42 
samples, the final concentration of each peptide in the mixture was 10 μM. The peptides 
were incubated in 1 mm path length cuvettes, without shaking, at 37 ºC. Spectra were 
acquired using a JASCO J-810 spectropolarimeter (Tokyo, Japan) every 15 min for the first 
3 h and subsequently every 30-60 min. CD measurement parameters were: wavelength range, 
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190–260 nm; data pitch, 0.2 nm; continuous scan mode; scan speed, 100 nm/min; response 
time, 1 s; band width, 2 nm; scan number per sample, 7. The raw spectra were smoothed 
using the means movement smoothing parameters within the data acquisition software 
(Spectra Manager 2). The data were subsequently plotted in KaleidaGraph (v 4.1, Synergy 
Software, Reading, PA). 
Electron microscopy (EM). Formvar 400 mesh grids were glow discharged on a 
Med010 mini-deposition system EM glow discharge attachment model BU007284-T 
(Balzers Union Ltd, Hudson, NH) containing a cylindrical discharge compartment and an 
adjacent discharge control and timer unit. Aβ42 was incubated at 37°C with continuous 
shaking (160 rpm). Eight μl aliquots were mixed thoroughly and then they were applied to 
the grid at days 0 and 7. The grid was covered and incubated for 20 min at RT. Liquid was 
wicked off carefully using a filter paper wick by gently touching the tip of the filter paper to 
the edge of the grid. Five μl of 2.5% (v/v) glutaraldehyde in water were added to the grid, 
which then was incubated for 3 min in the dark. The glutaraldehyde solution was wicked off 
and replaced with 5 μl of 1% (w/v) uranyl acetate in water, which then was incubated for 3 
minutes in the dark. The grids then were wicked off and air-dried. A JEOL 1200 EX (JEOL 
Ltd., Tokyo, Japan; 40-120 kV) transmission electron microscope used to visualize the 
samples on the grid27. 
Neuronal Cell Cultures. Primary cortical or hippocampal neurons were prepared as 
described previously 28. Briefly, pregnant E18 rats were euthanized with CO2 and the pups 
were removed immediately. Brains were dissected in chilled Leibovitz’s L-15 medium, pH 
7.5, (ATCC, Manassas, VA) in the presence of 1 μg/ml penicillin/streptomycin (Invitrogen, 
Carlsbad, CA). The tissue was incubated with 0.25% (w/v) trypsin in phosphate-buffered 
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saline, pH 7.5 (PBS), containing 0.02% (w/v) EDTA for 30 min and then mechanically 
dissociated in a small volume of Leibovitz’s L-15 medium using a fire-polished Pasteur 
pipette. The neurons were suspended in Dulbecco’s modified Eagle’s medium, pH 7.5, 
(DMEM; ATCC) containing 10% (v/v) heat-inactivated fetal bovine serum (FBS) (ATCC) 
and penicillin/streptomycin (1 μg/ml) and plated on poly-D-lysine (0.1 mg/ml, Sigma)-
coated 96-well COSTAR plates (Corning, Lowell, MA) at a density of 3 × 105 cells/ml. 
Twenty-four hours after the cells had been plated, the medium was replaced with fresh 
medium supplemented with 5 μM cytosine β-d-arabinofuranoside (Sigma Chemical Co, St 
Louis, MO) to inhibit the proliferation of glial cells. The cultures were maintained for 6 d 
before being treated with Aβ42. PC-12 cells were cultured and differentiated with 50 ng/ml 
nerve growth factor (NGF) 24 h prior to treatment with peptides, as described previously29. 
Human SHSY-5Y cells were grown in DMEM/F12K (1:1) media, pH 7.5, containing 10% 
(v/v) heat-inactivated FBS and penicillin/streptomycin (1μg/ml), 2 mM glutamine, and 1.5 
g/L sodium bicarbonate. The cultures were maintained at 37°C in a humidified atmosphere 
of 5% (v/v) CO2. 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Assay. Cell 
metabolism was evaluated using the MTT assay, as described previously 30. Briefly, rat 
primary cortical neurons or NGF-differentiated PC12 cells were treated with 10 μM freshly 
prepared Aβ42 for 24 h at 37 °C. Following treatment, 15 μl of MTT, prepared by 
dissolution in 10% (v/v) Triton-X 100 in 2-propanol containing 0.1N HCl, according to the 
manufacturer’s instructions (Promega, Madison, WI), was added to each well and the 
samples were incubated for 4 h at 37°C. “Stop solution” (Promega, Madison, WI) then was 
added and the samples were incubated overnight at RT. OD570-630 was measured using a 
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Synergy plate reader (Bio-TEK Instruments, Winooski, VT). A minimum of three 
independent experiments (six wells per data point) were performed. Data were normalized to 
the medium control group and expressed as the mean ± the standard error of the mean 
(SEM). 
LDH (Lactate Dehydrogenase) Assay. Rat primary cortical neurons and NGF-
differentiated PC12 cells were incubated with 10 μM Aβ42 peptide for 48 h at 37°C in 
Eagle's minimal essential medium (MEM, Earle's salts, supplied glutamine-free) 
supplemented with 5% (v/v) heat-inactivated horse serum, 5% (v/v) fetal bovine serum, 2 
mM glutamine, and 25 mM glucose. Cell death was assayed by measuring released LDH 
activity, as described previously27. Data from a minimum of three independent experiments 
(six wells per data point) were normalized to media control and expressed as mean ± SEM. 
Apoptosis Assay: Apoptosis was estimated using Annexin V-FITC fluorescence. 
Briefly, SH-SY5Y neuroblastoma cells (ATCC® CRL-2266) were grown on cover slips 
coated with poly D-lysine (0.1 mg/ml) in DMEM/F12K (1:1) medium containing 10% (v/v) 
heat-inactivated fetal bovine serum (FBS), penicillin/streptomycin (1 μg/ml), 2 mM 
glutamine, and 1.5 g/L sodium bicarbonate. The cells were maintained at 37°C in a 
humidified atmosphere of 5% (v/v) CO2 in air until a cell density of 1-5 × 105 cells per well 
was obtained, at which point the cells were exposed to peptide (10 μM final concentration) 
for 24 h. The peptides were prepared by dissolution of HFIP films in cell culture medium. 
Staurosporine (1 μM final concentration) was added to cells as a positive control for 
apoptosis. The negative control was cells treated with medium containing no Aβ42. After 
the incubation period, the coverslip was washed in PBS and fixed with 4% (v/v) 
paraformaldehyde in PBS. The cells were stained with an Annexin V-FITC apoptosis 
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detection kit (Bio Vision Incorporate, Milpitas, CA) according to the manufacturer’s 
instructions. Images were recorded using a confocal laser scanning microscope (Zeiss, 
Model: LSM 700; λex=488 nm and λem=535 nm). The numbers of apoptotic cells were 
counted in a 100 μm2 area using Image-J software (Image-J, NIH). A minimum of 30 
microscopic fields was used for morphometric analysis from two independent experiments. 
8.3 Results and Discussion 
8.3.1 Ion mobility-mass spectrometry (IM-MS) and Aβ42 monomer structure 
To probe the effects of primary sequence difference (Figure 8.1) on the peptide 
structure and oligomer distributions of all Aβ42 alloforms, we performed an ion mobility 
coupled with mass spectrometry (IM-MS) analysis. The mass spectra of all three Aβ42 
alloforms immediately after preparation were recorded and shown in Figure 8.2. All 
alloforms show three peaks corresponding to the z/n = -4, -3, and -5/2 charge states, where z 
is the charge and n is the oligomer number. It is notable that the relative intensity of the z/n 
= -5/2 peak for Mm is relatively higher than that of the Aβ42 or Od, suggesting the oligomer 
formation for Mm is more abundant. In addition, there is a z/n = -2 peak which might 
contain oligomer species observed for Mm. These mass spectrometry results suggest that 
Mm oligomerizes more readily than do Aβ42 or Od. Interestingly, this suggestion is 
consistent with the observation that the Mm sample clogged the nano-electrospray tips more 
easily during the experiment than either Aβ42 or Od. 
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 Figure 8.2 Mass spectra of all Aβ42 alloforms. The charge state z/n is noted for each 
species where z is the charge and n is the oligomer number.  
 
To probe whether these Aβ42 alloform have different monomer structures, the ATDs 
for the z/n = -3 species were recorded and shown in Figure 8.3. The ATD of the z/n = -3 
Aβ42 (Figure 8.3a) has been studied in previous studies 31-32 showing two major features 
with arrival times at ~620 and 670 μs which were assigned as a compact solvent free-like 
conformer and an extended solution-like conformer, respectively. Similarly, the ATD of the 
z/n = -3 Od shows two features which can be assigned as compact solvent free and extended 
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solution-like conformers, based on their cross sections. Interestingly, the ATD of the z/n = -
3 Mm displays three features, two with similar arrival times as Aβ42 or Od and one with a 
longer arrival time, which is not observed for Aβ42 or Od species. This indicates there is an 
additional monomer conformer with more extended structure for Mm. As shown in Table 
8.1, the collision cross sections of M1 and M2 monomers for each peptide are very similar, 
suggesting that all three Aβ42 alloforms have similar monomer conformations (M1 and M2). 
Mm forms one additional extended conformer (M3), which may be of relevant to its 
aggregation kinetics. 
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 Figure 8.3 The ATDs of the z/n = -3 for all Aβ42 alloforms. M1, M2 and M3 represent three 
monomer conformers with different sizes.   
  
 206 
 
Table 8.1 Cross sections of the monomers and oligomers for all Aβ42 alloforms in Å2. σ is 
the cross section and σ/n represents the cross section for the monomer in the oligomer.   
 
Oligomer Charge state 
Aβ42 Od Mm 
σ σ/n σ σ/n σ σ/n 
Monomer 
-2 - - - - 618 618 
-3 (M1) 643 643 630 630 635 635 
-3 (M2) 702 702 692 692 698 698 
-3 (M3) - - - - 757 757 
-4 792 792 790 790 807 807 
Dimer 
-4 - - - - 968 484 
-5 1246 623 1218 609 1234 617 
Trimer -6 - - - - 1275 425 
Tetramer -10 2172 543 2156 539 2204 551 
Hexamer -15 2838 473 2928 488 2910 485 
Dodecamer -30 4560 380 4512 376 - - 
 
 
8.3.2 Ion mobility spectrometry and Aβ42 oligomer distributions  
To understand the early oligomer distributions of the Aβ42 species, the ATDs of the 
z/n = -5/2 peaks were recorded and are shown in Figure 8.4. The ATD of Aβ42 shows four 
features with arrival times at ~710, 680, 620 and 540 μs, which have previously 31,33 been 
assigned as dimer, tetramer, hexamer and dodecamer based on their cross section values 
(Table 8.1, also see reference 25 for a detailed discussion of the Aβ42 oligomer 
assignments). Similarly, the ATD of Od shows four features corresponding to dimer, 
tetramer, hexamer and dodecamer. However, the ATD of Mm shows only three features 
corresponding to dimer, tetramer and hexamer. Finally, the ATD of the z/n = -2 Mm was 
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recorded and shows two primary features corresponding to dimer and trimer (Figure 8.4d), 
indicating that Mm forms trimer, which is not observed for Aβ42 or Od under these 
experimental conditions. The lack of dodecamer in mouse is interesting as it may correlates 
with the fact Mm does not naturally display AD-like neuropathology, in contrast to mice 
expressing the human form of Aβ34, which express substantial levels of Aβ*56, a dodecamer 
linked to memory deficits.  
 
 
Figure 8.4 Ion mobility spectrometry and Aβ42 oligomer distributions. a-c) The ATDs of 
the z/n = -5/2 peaks for all Aβ42 alloforms. d) The ATD of the z/n = -2 peak for mouse 
Aβ42. The oligomer number (n) is noted for each feature. 
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8.3.3 Monitoring Aβ assembly by quasielastic light scattering spectroscopy (QLS) 
 QLS is a method for the non-invasive monitoring of the diffusion coefficients (D) of 
particles in solution35. We used QLS, and the Stokes-Einstein equation (see Methods), to 
derive RH distributions of each peptide after 0.5 h and 24 h of incubation (Figure 8.5). Aβ42 
initially produced a distribution composed primarily of small particles of RH ≈ 8-10 nm 
(darkened area). Particles of RH  ~ 100–1000 nm also were observed, but because scattering 
intensity is proportional to the square of molecular weight, these peaks must have been 
produced by relatively few particles. After 24 h, the contributions to the scattered light 
intensity of larger particles had increased substantially, consistent with a process of Aβ 
assembly. However, oligomers of RH ≈ 8-10 nm remained 1. Such oligomers have been 
reported previously29. In contrast, the other peptides did not form oligomers of this size. 
After 24 h of incubation, the distribution of Mm changed little, showing only a slightly 
increased average RH of its predominant peak. Deconvolution of RH distributions depends on 
the specific parameterizations used, especially that for data smoothing35. Although 
deconvolution yielded two peaks for Mm, it is possible that only one heterodisperse 
population of scatterers was present. For this reason, the average RH was calculated across 
the entire distribution. Od showed substantial increases in RH over 24 h, yielding three nodes 
of RH intensity, at ≈90 nm, ≈500 nm, and ≈4000 nm. The average RH was 1740 nm. 
Interestingly, the time-dependence of the distributions of RH showed that those of Aβ42 and 
Od primarily comprised relatively small scatterers initially (𝑅𝑅𝐻𝐻 ≈ 10 𝑛𝑛𝑛𝑛 and 𝑅𝑅𝐻𝐻 ≈ 62 𝑛𝑛𝑛𝑛, 
respectively) but that after 24 h the distribution range expanded to larger sizes with maximal 
a The scattering intensity varies as the square of the molecular weight of the scatterer. The maximum intensity 
of small scatterers (shaded bars) was equivalent to those for larger scatterers (unshaded bars), which means that 
a disproportionate percentage of scatterers in this mixture were small. For the purpose of comparison between 
the two time points, we focused on these small scatterers when we calculated scatterer RH. 
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𝑅𝑅𝐻𝐻 > 1000 𝑛𝑛𝑛𝑛. Mm was unique in initially displaying larger scatterers (𝑅𝑅𝐻𝐻 ≈ 233 𝑛𝑛𝑛𝑛) 
whose size remained relatively constant over 24 h. 
 
Figure 8.5 Quasielastic light scattering spectroscopy (QLS). Intensity (counts/sec) is 
plotted versus hydrodynamic radius (RH in nm). The data are from samples monitored ≈. The 
number in the top right corner of the panel represents the average RH for the shaded regions 
of the distributions. Buffer spectra produce no scattering and thus are not shown. 
 It should be noted that all samples were filtered through a 20 nm porosity filter 
immediately after preparation. During the first 30 min of monitoring, for all peptides except 
Aβ42, we observed a rapid increase in scatterer size, reflecting a rapid assembly process. 
The particle size distributions then were relatively stable while overall scattering intensity 
continued to rise due to increasing contribution to scattering from large particles. We 
calculated the rate of growth in the scattering intensity during the first hour of incubation 
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(Table 8.2). Rates for Aβ42 and Mm were moderate, consistent with relative constancy of 
their particle size distributions. 
 Taken together, the data on the time-dependent evolution of RH and scattering 
intensity suggest that Mm rapidly forms small aggregates that are relatively stable, whereas 
both Aβ and Od display a lag time before fibril assembly is observed. 
 
Table 8.2 Rate of change in scattering intensity. The rate of change in scattering intensity, 
dI/dt, determined by fitting It to a linear function spanning the first hour of incubation. I0 
was determined from the derived line It = dI/ dt × t + I0 by substitution of t=0. Both dI/dt 
and I0 depend on the aperture in which light is collected, which in turn is a function of the 
instrument used. To determine the instrument-independent rate of change in relative 
intensity, we report the normalized quantity (dI/dt)/I0. We note that these quantities are 
precise, but likely not absolutely accurate, because the intensity versus time dependency 
over this time interval is significantly non-linear.  
 
 
8.3.4 Monitoring Aβ42 assembly kinetics by ThT fluorescence.  
 ThT binding was performed to monitor the assembly of β-sheet-rich structures 36-38 
(Figure 8.6A). Aβ42 displayed a classical ThT fluorescence curve starting at a low 
fluorescence level (~25 FU), remaining constant for ≈1 h, and then monotonically increasing 
during the next 5 h. In contrast, Mm fluorescence tripled within the first hour. Od displayed 
a somewhat higher initial level of ThT fluorescence than did Aβ42 but only a gradual 
increase during the initial 6 h. We continued monitoring for 21 d, during which time all 
three peptides displayed increasing rates of increase of ThT fluorescence ( ), until a 
plateau level was reached. The final fluorescence level of Aβ42 was substantially lower than 
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that of Mm (≈425 versus ≈800 FU) and somewhat lower than that of Od (≈425 versus ≈500 
FU). It was interesting that the maximal value of  for each peptide was similar. A 
similar behavior as in QLS was observed in the ThT experiments in that Mm quickly 
displayed substantial fluorescence that remained relatively constant for the first day, before 
increasing substantially over the next three weeks. The ThT fluorescence of Aβ42, as with 
its RH, was the lowest among the four peptides after the first day of incubation. 
 
Figure 8.6 Aβ assembly kinetics. ThT fluorescence. Peptides (20 µM) were incubated with 
40 μM ThT at pH 7.5 and 37°C with shaking. Data are present on a semi-log plot to allow 
visualization of data in a single figure for the entire time range (t=0 d, 0.04 d (1h), up to 21 
d). 
 
These data are consistent with a reaction coordinate model (Figure 8.7) in which Mm 
has a relatively low activation energy for formation of relatively stable oligomers. This 
produces the rapid kinetics for oligomer formation and the relatively long lifetimes of the 
oligomers thus formed. However, thermodynamically, the ΔG for fibril formation is similar 
to those of Aβ and Od (Table 8.3), thus eventually Mm does from fibrils. 
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 Figure 8.7 Reaction coordinate for peptide assembly. The graph illustrates one reaction 
coordinate that is consistent with the results of our experiments. The assembly of 
monomeric peptides into oligomers, and then into fibrils, is illustrated for the Mm and Aβ42 
peptides. For clarity, Od, which behaves similarly to Aβ42, is not illustrated. The assembly 
of peptide monomers into oligomers is accompanied by an activation energy (Ea1), 
illustrated pictorially by red (Mm) and blue (Aβ42) arrows. Ea1 for Mm is lower than for 
Aβ42, explaining the more rapid oligomerization of the former peptide. In addition, the Mm 
oligomers appear to be more stable, suggesting a lower free energy of formation compared 
to Aβ42 oligomers (note the larger oligomerization free energy (ΔGOl) of Mm 
oligomerization). In contrast, the experimentally determined free energies of fibril formation 
(ΔGFF) are similar (Table 8.2). This explains why the end-state assembly for all three 
peptides is fibrils, and why although the Mm oligomers are most stable, their conversion into 
fibrils is thermodynamically favored. 
 
Table 8.3 Determination of critical concentration and free energy of fibril formation. 
Peptides were incubated at a concentration of 20 μM in 20 mM phosphate buffer, pH 7.5, at 
37°C for 21 days without shaking. The samples then were centrifuged at 436,000 × g for 1 h 
(TLA 120.2 rotor; 120,000 rpm; Beckman Optima TLX Ultracentrifuge). The concentration 
of Aβ monomer1 present in the supernate was quantified by amino acid analysis (AAA). 
This concentration is equal to the critical concentration, Cr, which is the inverse of the 
amyloid fibril equilibrium constant, i.e., k=1/Cr (1, 2). The Gibb’s free energy change for 
monomer binding to fibrils then was determined according to the formula ΔG0 = -RT ln k. 
Statistical analysis was performed using t-test (paired) and Mann Whitney Rank (MWR) test 
in SigmaStat (Jandel Scientific Corp, San Jose, CA). The values shown are averages ± S.D. 
(in parentheses) derived from four independent experiments. p-values are relative to Aβ42. 
The range of Cr values varied over an order of magnitude, from ≈0.5-5 μM, displaying a 
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rank order of concentration of Mm < Aβ42 << Od. The ΔG0 values varied proportionately, 
from -9.20 to -7.64 kcal/mole, respectively. Mm fibrils were the most stable. Aβ42 fibrils 
displayed a similar but lesser stability. In contrast, Od fibrils were significantly less stable 
than were Aβ42 fibrils. 
 
 
8.3.5 Exposure of hydrophobic surfaces during Aβ42 assembly by Bis-ANS 
Fluorescence.  
We monitored exposure of hydrophobic surfaces during peptide assembly using Bis-
ANS fluorescence (Figure 8.8). Bis-ANS is a hydrophobic molecular probe that is 
essentially non-fluorescent in water but fluorescent in nonpolar or hydrophobic 
environments. This property makes it a sensitive indicator of protein conformation (e.g., 
molten globules, exposed hydrophobic surfaces, or native folds)39-43.  
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 Figure 8.8 Bis-ANS fluorescence. Aliquots from Aβ assembly reactions were removed at 
regular intervals, mixed with Bis-ANS, and then monitored for fluorescence (as arbitrary 
fluorescence units (FU)). 
 
 Aβ42 showed a rapid but modest increase in fluorescence during the first 4 h of 
incubation (to ≈200 AU), after which a slow monotonic decrease in fluorescence was 
observed. Mm displayed the highest initial fluorescence level among these peptides, the 
most rapid increase in fluorescence, and the highest plateau value (≈950 AU). Fluorescence 
then decreased monotonically with time. Od displayed the second highest rate of increase, 
and plateau level, of fluorescence. Peak fluorescence occurred at ≈24 h, later than for Aβ42 
or Mm. Experiments also were done with SYPRO Orange (data not shown), a dye with 
properties similar to that of Bis-ANS. The rates of fluorescence increase and the plateau 
levels of fluorescence produced by SYPRO Orange exhibited the same rank order as with 
Bis-ANS, namely Mm > Od > Aβ42. 
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The rapid increase in fluorescence in the Mm sample suggests early exposure of 
hydrophobic surfaces. The formation of such surfaces has been postulated to occur as the 
intrinsically disordered Aβ monomer begins folding44-45. This phenomenon would produce 
rapid aggregation, as seen by ThT (Figure 8.6). The different initial fluorescence levels 
observed between Od and Aβ42 also is consistent with the ThT fluorescence data, which 
showed higher initial levels of β-sheet in Od compared to Aβ42. 
8.3.6 Determining secondary structure dynamics by CD spectroscopy 
 We used circular dichroism spectroscopy (CD) to determine the time-dependence of 
the distribution of secondary structures for each peptide (Figure 8.9)46-47. Aβ42 displayed 
statistical coil structure initially, but then exhibited a progressive increase in β-sheet content 
that was clear within hours and produced a classical β-sheet spectrum at 24 h. The spectra 
appeared to display an isodichroic point at ≈208 nm. This isodichroic point was observed 
with all these peptides, suggesting the existence of a two-state transition (likely statistical 
coil→α-helix)48. Mm exhibited some β-sheet content immediately after preparation. 
Progressive increases in β-sheet were observed throughout the 24 h monitoring period, as 
with Aβ42. However, the level of β-sheet was higher than in Aβ42, as indicated by the 
relative increase in absolute values of the molar ellipticities at ≈195 and ≈215 nm. Od had 
the least statistical coil content of any of the peptides when its CD spectrum was first 
acquired, and the highest β-sheet content. Progressive increases in β-sheet structure then 
were observed. 
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 Figure 8.9 Secondary structure dynamics. CD spectroscopy was used to monitor temporal 
changes in secondary structure. Numbers shown vertically at the 190 nm tick marks are the 
times (h) at which the respective spectra were collected. 
 
 To visualize the relative rates of change in β-sheet content, we plotted [Θ]215 versus 
time (Figure 8.10). Mm showed the highest initial β-sheet content, the fastest increase in the 
level of this secondary structure element, and the highest overall β-sheet content at the end 
of the experiment. Od also displayed relatively high initial β-sheet content, but the evolution 
of β-sheet occurred at a slower rate. Aβ42 had the lowest initial β-sheet level, but this level 
eventually reached that of Od. The high initial β-sheet in the Mm peptide is consistent with 
its rapid oligomerization. The monotonic increase in β-sheet for all three peptides suggests a 
progressive assembly phenomenon that was confirmed in subsequent EM experiments. 
Wavelength (nm)
a) b) c)
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 Figure 8.10 Time-dependence of [Θ]215. Molar ellipticity at 215 nm is plotted versus time 
as a measure of time-dependent changes in β-sheet secondary structure. 
 
8.3.7 Assembly Morphology of Aβ42 alloforms 
 We used electron microscopy to determine the morphologies of assemblies present at 
the initiation of peptide incubation and after the assembly process was complete (day 7) 
(Figure 8.11A, B). Small structures (“globules”) were observed initially in the Aβ42 sample. 
These globules ranged in diameter from 11-23 nm (white arrows, Figure 8.11A), often 
displaying pore-like central cavities filled with uranyl acetate stain. These annuli had outside 
diameters ranging from ≈13-25 nm and inside diameters ranging from ≈4-11 nm. Mm, in 
contrast, formed aggregates comprising short beaded chains of different diameters (black 
arrows) and irregular structures (open arrows). These irregular assemblies ranged in 
diameter from 11-21 nm and had lengths from 16-75 nm. Od displayed filamentous 
aggregates (open arrows), as well as occasional long filaments to which smaller assemblies 
appeared to be associated (curved arrow). Small globules (black arrows) were interspersed 
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among these other structures. The globules range in diameter from 11-54 nm. The diameters 
of the long fibrils ranged from ≈7-19 nm. 
 
Figure 8.11 Assembly morphology. EM was used to determine assembly morphology. 
Aliquots of assembly reactions were removed at days 0 (panel A) and 7 (panel B). 
Determination of geometric parameters (lengths, diameters) was done using Image J 
software. Scale bars are 200 nm. 
 
Considering the heterogeneity of assembly morphologies observed immediately after 
sample preparation, it was interesting that by 7 days all samples formed long straight or 
curved fibrils (Figure 8.11B). Aβ42 predominately formed fibrils of quite different lengths 
(56-303 nm) and with diameters of ≈7-12 nm (Table 8.3). Long fibrils had a diameter of 9-
21 nm. The Mm sample contained numerous fibrils that were thinner than those of Aβ42 
(Table 8.4), but also abundant smaller curved “protofibril-like” structures (black and white 
arrows) 23. Od formed long and short fibrils interspersed with numerous globules. Bifilar 
structures with helical twist were observed (thick black arrow) along with thinner fibrils, 
Day 1
Day 7
a)
b)
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often with helical twists (thin black arrows). A number of annuli also were observed (white 
arrows).  
The results of electron microscopic examination of assembly morphology correlated 
with the results from the prior experiments. For example, the initial rank order of average 
assembly size was Mm > Od > Aβ42, and as would be predicted from the QLS, ThT, and 
CD experiments, large (fibrillar) assemblies were observed after 7 d. Mm continued to 
behave somewhat uniquely in that the distribution of assemblies at day 7 included abundant 
protofibrillar species (not seen with the other peptides) and narrower fibrils. The continued 
presence of the small protofibrils is consistent with the relatively constant distribution of 
scatter sizes seen during the first 24 h by QLS. 
 
Table 8.4 Dimensions of assemblies observed by EM. Peptides were incubated at 37°C with 
shaking. Aliquots of assemblies were removed at day 0 and day 7. Following incubation, 
different classes of assemblies were observed, including globules, short fibrils, and long 
fibrils. If present, the numbers represent the size range, in units of nm, of each assembly 
type. Assembly lengths are reported in nm within parentheses. 
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8.3.8 Neurotoxic activities of Aβ assemblies. 
MTT assays were performed to evaluate the effects of freshly prepared peptides on 
MTT metabolism49. The assay was performed both on PC12 cells (Figure 8.12A) and rat 
primary cortical neurons (Figure 8.12B). AΒ42 caused an ≈23% decrease in MTT 
metabolism in PC12 cells, whereas Mm and Od were non-toxic. The differences in toxicity 
between Aβ42 and each of the other peptides was highly significant (p<0.001). The data 
from primary cortical neurons were similar to the same as those from PC12 cells 
Quantitatively, the levels of toxicity of all peptides assayed with primary cortical neurons 
was greater than with PC12 cells. LDH assays were performed to measure cell death. The 
results of these assays were consistent with those of the MTT assays (Figure 8.12C, D). 
Aβ42 was most toxic while Mm and Od were least toxic. 
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Figure 8.12 Peptide neurotoxicity. To determine the effects of the different peptides on 
cellular metabolism, MTT assays were performed using (A) differentiated PC12 cells or (B) 
rat primary cortical neurons. Freshly prepared peptides were added to the cultures for 24h at 
37°C, after which MTT was added and incubated for 4h at 37°C, stop solution was added to 
the cultures, the cultures were incubated overnight, and then formazan optical absorbance 
was measured at 570-630 nm (OD570-630). Data are representative of that obtained in three 
independent experiments (6 wells per data point). The data are normalized to the media 
control group and expressed as mean ± the standard error of the mean (SEM). Statistical 
significance between samples is indicated by asterisks (*** and ** indicate p values < 0.001 
and <0.01 respectively). NS is “not significant.” To determine cell death, LDH activity was 
measured in the media from (C) differentiated PC12 cells or (D) rat primary cortical neurons 
after 48 h of incubation of the cells with the different peptides. Data are representative of 
that obtained in three independent experiments (6 wells per data point). The data are 
normalized to the media control group and expressed as mean ± the standard error of the 
mean (SEM).  Statistical significance between samples is indicated by asterisks (*** and ** 
indicate p values < 0.001 and <0.01 respectively). NS is “not significant.” 
 
To measure the level of apoptosis induced by freshly prepared Aβ, SHSY-5Y cells 
were stained for phosphatidylserine using Annexin-V conjugated FITC50-51. Propidium 
iodide (PI) staining was done concurrently to reveal cell nuclei. Negative control samples 
displayed only red nuclei, but no cell surface Annexin-V fluorescence. Positive control 
samples incubated with 1 µM staurosporine, showed complete disruption of membrane 
integrity (data not shown). All peptides produced green fluorescence, indicating binding of 
Annexin-V (Figure 8.13). Quantitative analysis of the number of Annexin-V-positive 
(fluorescent) cells per 100 µm2 field (Figure 8.13B, bar graph) revealed an average of 4.7 for 
Aβ42 and 4.2 for Od, a difference that was not statistically significant. Mm showed 
significantly lower numbers (3.3; p<0.01) than did Aβ42. The difference in fluorescence 
between Od and Mm was not significant. 
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 Figure 8.13 Monitoring apoptosis. (A) Annexin-V staining of human SH-SY5Y cells treated 
with each of the peptides was performed to estimate apoptosis levels. The SH-SY5Y cells 
were grown on cover slips and treated with freshly prepared Aβ42 peptides for 24h, after 
which they were stained with Annexin V-FITC. Images were recorded using confocal laser 
scanning microscopy. (B) Bar graph: Quantitation of Annexin-V staining. The number of 
apoptotic cells was counted in a 100 μm2 area using Image-J software. A minimum of 30 
microscopic fields was used in each of two independent experiments. Significance between 
groups is indicated by asterisks (*** and ** indicate p values of <0.001 and <0.01, 
respectively). No significant difference existed between Mm and Od, although it is possible 
that Od trended towards greater apoptotic activity. 
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Taken together, the results among these assays were consistent and showed a rank 
order of toxicity of Aβ42 >> Mm ≥ Od. An identical rank order was observed in our 
Annexin-V fluorescence apoptosis assay. This rank order was the opposite of the rank order 
observed in our biophysical studies. Considered from the broad perspective of assembly 
rate/size versus toxicity, our data suggest that assembly populations comprising smaller 
assemblies are relatively more toxic than are those containing larger assemblies. This result 
agrees with the hypothesis that the most important neurotoxin in AD are the small, 
presumably oligomeric, assemblies52-53,54. However, our data extend this hypothesis by 
providing evidence, through the use of peptides from different species (and of different 
primary structure), that assembly state, rather than primary structure per se, is likely to 
contribute most significantly to peptide neurotoxicity. 
It is important to note that we do not argue that primary structure is irrelevant with 
respect to determining peptide neurotoxic activity55, as some have with respect to the 
existence of “generic” amyloid structures56-59. Instead, we suggest that it is the combination 
of at least three factors that control peptide neurotoxicity: (1) primary structure; (2) 
assembly structure; and (3) cellular responses. Primary structure determines the intrinsic 
propensity of a peptide sequence to fold into an energetically determined distribution of 
tertiary structures, according to Anfinsen60. It is the basis of Factor #2, which encompasses 
the vast and complex folding landscape of Aβ and other amyloid proteins 58 that includes 
assemblies such as oligomers (irregular, globular, annular, worm-like), protofibrils, and 
fibrils. Factor #3 encompasses how distinct cell types (e.g., neurons, glia, microglia, or non-
neuronal) respond to extracellular or intracellular (including cytoplasmic and intra-
organellar or intramembranous (plasma, endosomal, lysosomal, mitochondrial, nuclear)) Aβ 
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assemblies. This response includes components of the unfolded protein response, 
chaperones, and lysosomal activities. It also includes anabolic features of Aβ metabolism, 
which help to determine steady state concentrations of Aβ in different anatomic sites). 
Factors #1 and #2 are intrinsic to the Aβ peptide per se. Factor #3 is specific to each type of 
organism and falls under the rubric of specific organismal responses to neurotoxins, such as 
Aβ. Organismal responses determine both the assembly space of Aβ aggregates as well as 
their biological half-lives. An excellent example of "organismal control" comes from recent 
studies of superoxide dismutase 1 (SOD1) aggregation in transgenic mouse models of 
amyotrophic lateral sclerosis. Bergh et al.61 report that SOD1 aggregates formed in the 
brains and spinal cords of these animals differ in structure from those produced in vitro—a 
clear example of how organismal factors mediate the intrinsic assembly propensities of 
amyloid proteins and thus may affect their neurotoxic activities. 
 
8.4 Conclusions 
Taken together, these data do not support long-standing hypotheses that the primary 
factor controlling development of AD-like neuropathology in rodents is Aβ sequence. If it 
were, then we would not expect, a priori, to observe the folding and assembly of rodent 
peptides into intrinsically toxic oligomeric, protofibrillar, and fibrillar structures. Instead, 
our data support the hypothesis that the factors of assembly quaternary structure and 
organismal response control development of neuropathology. The implication of this 
hypothesis is that a valid understanding of disease causation within a given system 
(organism, tissue, etc.) requires the co-evaluation of both biophysical and physiologic 
properties of that system. One obvious property that might contribute to amyloid formation 
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is life span. AD amyloidosis in humans is a neuropathologic phenomenon that is age-
dependent. Rats of the species O. degus, like the naked mole rat, live substantially longer 
than do animals of the species M. musculus (≈6-8 in captivity versus ≈2 years) and thus they 
may be more likely to develop amyloid and experience its attendant effects. Another 
interesting possibility, although one beyond the scope of study at this time, is that O. degus 
neurons are more susceptible to Aβ-induced toxicity. 
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